Datasets:

ChatDOC
/

OCRFlux-pubtabnet-single

Dataset card Data Studio Files Files and versions Community

Split (1)

train · 9.06k rows

image_name stringlengths 68 68	type stringclasses 2 values	gt_table stringlengths 116 12.6k
c04d22655e345df8821e0568fe9546cd8e370b5d9c4c030bd5ef05c03682cec6.png	simple	<table><tr><td>Barriers to delivery</td><td>Quotes</td></tr><tr><td>Time</td><td><i>“Did not have time to complete all activities”.</i> (Teacher, school 20, self-evaluation data)</td></tr><tr><td>Environment</td><td><i>“It was weather more than anything you know. The game where we had to have the cones and you had to turn them over, we were out in a force 10 gale and they were just blowing everywhere and they were getting really upset”.</i> (Teacher, school 1, interview data)</td></tr><tr><td>Educational understanding</td><td><i>“Some children didn’t have good knowledge of human body - this meant that they needed lots of support with bean bag game”.</i> (Teacher (1), school 41, self-evaluation data)</td></tr><tr><td>Behaviour</td><td><i>“I quite often had characters in a bit of a sulk because of it [being put on the ‘smokers’ team]”.</i> (Teacher, school 13, interview data)</td></tr><tr><td>Children’s preferences</td><td><i>“Used the same messages but changed the sport to basketball instead of football due to previous issues with some of the girls engaging with the context. The children loved the session”.</i> (Teacher (1), school 8, self-evaluation data)</td></tr></table>
69de3cdff912bbb3213b7132d10b181890735dc7a04fd948739331c9d9e39fbb.png	complex	<table><tr><td colspan="4">Total = 939 individuals</td></tr><tr><td>Parameter</td><td>NGT <i>n</i> = 473 (50.4%)</td><td>Pre-DM <i>n</i> = 250 (26.6%)</td><td>T2DM <i>n</i> = 216 (23%)</td></tr><tr><td>Age (years)</td><td> </td><td> </td><td> </td></tr><tr><td> Mean ± SD</td><td>48.5 ± 12.9</td><td>52 ± 10.6</td><td>55.8 ± 10.4<sup>∗†</sup></td></tr><tr><td> Median [IQR]</td><td>50 [40–58]</td><td>52 [45–59]</td><td>57 [49–62]</td></tr><tr><td>Women, <i>n</i> (%)</td><td>328 (69.3)</td><td>168 (67.2)</td><td>142 (65.7)</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td> </td><td> </td><td> </td></tr><tr><td> Mean ± SD</td><td>28 ± 4.6</td><td>29.3 ± 4.4</td><td>30.4 ± 5.2<sup>∗†</sup></td></tr><tr><td> Median [IQR]</td><td>27.5 [24.7–31]</td><td>29 [26.1–31.7]</td><td>29.6 [26.8–32.8]</td></tr><tr><td>BMI ≥ 30 kg/m<sup>2</sup>, <i>n</i> (%)</td><td>150 (31.7)</td><td>99 (39.6)</td><td>102 (47.2)</td></tr><tr><td>WC (cm)</td><td> </td><td> </td><td> </td></tr><tr><td> Mean ± SD</td><td>91.3 ± 12.2</td><td>95.6 ± 9.9</td><td>98.3 ± 11.2<sup>∗†</sup></td></tr><tr><td> Median [IQR]</td><td>91 [82–99]</td><td>95 [89–102]</td><td>98 [91-105]</td></tr><tr><td>Hypertension, <i>n</i> (%)</td><td>137 (28.9)</td><td>77 (30.8)</td><td>117 (54.1)<sup>∗†</sup></td></tr><tr><td>Currents smoking, <i>n</i> (%)</td><td>107 (22.6)</td><td>48 (19.2)</td><td>48 (22.2)</td></tr><tr><td>FH of T2DM, <i>n</i> (%)</td><td>234 (49.4)</td><td>146 (58.4)</td><td>147 (68)*</td></tr><tr><td>FH of CVD, <i>n</i> (%)</td><td>71 (15)</td><td>38 (15.2)</td><td>34 (15.7)</td></tr></table>
b846c825c5035601859957b0bad526498bed21698680b44b0855e3e69469a345.png	simple	<table><tr><td>Variable</td><td>Placebo Frequency (%)</td><td>Caffeine Frequency (%)</td></tr><tr><td>Nervousness</td><td>1 (4.8)</td><td>5 (23.8)</td></tr><tr><td> AA homozygotes</td><td>1 (20)</td><td>0 (0)</td></tr><tr><td> C allele carriers</td><td>0 (0)</td><td>5 (31.3)</td></tr><tr><td>Insomnia</td><td>3 (14.3)</td><td>7 (33.3)</td></tr><tr><td> AA homozygotes</td><td>0 (0)</td><td>2 (40.0)</td></tr><tr><td> C allele carriers</td><td>3 (18.8)</td><td>5 (31.3)</td></tr><tr><td>Gastrointestinal problems</td><td>0 (0)</td><td>3 (14.3)</td></tr><tr><td> AA homozygotes</td><td>0 (0)</td><td>1 (20.0)</td></tr><tr><td> C allele carriers</td><td>0 (0)</td><td>2 (12.5)</td></tr><tr><td>Activeness</td><td>3 (14.3)</td><td>6 (28.6)</td></tr><tr><td> AA homozygotes</td><td>2 (40.0)</td><td>1 (20.0)</td></tr><tr><td> C allele carriers</td><td>1 (6.3)</td><td>5 (31.3)</td></tr><tr><td>Irritability</td><td>0 (0)</td><td>2 (9.5)</td></tr><tr><td> AA homozygotes</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td> C allele carriers</td><td>0 (0)</td><td>2 (12.5)</td></tr><tr><td>Muscular pain</td><td>4 (19)</td><td>3 (14.3)</td></tr><tr><td> AA homozygotes</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td> C allele carriers</td><td>4 (25.0)</td><td>3 (18.8)</td></tr><tr><td>Headache</td><td>5 (23.8)</td><td>4 (19.0)</td></tr><tr><td> AA homozygotes</td><td>1 (20)</td><td>1 (20)</td></tr><tr><td> C allele carriers</td><td>4 (25.0)</td><td>3 (18.8)</td></tr></table>
03bd96e1d1a07f972a8bfa3c2371aa9e55ebc1a72f25d214fff3a3834f4ade03.png	simple	<table><tr><td>S.no.</td><td>Lab. no.</td><td>Binary code</td><td>Octal code</td><td>ST</td><td>Lineage</td></tr><tr><td>1</td><td>LN 8</td><td>□□□■■■□■■■■■■■■■■■■■■■■■■■■■□□□□■□■■□□□■■■■</td><td>73777777413071</td><td>Unidentified</td><td>Unidentified</td></tr><tr><td>2</td><td>AC 74</td><td>■□□□□□□■■■■■■■■■■■■■□□□■■■■■□■■■□□□□■■■■■■■</td><td>403777617560771</td><td>Unidentified</td><td>Unidentified</td></tr><tr><td>3</td><td>AC 544</td><td>■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■</td><td>777777777760771</td><td>53</td><td>T1</td></tr><tr><td>4</td><td>F 85</td><td>□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■</td><td>3771</td><td>1</td><td>BEIJING</td></tr><tr><td>5</td><td>F99</td><td>■■■■■■■■■■■■■■■■■■■■■■■■■□■□□□□■□□□□■■■■■■■</td><td>777777775020771</td><td>Unidentified</td><td>Unidentified</td></tr></table>
e1a0a7b3a75f725d8024a435bcd38a565c088f5c9430518aa7bab3e7cfafa785.png	simple	<table><tr><td>Variable</td><td>Dominant</td><td>Non-dominant</td><td>Diff</td><td>AI%</td><td>p value</td><td>Effect size</td></tr><tr><td>Ankle angles (deg)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>DorsiF (+)/PlantF(−)</td><td>11.1 ± 7.6</td><td>12.0 ± 7.3</td><td>0.9</td><td>8</td><td>0.28</td><td>0.41</td></tr><tr><td>Ever(+)/ Inv(−)</td><td>5.4 ± 2.4</td><td>4.5 ± 2.7</td><td>0.9</td><td>17</td><td>0.39</td><td>0.33</td></tr><tr><td>IntR(+)/ExtR(−)</td><td>−33.5 ± 13.2</td><td>−29.1 ± 12.4</td><td>4.4</td><td>14</td><td>0.37</td><td>0.35</td></tr><tr><td>Ankle moments (Nm/kg)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>PlantF(+)/DorsiF(−)</td><td>1.9 ± 0.4</td><td>2.0 ± 0.4</td><td>0.1</td><td>5</td><td>0.59</td><td>0.21</td></tr><tr><td>Ever(+)/ Inv(−)</td><td>0.7 ± 0.2</td><td>0.7 ± 0.1</td><td>0.0</td><td>0</td><td>0.91</td><td>0.04</td></tr><tr><td>IntR(+)/ExtR(−)</td><td>0.1 ± 0.1</td><td>0.2 ± 0.1 *</td><td>0.1</td><td>67</td><td>0.04</td><td>0.74</td></tr><tr><td>Knee angles (deg)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Flex(+)/Ext(−)</td><td>57.4 ± 6.0</td><td>60.3 ± 10.2</td><td>2.9</td><td>5</td><td>0.37</td><td>0.35</td></tr><tr><td>Var(+)/Valg(−)</td><td>−7.5 ± 5.0</td><td>−6.1 ± 7.1</td><td>1.4</td><td>21</td><td>0.54</td><td>0.23</td></tr><tr><td>IntR(+)/ ExtR(−)</td><td>21.2 ± 9.4</td><td>24.7 ± 10.5</td><td>3.5</td><td>15</td><td>0.36</td><td>0.35</td></tr><tr><td>Knee moments (Nm/kg)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ext (+)/Flex(−)</td><td>2.6 ± 0.5</td><td>2.5 ± 0.6</td><td>0.1</td><td>4</td><td>0.84</td><td>0.08</td></tr><tr><td>Valg(+)/Var(−)</td><td>−2.5 ± 1.0</td><td>−2.3 ± 0.8</td><td>0.2</td><td>8</td><td>0.55</td><td>0.23</td></tr><tr><td>IntR(+)/ExtR(−)</td><td>0.4 ± 0.1</td><td>0.3 ± 0.2</td><td>0.1</td><td>29</td><td>0.23</td><td>0.46</td></tr><tr><td>Hip angles (deg)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Flex(+)/Ext(−)</td><td>45.1 ± 11.9</td><td>49.4 ± 15.9</td><td>4.3</td><td>9</td><td>0.42</td><td>0.31</td></tr><tr><td>Add(+)/ Ab(−)</td><td>−17.9 ± 6.7</td><td>−18.0 ± 7.6</td><td>0.1</td><td>1</td><td>0.96</td><td>0.02</td></tr><tr><td>IntR(+)/ExtR(−)</td><td>22.4 ± 10.1</td><td>27.2 ± 12.5</td><td>4.8</td><td>20</td><td>0.27</td><td>0.42</td></tr><tr><td>Hip moments (Nm/kg)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ext (+)/Flex(−)</td><td>4.0 ± 1.4</td><td>4.5 ± 1.6</td><td>0.5</td><td>12</td><td>0.34</td><td>0.37</td></tr><tr><td>Ab(+)/Add(−)</td><td>−3.6 ± 1.4</td><td>−3.3 ± 1.3</td><td>0.3</td><td>9</td><td>0.61</td><td>0.20</td></tr><tr><td>IntR(+)/ExtR(−)</td><td>1.3 ± 0.5</td><td>1.2 ± 0.5</td><td>0.1</td><td>8</td><td>0.91</td><td>0.04</td></tr><tr><td>Pelvis angles (deg)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>AntT(+)/PostT(−)</td><td>2.2 ± 5.1</td><td>3.7 ± 7.5</td><td>1.5</td><td>49</td><td>0.56</td><td>0.23</td></tr><tr><td>Contra Drop(+)/Contra Lift(−)</td><td>15.0 ± 5.9</td><td>14.4 ± 7.8</td><td>0.6</td><td>4</td><td>0.81</td><td>0.09</td></tr><tr><td>IntR(+)/ExtR(−)</td><td>−11.1 ± 13.1</td><td>−11.2 ± 12.3</td><td>0.1</td><td>1</td><td>0.98</td><td>0.01</td></tr><tr><td>Thorax angles (deg)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Flex(+)/Ext(−)</td><td>30.5 ± 5.8</td><td>28.5 ± 6.4</td><td>2.0</td><td>7</td><td>0.41</td><td>0.32</td></tr><tr><td>LatFlex(+)/MedFlex(−)</td><td>21.0 ± 7.9</td><td>21.8 ± 5.5</td><td>0.8</td><td>4</td><td>0.75</td><td>0.12</td></tr><tr><td>ExtR(+)/ IntR(−)</td><td>−11.8 ± 6.6</td><td>−11.6 ± 5.6</td><td>0.2</td><td>2</td><td>0.93</td><td>0.03</td></tr><tr><td>Ground reaction forces (N/kg)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Vertical</td><td>15.1 ± 2.9</td><td>16.9 ± 4.4</td><td>1.8</td><td>11</td><td>0.21</td><td>0.48</td></tr><tr><td>Medial/lateral</td><td>1.3 ± 0.8</td><td>1.5 ± 1.1</td><td>0.2</td><td>14</td><td>0.52</td><td>0.25</td></tr><tr><td>Longitudinal</td><td>9.5 ± 1.7</td><td>10.2 ± 2.7</td><td>0.7</td><td>7</td><td>0.42</td><td>0.31</td></tr><tr><td>Timing (s)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ground contact time</td><td>0.32 ± 0.04</td><td>0.35 ± 0.06</td><td>0.03</td><td>9</td><td>0.11</td><td>0.6</td></tr></table>
f866d059ff9e2e9e43958b73dda26d048f9f3618b5fc1652ccde35e08f4156af.png	complex	<table><tr><td colspan="4">Escalation phase</td><td colspan="3">Extension phase</td></tr><tr><td>Dose level(mg/kg)</td><td>No. of patients</td><td>DLT</td><td>Patients with grade 3–4 lirilumab-related adverse events</td><td>Dose level(mg/kg)</td><td>No. of patients</td><td>Patients with grade 3–4 lirilumab-related adverse events</td></tr><tr><td>0.015</td><td>3</td><td>0</td><td>0</td><td>0.015</td><td>9</td><td>5</td></tr><tr><td>0.3</td><td>3</td><td>0</td><td>0</td><td></td><td></td><td></td></tr><tr><td>1</td><td>4</td><td>0</td><td>0</td><td></td><td></td><td></td></tr><tr><td>3</td><td>4</td><td>0</td><td>0</td><td>3</td><td>8</td><td>2</td></tr><tr><td>6</td><td>3</td><td>0</td><td>1<sup>a</sup></td><td></td><td></td><td></td></tr><tr><td>10</td><td>3</td><td>0</td><td>0</td><td></td><td></td><td></td></tr></table>
10a117046b4327a28e1880d1d547175d136114b5f1b19b1be6158055a90fe48b.png	simple	<table><tr><td>Protein</td><td>Activator</td><td>Repressor</td></tr><tr><td>AP1</td><td>[AP1 SEP]</td><td>[AG AG]</td></tr><tr><td>AP3</td><td>[AP1 SEP], [AG SEP], [AP3 PI]</td><td></td></tr><tr><td>PI</td><td>[AP1 SEP], [AG SEP], [AP3 PI]</td><td></td></tr><tr><td>AG</td><td>[AG SEP], [AG AG]</td><td>[AP1 AP1]</td></tr><tr><td>SHP</td><td>[AG SEP]</td><td>[PI AP3]</td></tr><tr><td>SEP</td><td>[AG SEP], [AP1 SEP], [SEP SEP]</td><td></td></tr></table>
f445175256256a0eb673cc8a54afc8f7f3025f92b9943d5857cc107ae8c7ad0e.png	simple	<table><tr><td>Solvent</td><td>Δ<i>f</i></td><td>Ex</td><td>Em<sub>max</sub></td><td>(vA-vF)*(10<sup>-3</sup>) cm<sup>-1</sup></td><td>Symbols and labels in Figure 3</td></tr><tr><td>AB</td><td>0.32</td><td>275</td><td>388</td><td>10.6</td><td> AB</td></tr><tr><td>AB</td><td>0.32</td><td>280</td><td>389 <sup>a</sup></td><td>10.0</td><td> AB</td></tr><tr><td>AB</td><td>0.32</td><td>237</td><td>396 <sup>a</sup></td><td>16.9</td><td> (AB)</td></tr><tr><td>AN</td><td>0.30</td><td>275</td><td>346 <sup>b</sup></td><td>7.5</td><td> AN</td></tr><tr><td>AN</td><td>0.30</td><td>275</td><td>402 <sup>b</sup></td><td>11.5</td><td> AN</td></tr><tr><td>AN</td><td>0.30</td><td>272</td><td>343 <sup>c</sup></td><td>7.6</td><td> AN</td></tr><tr><td>AN</td><td>0.30</td><td>231</td><td>344 <sup>c</sup></td><td>14.2</td><td> (AN)</td></tr><tr><td>EtOH</td><td>0.30</td><td>275</td><td>365</td><td>9.0</td><td> EtOH</td></tr><tr><td>EtOH</td><td>0.30</td><td>275</td><td>365 <sup>d</sup></td><td>9.0</td><td> EtOH</td></tr><tr><td>EtOH</td><td>0.30</td><td>235</td><td>373 <sup>d</sup></td><td>15.7</td><td> (EtOH)</td></tr><tr><td>DMSO</td><td>0.26</td><td>280</td><td>353</td><td>7.4</td><td> DMSO</td></tr><tr><td>DMSO</td><td>0.26</td><td>276</td><td>351</td><td>7.7</td><td> DMSO</td></tr></table>
b6f7460913ddd51609a6828a52ae7a2e20d89ee91b96056adefce7ca51bf4bd5.png	complex	<table><tr><td rowspan="2">Blend composition</td><td colspan="3">Electrospinning parameters</td></tr><tr><td>Voltage, kV</td><td>Solution supply rate, ml/h</td><td>Distance between spinneret and collector, cm</td></tr><tr><td>3% Tec-80A + 5% GL</td><td>19.0</td><td>1.3</td><td>20</td></tr><tr><td>3% Tec-80A + 10% GL</td><td>18.5</td><td>1.3</td><td>20</td></tr><tr><td>3% Tec-80A + 15% GL</td><td>18.5</td><td>1.2</td><td>19.5</td></tr><tr><td>3% Tec-80A + 20% GL</td><td>20.0</td><td>1.2</td><td>19.5</td></tr><tr><td>5% Tec-80A + 5% GL</td><td>19.5</td><td>1.3</td><td>20</td></tr><tr><td>5% Tec-80A + 10% GL</td><td>22.5</td><td>1.4</td><td>20</td></tr><tr><td>5% Tec-80A + 15% GL</td><td>21.0</td><td>1.4</td><td>18.5</td></tr><tr><td>5% Tec-80A + 20% GL</td><td>20.0</td><td>1.3</td><td>18.5</td></tr><tr><td>7% Tec-80A + 5% GL</td><td>21.0</td><td>1.5</td><td>20</td></tr><tr><td>7% Tec-80A + 10% GL</td><td>22.1</td><td>1.3</td><td>20</td></tr><tr><td>7% Tec-80A + 15% GL</td><td>24.0</td><td>1.2</td><td>19</td></tr><tr><td>7% Tec-80A + 20% GL</td><td>24.0</td><td>1.0</td><td>19</td></tr></table>
2230919cc25a176bc176c47739a007797866abb3fd4655c2cd5271eb1b7e1dfb.png	complex	<table><tr><td> </td><td colspan="4">UEBMI</td><td colspan="4">NCMS</td></tr><tr><td> </td><td>Expenditure (¥)</td><td>Out-of-pocket payment (%)</td><td>Hospital stay (day)</td><td>Expenditure per day (¥)</td><td>Expenditure (¥)</td><td>Out-of-pocket payment (%)</td><td>Hospital stay (day)</td><td>Expenditure per day (¥)</td></tr><tr><td>2004</td><td>4786.32</td><td>2147.93(44.88)</td><td>10.36</td><td>462.00</td><td>4208.13</td><td>3786.05(89.97)</td><td>8.65</td><td>486.49</td></tr><tr><td>2005</td><td>4956.01</td><td>2113.56(42.65</td><td>10.45</td><td>474.26</td><td>4430.15</td><td>3889.23(87.79)</td><td>8.14</td><td>544.24</td></tr><tr><td>2006</td><td>4869.11</td><td>2032.97(41.75)</td><td>11.08</td><td>439.45</td><td>4275.56</td><td>3653.04(85.44)</td><td>7.46</td><td>573.13</td></tr><tr><td>2007</td><td>9935.18</td><td>2990.43(30.10)</td><td>14.67</td><td>677.24</td><td>4485.92</td><td>3803.16(84.78)</td><td>9.03</td><td>496.78</td></tr><tr><td>2008</td><td>6908.14</td><td>2561.68(37.08)</td><td>13.11</td><td>526.94</td><td>4362.49</td><td>3693.41(84.66)</td><td>8.20</td><td>532.01</td></tr><tr><td>2009</td><td>7080.39</td><td>2416.01(34.12)</td><td>14.02</td><td>505.02</td><td>5596.96</td><td>4375.81(78.18)</td><td>10.28</td><td>544.45</td></tr><tr><td>2010</td><td>7299.08</td><td>2277.33(31.20)</td><td>13.87</td><td>526.25</td><td>5875.66</td><td>3874.93(65.95)</td><td>10.39</td><td>565.51</td></tr><tr><td>2011</td><td>6458.69</td><td>1669.90(25.86)</td><td>12.68</td><td>509.36</td><td>5590.74</td><td>3099.93(55.45)</td><td>9.84</td><td>568.16</td></tr><tr><td>2012 1<sup>st</sup>half</td><td>5830.09</td><td>1427.57(24.49)</td><td>10.17</td><td>573.26</td><td>5903.05</td><td>2596.72(43.99)</td><td>10.38</td><td>568.69</td></tr></table>
a0fed634a847eb48e3f721386b2f7ee042d21fe7a86710b48141f3f57195eaef.png	simple	<table><tr><td>Gene</td><td>Accession number</td><td>Probe sequence (5′-> 3′)</td></tr><tr><td>Cd68</td><td>NM_001031638</td><td>ATCCTCATTTCTTCAGCATGCAATTGACTCAACAGAGTTATCTCCCTTCTCTGTCTTTAAA</td></tr><tr><td>RT1-B<sup>b</sup></td><td>NM_001004084</td><td>CAGCTGTGACAGTTGTGAAATACCCTAGCTTCTGATAACAGAATGAGTTACTTCTTCCCAA</td></tr><tr><td>Cd86</td><td>NM_020081</td><td>TAAGCAAGGATACCCGAAACCTACAAAGATGTATTTTTTGATAACTAATA</td></tr><tr><td>Cd80</td><td>NM_012926</td><td>TGAATCTGAGCTGTACACCATTAGTAGCCAACTAGACTTCAACACGACGTACGACCACTTA</td></tr><tr><td>Ccl17</td><td>NM_057151</td><td>CTGCACAGACCCCAAAGACAAGCATGTGAAGAAGGCCATCAGACACCTGAAAAACCAAAGA</td></tr><tr><td>Ccl22</td><td>NM_057203</td><td>GATATCTGTGCTGACCCCAGGATGCTCTGGGTGAAGAAGATACTCCACAAGTTGGCCTAGA</td></tr><tr><td>Ccl22</td><td>NM_057203</td><td>AAATAAATTTGCTTGCTCCTTTGGAGGGAACAGTGGCCTGGCTTAGCTGAGTGAATGGATA</td></tr><tr><td>II12a</td><td>NM_053390</td><td>ACTTCAGAGCCACAATCATCAGCAGATCACTCTGGACAGAAACATGCTGATGGCTATTGAA</td></tr><tr><td>II12b</td><td>NM_022611</td><td>TTGGTCCACCGAGATTTTAAAAAATTTCAAAAATAAGACTTTCCTGAAGTGTGAAGCACCA</td></tr><tr><td>Cd40</td><td>NM_134360</td><td>ATGGAGGAAAAGCTTTGGCGTCAGGGGTCCGCAGTAATATCTACAGAGTGCAGCAATGCAA</td></tr><tr><td>Cd40</td><td>NM_134360</td><td>ACTGCACAGCTCTTGAGAAGACCCAATGCCAACCGTGCGACTCAGGCGAATTCTCAGCTCA</td></tr><tr><td>Ox40L</td><td>NM_053552</td><td>TTGTGTTACAATACAGTGCGTATGTCTTGAACCTCCAGAAAGTCTGAAGGCTACTAATCCA</td></tr></table>
eff8e68bafd953e895ee9285333302ab040168cd8521cd02fff737e0fdd1ef3a.png	complex	<table><tr><td rowspan="2">Variables</td><td rowspan="2">Number (n)</td><td colspan="2">R-Ras expression</td><td rowspan="2"><i>p</i>-value</td></tr><tr><td>Positive (n=83)</td><td>Negative (n=109)</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td>0.389</td></tr><tr><td> Male</td><td>112</td><td>45</td><td>67</td><td></td></tr><tr><td> Female</td><td>80</td><td>38</td><td>42</td><td></td></tr><tr><td>Ages (years)</td><td></td><td></td><td></td><td>0.528</td></tr><tr><td> >=65</td><td>91</td><td>42</td><td>49</td><td></td></tr><tr><td> <65</td><td>101</td><td>41</td><td>60</td><td></td></tr><tr><td>Tumor location</td><td></td><td></td><td></td><td>0.661</td></tr><tr><td> ascending colon</td><td>97</td><td>41</td><td>56</td><td></td></tr><tr><td> transverse colon</td><td>7</td><td>2</td><td>5</td><td></td></tr><tr><td> descending colon</td><td>88</td><td>40</td><td>48</td><td></td></tr><tr><td>CEA level (mg/L)</td><td></td><td>7.20±7.00</td><td>17.46±34.66</td><td>0.008<sup>*</sup></td></tr><tr><td>Tumor differentiation</td><td></td><td></td><td></td><td>0.886</td></tr><tr><td> Well</td><td>21</td><td>10</td><td>11</td><td></td></tr><tr><td> Moderate</td><td>135</td><td>57</td><td>78</td><td></td></tr><tr><td> Poor</td><td>36</td><td>16</td><td>20</td><td></td></tr><tr><td>AJCC stage</td><td></td><td></td><td></td><td>0.751</td></tr><tr><td> IIIA</td><td>7</td><td>4</td><td>3</td><td></td></tr><tr><td> IIIB</td><td>124</td><td>53</td><td>71</td><td></td></tr><tr><td> IIIC</td><td>61</td><td>26</td><td>35</td><td></td></tr></table>
e2e7191040fb4419f3fae2679d3706056963bb4f8438277e1bd514f159baba36.png	simple	<table><tr><td>Clinical parameters</td><td>Correlation coefficient</td><td>P-value (2-tailed)</td></tr><tr><td>CEA</td><td>−0.023</td><td>0.885</td></tr><tr><td>CA125</td><td>−0.025</td><td>0.883</td></tr><tr><td>CA153</td><td>0.007</td><td>0.966</td></tr><tr><td>CA199</td><td>−0.048</td><td>0.761</td></tr><tr><td>CA724</td><td>0.175</td><td>0.288</td></tr><tr><td>CYFRA21-1</td><td>−0.110</td><td>0.493</td></tr><tr><td>NSE</td><td>−0.168</td><td>0.308</td></tr><tr><td>SCC</td><td>−0.398</td><td>0.012<sup>a</sup></td></tr></table>
2972820ffda8da206ef95f5b44b7f9e02f98d5a5734c21c5638a2dc5571a44d2.png	complex	<table><tr><td></td><td></td><td colspan="3">Women</td><td colspan="3">Men</td></tr><tr><td>Increased use</td><td></td><td>OR</td><td colspan="2">95% CI</td><td>OR</td><td colspan="2">95% CI</td></tr><tr><td>Any substance</td><td>PTSD symptoms</td><td>1.143</td><td>1.112</td><td>1.174</td><td>1.108</td><td>1.088</td><td>1.129</td></tr><tr><td></td><td>Exposure to incident</td><td>1.215</td><td>1.080</td><td>1.367</td><td>1.106</td><td>1.000</td><td>1.223</td></tr><tr><td>Pharmaceuticals</td><td>PTSD symptoms</td><td>1.172</td><td>1.125</td><td>1.221</td><td>1.139</td><td>1.103</td><td>1.176</td></tr><tr><td></td><td>Exposure to incident</td><td>1.304</td><td>1.122</td><td>1.517</td><td>1.206</td><td>1.042</td><td>1.397</td></tr><tr><td>Alcohol</td><td>PTSD symptoms</td><td>1.116</td><td>1.074</td><td>1.159</td><td>1.110</td><td>1.086</td><td>1.135</td></tr><tr><td></td><td>Exposure to incident</td><td>1.177</td><td>1.010</td><td>1.372</td><td>1.008</td><td>0.892</td><td>1.139</td></tr><tr><td>Cannabis</td><td>PTSD symptoms</td><td>1.148</td><td>1.057</td><td>1.246</td><td>1.101</td><td>1.068</td><td>1.135</td></tr><tr><td></td><td>Exposure to incident</td><td>1.517</td><td>1.180</td><td>1.951</td><td>1.076</td><td>0.918</td><td>1.261</td></tr><tr><td>Tobacco</td><td>PTSD symptoms</td><td>1.098</td><td>1.066</td><td>1.132</td><td>1.078</td><td>1.055</td><td>1.100</td></tr><tr><td></td><td>Exposure to incident</td><td>1.095</td><td>0.959</td><td>1.250</td><td>1.117</td><td>0.999</td><td>1.249</td></tr></table>
bc72c638101c3f9e34b20f8676f73fdf4a6c69803c5bcf32614a9b9d09e589a1.png	complex	<table><tr><td></td><td colspan="2">3 weeks</td><td colspan="2">5 weeks</td></tr><tr><td></td><td>HF</td><td>HFPL</td><td>HF</td><td>HFPL</td></tr><tr><td></td><td>(n = 10)</td><td>(n = 8)</td><td>(n = 9)</td><td>(n = 10)</td></tr><tr><td>Initial body wt (g)</td><td>17.6 ± 0.5</td><td>17.1 ± 0.9</td><td>18.0 ± 0.5</td><td>17.6 ± 0.8</td></tr><tr><td>Final body wt (g)</td><td>23.6 ± 0.5</td><td>23.8 ± 0.6</td><td>27.7 ± 0.6</td><td>28.8 ± 0.8</td></tr><tr><td>Wt gain (g)</td><td>6.0 ± 0.3</td><td>6.7 ± 0.6</td><td>9.7 ± 0.7</td><td>11.3 ± 0.5</td></tr><tr><td>Liver wt (g)</td><td>1.20 ± 0.04</td><td>1.07 ± 0.06</td><td>1.35 ± 0.06</td><td>1.29 ± 0.04</td></tr><tr><td>Liver wt/body wt (g/100 g)</td><td>5.07 ± 0.17</td><td>4.48 ± 0.15 *</td><td>4.90 ± 0.20</td><td>4.47 ± 0.09</td></tr><tr><td>Food intake (g/mouse/day)</td><td>3.5 ± 0.3</td><td>3.2 ± 0.1</td><td>2.9 ± 0.1</td><td>3.1 ± 0.1</td></tr><tr><td>Fecal excretion (g/mouse/day)</td><td>0.23 ± 0.02</td><td>0.26 ± 0.01</td><td>0.23 ± 0.01</td><td>0.22 ± 0.01</td></tr></table>
c2c8769a0dda7e26240b01ae46f5563e1206b91130d08adecf6f830aa27b5fcb.png	complex	<table><tr><td rowspan="2">Model 2</td><td>B</td><td>SE</td><td>HR</td><td colspan="2">95% CI</td><td rowspan="2">p</td></tr><tr><td></td><td></td><td></td><td>Inferior</td><td>Superior</td></tr><tr><td>Male gender</td><td>.68</td><td>.23</td><td>1.97</td><td>1.27</td><td>3.08</td><td>0.003</td></tr><tr><td>Age</td><td>.09</td><td>.01</td><td>1.09</td><td>1.06</td><td>1.12</td><td><0.001</td></tr><tr><td>Lipid-lowering drugs</td><td>-.57</td><td>.24</td><td>.56</td><td>.35</td><td>.91</td><td>0.019</td></tr><tr><td>Triglycerides ADA categories</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- Satisfying criteria</td><td></td><td></td><td>1</td><td></td><td></td><td>0.025</td></tr><tr><td>- Partially satisfying criteria</td><td>.72</td><td>.30</td><td>2.05</td><td>1.14</td><td>3.68</td><td>0.017</td></tr><tr><td>- Not satisfying criteria</td><td>.55</td><td>.24</td><td>1.73</td><td>1.08</td><td>2.77</td><td>0.022</td></tr><tr><td>Antidiabetic treatment</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- Diet</td><td></td><td></td><td>1</td><td></td><td></td><td>0.006</td></tr><tr><td>- Biguanides</td><td>-.79</td><td>.38</td><td>.45</td><td>.22</td><td>.96</td><td>0.038</td></tr><tr><td>- Sulfonylureas</td><td>-.73</td><td>.64</td><td>.48</td><td>.14</td><td>1.68</td><td>0.253</td></tr><tr><td>- Biguanides + Sulfonylureas</td><td>-.86</td><td>.35</td><td>.42</td><td>.21</td><td>.84</td><td>0.014</td></tr><tr><td>- Insulin</td><td>.17</td><td>.35</td><td>1.18</td><td>.60</td><td>2.33</td><td>0.630</td></tr><tr><td>- Insulin + OHA</td><td>-.18</td><td>.37</td><td>.84</td><td>.41</td><td>1.72</td><td>0.631</td></tr></table>
811722f84b8d9ff3acf3bdbab19c27ad19c1612dba2dc49d9ec3bb6425560193.png	complex	<table><tr><td>Threshold on Wells scale = 2</td><td>Thrombosis</td><td>Without Thrombosis</td></tr><tr><td>Number of points on the Wells scale: >2</td><td>40</td><td>60</td></tr><tr><td>Number of points on the Wells scale: ≤2</td><td>20</td><td>928</td></tr><tr><td>Sensitivity: 66.66%</td><td colspan="2">Positive predictive value: 40.00%</td></tr><tr><td>Specificity: 93.93%</td><td colspan="2">Negative predictive value: 97.89%</td></tr></table>
07e23531990c097fa14476b97e30446c4cf991e745fbf918f260e7c70b9c8af8.png	complex	<table><tr><td></td><td colspan="5">Probabilities</td></tr><tr><td>Variable</td><td><i>No RX</i></td><td><i>rFVIIa (40 mcg)</i></td><td><i>rFVIIa (80 mcg)</i></td><td>Utilities</td><td><i>Range</i></td></tr><tr><td>Mild post-ICH deficit (mRS 0–1)</td><td>0. 08</td><td>0. 17</td><td>0. 21</td><td>0. 81</td><td>0. 70–0. 95</td></tr><tr><td>Moderate post-ICH deficit (mRS 2–3)</td><td>0. 23</td><td>0. 29</td><td>0. 29</td><td>0. 55</td><td>0. 2–0. 65</td></tr><tr><td>Severe post-ICH deficit (mRS 4–5)</td><td>0. 40</td><td>0. 37</td><td>0. 30</td><td>0. 25</td><td>(-0. 2)-0. 45</td></tr><tr><td>Death after ICH</td><td>0. 29</td><td>0. 18</td><td>0. 18</td><td>0</td><td>0</td></tr><tr><td>Arterial thromboembolic event</td><td></td><td>0. 02</td><td>0. 02</td><td>0. 55</td><td></td></tr><tr><td>Probability of dying after ATE</td><td></td><td>0. 29</td><td>0. 29</td><td></td><td></td></tr></table>
9d518739fc19da9cbe17f839963dafa2663209a7ed2db57b203b53d8807e7b3b.png	simple	<table><tr><td> </td><td>1.5T SSFP 1.2x1.2x6mm<sup>3</sup></td><td>7T FGRE 1.2x1.2x6mm<sup>3</sup></td><td>7T FGRE 1.3x1.3x4mm<sup>3</sup></td><td>p-value</td></tr><tr><td>RVEDV [ml]</td><td> </td><td> </td><td> </td><td>0.5850</td></tr><tr><td>Median</td><td>146.2</td><td>138.6</td><td>152.1</td><td> </td></tr><tr><td>Min. - Max.</td><td>127.4 - 202.3</td><td>124-0 - 207.7</td><td>121.4 - 222.8</td><td> </td></tr><tr><td>RVESV [ml]</td><td> </td><td> </td><td> </td><td>0.5462</td></tr><tr><td>Median</td><td>65.2</td><td>62.4</td><td>69.3</td><td> </td></tr><tr><td>Min. - Max.</td><td>57.4 - 91.1</td><td>53.7 - 93.5</td><td>54.6 - 103.6</td><td> </td></tr><tr><td>RVEF [%]</td><td> </td><td> </td><td> </td><td>0.2789</td></tr><tr><td>Median</td><td>55.0</td><td>56.7</td><td>55</td><td> </td></tr><tr><td>Min. - Max.</td><td>54 - 57</td><td>54 - 58</td><td>54 - 58</td><td> </td></tr><tr><td>RVM [g]</td><td> </td><td> </td><td> </td><td>0.0743</td></tr><tr><td>Median</td><td>35</td><td>36</td><td>33</td><td> </td></tr><tr><td>Min. - Max.</td><td>26 - 49</td><td>24 - 53</td><td>26 - 51</td><td> </td></tr></table>
5f366d6745474851aa3e7d5521ea9ed0a6f95daaf03a89716e8437c3fd73ec14.png	complex	<table><tr><td>Country</td><td>Existing laws alluding to quality and patient safety</td></tr><tr><td rowspan="2">Jordan</td><td>In Jordanian law, the Public Health Code includes articles that emphasize the state’s responsibility to provide healthcare, and the Ministry of Health’s responsibility regarding health matters as follows: - Provide illness prevention, curative measures and supervisory services. - Organize and supervise private and public sector health services. - Provide citizens with health insurance within the allotted parameters. - Establish health, educational and training institutions related to the Ministry and to supervise their management once established.</td></tr><tr><td>As stipulated in Jordanian Law 9 (1999), the High Health Council is responsible for drafting health policies and developing strategic plans as well as planning health services to ensure equitable access to and provision of outstanding health services to all population. Other institutions include Jordanian Medical Council, Supreme Council for Population, Jordanian Nursing Council, National Council for Family Affairs, General Organization for Food and Drug Administration and Department of Joint Procurement</td></tr><tr><td>Lebanon</td><td>The Ministerial Decree 7612, issued by the parliament in 2002, which amends the legislative decree 139/83 (1983), states that “the MOPH has the right to evaluate, classify and accredit hospitals according to their status, field of specialty and range of services provided”. The decree 482/1 (2009) sets a national Committee for Accreditation of Hospitals, chaired by the Director General of Health.</td></tr></table>
1bd418ad17484dd8463c95684fc3d68b6be599b26b44ce3a018cfd822421ba36.png	simple	<table><tr><td>Type of paper</td><td>EpidemiologyN papers (%)N citations</td><td>Eur Respir JN papers (%)N citations</td></tr><tr><td>National</td><td>17 (71)53</td><td>10 (53)18</td></tr><tr><td>(US)</td><td>9 (38)68</td><td>1 (5)6</td></tr><tr><td>(other)</td><td>8 (33)37</td><td>9 (48)18</td></tr><tr><td>International</td><td>7 (29)54</td><td>9 (48)23</td></tr><tr><td>Inter-European</td><td>1 (4)16</td><td>6 (32)25</td></tr></table>
b431b4af9df6f8163bbccbdd90615c9e26e318e2eeaa2c7df5768ff8b6e1c766.png	simple	<table><tr><td>Patients</td><td>Professionals</td></tr><tr><td>- Do you know anything about lifestyle modification (diet, exercise, etc.) in order to change your mood and depression?- All of you have taken part in a research project about modifying lifestyles. Did these recommendations that were given to you show you something new that you did not know?- Did you follow the recommendations for modifying lifestyles?If NOT, why didn’t you follow them?- How did you feel when you followed the recommendations? And when you didn’t?- What difficulties did you encounter in implementing the recommendations?- Do you think these recommendations helped you?- What do you think about the doctor’s role?- And about the way of carrying out this modification?- Do you think another type of intervention would have helped you? Would an educational group or another kind of intervention have helped you?- Do you think there is something more that can be done to help you to modify your lifestyle when depressed?</td><td>- How do you think you should make recommendations for modifying life styles?- And to a patient with depression?- Do you know how this intervention can help him/her?- Do you think these recommendations can be effective? And do you believe the patient thinks that they work?- What difficulties do you think depressed patients have in changing their behaviour?- And what feelings do they have?- And as for modifying lifestyles, do you work in a different way in the case of a depressed patient?- What do you think is necessary in order to be effective when modifying lifestyles?- What do you think about educational groups?- And about follow-up?- Do you think these interventions are feasible from PC?- What difficulties do you encounter when giving this type of advice?- What is the appropriate level (or department or system) to implement this kind of interventions?</td></tr></table>
ce26ba3a0847e8e040f92d0a769be3317248b0c8fc4de91c97df3c28ac3d16f2.png	simple	<table><tr><td> </td><td>Risperidone</td><td>Olanzapine</td><td>Quetiapine</td><td>Ziprasidone</td><td>Aripiprazole</td><td>FGAs</td><td>No medication</td></tr><tr><td>Subjects (M/F)</td><td>47 (35/12)</td><td>13 (6/7)</td><td>44 (29/15)</td><td>2 (2/0)</td><td>1 (0/1)</td><td>5 (3/2)</td><td>39 (22/17)</td></tr><tr><td>Mean Age (SD)</td><td>11.54 (3.13)</td><td>15.16 (2.12)</td><td>13.31 (2.97)</td><td>14.63 (0.36)</td><td>16.77</td><td>15.22 (1.16)</td><td>11.88 (3.27)</td></tr><tr><td>Mean Dose mg (SD)</td><td>1.18 (0.78)</td><td>10.77 (4.83)</td><td>196.02 (175.58)</td><td>30.00 (14.14)</td><td>7.50</td><td>-</td><td>-</td></tr><tr><td>CPZ Equiv mg (SD)</td><td>58.78 (39.09)</td><td>215.38 (96.58)</td><td>261.36 (234.10)</td><td>50.00 (23.57)</td><td>100.00</td><td>119.29 (111.33)</td><td>-</td></tr><tr><td>On-Label Use (% of total on drug)</td><td>11 (23.4)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>1 (100.0)</td><td>0 (0.0)</td><td>-</td></tr><tr><td>Off-Label Use (% of total on drug)</td><td>36 (76.6)</td><td>13 (100.0)</td><td>44 (100.0)</td><td>2 (100.0)</td><td>0 (0.0)</td><td>5 (100.0)</td><td>-</td></tr><tr><td>Titrated Switch Pre Hosp (% of switches)</td><td>1 (3.1)</td><td>2 (6.3)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>1 (3.1)</td><td>2 (6.3)</td></tr><tr><td>Titrated Switch Post Hosp (% of switches)</td><td>1 (3.1)</td><td>2 (6.3)</td><td>2 (6.3)</td><td>0 (0.0)</td><td>1 (3.1)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr><tr><td>Immediate Switch Pre Hosp (% of switches)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>2 (6.3)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>2 (6.3)</td></tr><tr><td>Immediate Switch Post Hosp (% of switches)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr><tr><td>Gap Switch Pre Hosp (% of switches)</td><td>0 (0.0)</td><td>2 (6.3)</td><td>3 (9.4)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>3 (9.4)</td></tr><tr><td>Gap Switch Post Hosp (% of switches)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr><tr><td>Overlapped Switch Pre Hosp (% of switches)</td><td>3 (9.4)</td><td>1 (3.1)</td><td>4 (12.5)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>2 (6.3)</td></tr><tr><td>Overlapped Switch Post Hosp (% of switches)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>1 (3.1)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>0 (0.0)</td></tr></table>
6b70adadc433bce890c369b0f1a8fd5a9fc5f9c82e76c355b33f92289c6e5c5a.png	simple	<table><tr><td>Process</td><td>2<sup>o </sup>rate constant (#min<sup>-1</sup>)</td><td>Enzyme</td><td>Enz #</td><td>1<sup>o </sup>rate const (min<sup>-1</sup>)</td><td>PTM modifying rate</td><td>Rate MF</td><td>Reference</td></tr><tr><td>Synthesis (NULL → FOXO)</td><td>0.0055</td><td>E2F1</td><td>300</td><td>5.5</td><td> </td><td> </td><td>[45] Figure 1</td></tr><tr><td>Cytoplasm → nuclear transport</td><td>-</td><td>-</td><td>-</td><td>0.1/0.55 = 0.182</td><td> </td><td> </td><td>[3], [46]</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Akt-Phos Pa</td><td>0.1</td><td>[46]</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>IKK-Phos Pd</td><td>0.5</td><td>[47] Figure 1</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>JNK-Phos Pe</td><td>10</td><td>[44]</td></tr><tr><td>Nuclear → cytoplasm transport</td><td>-</td><td>-</td><td>-</td><td>0.1 × 0.55 = 0.055</td><td> </td><td> </td><td>[3], [46]</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Akt-Phos Pa</td><td>10</td><td>[46]</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>IKK-phos Pd</td><td>10</td><td>[47]</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>JNK-Phos Pe</td><td>0.1</td><td>[44]</td></tr><tr><td>Nuclear → DNAbound transport</td><td>-</td><td>-</td><td>-</td><td>0.25</td><td> </td><td> </td><td>[48]</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Akt-Phos Pa</td><td>0.5</td><td>[49] Figure 6B</td></tr><tr><td>DNAbound → Nuclear transport</td><td>-</td><td>-</td><td>-</td><td>0.25 × 0.5 = 0.125</td><td> </td><td> </td><td>[48]</td></tr><tr><td>basal phosphorylation</td><td>5 × 10<sup>-5</sup></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>basal dephosphorylation</td><td>1 × 10<sup>-6</sup></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>akt_phos_factor</td><td>6</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>ikk phos_factor</td><td>3</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>jnk phos_factor</td><td>2</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>FOXO → FOXO_Pa</td><td>akt phos_factor × basal phosphorylation</td><td>Akt</td><td>(10<sup>4</sup>)</td><td>0.5</td><td> </td><td> </td><td>[50] Figure 1C</td></tr><tr><td>FOXO_Pa → FOXO</td><td>basal dephosphorylation</td><td>PP2A</td><td>5 × 10<sup>5</sup></td><td>0.5</td><td> </td><td> </td><td> </td></tr><tr><td>FOXO → FOXO_Pd</td><td>ikk phos_factor × basal phosphorylation</td><td>IKK</td><td>(10<sup>4</sup>)</td><td>0.5</td><td> </td><td> </td><td>[47]</td></tr><tr><td>FOXO_Pd → FOXO</td><td>basal dephosphorylation</td><td>PP2A</td><td>5 × 10<sup>5</sup></td><td>0.5</td><td> </td><td> </td><td> </td></tr><tr><td>FOXO → FOXO_Pe</td><td>jnk phos_factor × basal phosphorylation</td><td>JNK</td><td>(10<sup>4</sup>)</td><td>0.5</td><td> </td><td> </td><td>[44]</td></tr><tr><td>FOXO_Pe → FOXO</td><td>basal dephosphorylation</td><td>PP2A</td><td>5 × 10<sup>5</sup></td><td>0.5</td><td> </td><td> </td><td> </td></tr><tr><td>FOXO → FOXO_pUb</td><td>1 × 10<sup>-6</sup></td><td>SCF/MDM2</td><td>10<sup>3</sup></td><td>10<sup>-3</sup></td><td> </td><td> </td><td>[45] Figure 1; also [51]</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Akt (Pa)</td><td>3</td><td>[45] Figure 1</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>IKK (Pd)</td><td>22</td><td>[47] Figure 5F</td></tr><tr><td>Degradation (FOXO_pUb → NULL)</td><td>1 × 10<sup>-4</sup></td><td>Proteasome</td><td>10<sup>3</sup></td><td>0.1</td><td> </td><td> </td><td>[45] Figure 1</td></tr></table>
80144ae0976f83febf9062f721907d1ce71d026636545456d15be48e15d51f4d.png	simple	<table><tr><td>Family</td><td>Species</td><td>Size of mt DNA (bp)</td><td>GenBank accession no.</td></tr><tr><td>Babesiidae</td><td><i>B. orientalis</i></td><td>5996</td><td>KF218819</td></tr><tr><td> </td><td><i>B. bovis</i></td><td>6005</td><td>EU075182</td></tr><tr><td> </td><td><i>B. bovis</i></td><td>5970</td><td>AB499088</td></tr><tr><td> </td><td><i>B. bigemina</i></td><td>5924</td><td>AB499085</td></tr><tr><td> </td><td><i>B. caballi</i></td><td>5847</td><td>AB499086</td></tr><tr><td> </td><td><i>B. gibsoni</i></td><td>5865</td><td>AB499087</td></tr><tr><td> </td><td><i>B. rodhaini</i></td><td>6929</td><td>AB624357</td></tr><tr><td>Theileriidae</td><td><i>T. parva</i></td><td>5895</td><td>Z23263</td></tr><tr><td> </td><td><i>T. parve</i></td><td>5924</td><td>AB499089</td></tr><tr><td> </td><td><i>T. equi</i></td><td>8246</td><td>AB499091</td></tr><tr><td> </td><td><i>T. orientalis</i></td><td>5957</td><td>AB499090</td></tr><tr><td> </td><td><i>T. annulata</i></td><td>5905</td><td>NT167255</td></tr><tr><td>Plasmodiidae</td><td><i>P. falciparum</i></td><td>5967</td><td>M76611</td></tr></table>
5f58c0352ce89fed92ec8b336522dacc5237a95cecc940b9e20ef018bf4b8b7c.png	complex	<table><tr><td>Simulation</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td></tr><tr><td></td><td colspan="4">First 1,000 iterations (the initial peak number = 11)</td><td></td><td></td></tr><tr><td>peak birth (RGP)</td><td>0.00E-4</td><td>0.00E-4</td><td>0.00E-4</td><td>0.00E-4</td><td>0.00E-4</td><td>0.00E-4</td></tr><tr><td>peak birth (RJ)</td><td>0.00E-4</td><td>0.00E-4</td><td>0.00E-4</td><td>0.00E-4</td><td>0.00E-4</td><td>0.00E-4</td></tr><tr><td>peak death (RGP)</td><td>6.70E-3</td><td>1.55E-2</td><td>1.55E-2</td><td>1.33E-2</td><td>1.55E-2</td><td>1.55E-2</td></tr><tr><td>peak death (RJ)</td><td>6.70E-3</td><td>1.55E-2</td><td>1.55E-2</td><td>1.33E-2</td><td>1.55E-2</td><td>1.55E-2</td></tr><tr><td>peak mutation (RGP)</td><td>1.72E-2</td><td>3.53E-2</td><td>3.94E-2</td><td>1.30E-2</td><td>5.90E-3</td><td>2.73E-2</td></tr><tr><td>peak mutation (RJ)</td><td>1.93E-2</td><td>3.33E-2</td><td>4.42E-2</td><td>1.30E-2</td><td>5.90E-3</td><td>2.17E-2</td></tr><tr><td></td><td colspan="4">First 50,000 iterations (the initial peak number = 1)</td><td></td><td></td></tr><tr><td>peak birth (RGP)</td><td>1.70E-4</td><td>1.26E-4</td><td>1.26E-4</td><td>1.70E-4</td><td>1.27E-4</td><td>8.50E-5</td></tr><tr><td>peak birth (RJ)</td><td>1.27E-4</td><td>1.26E-4</td><td>8.44E-5</td><td>1.28E-4</td><td>1.27E-4</td><td>8.43E-5</td></tr><tr><td>peak death (RGP)</td><td>0.00E-4</td><td>4.26E-5</td><td>2.12E-4</td><td>4.20E-5</td><td>2.53E-4</td><td>7.59E-4</td></tr><tr><td>peak death (RJ)</td><td>1.26E-4</td><td>4.25E-5</td><td>2.54E-4</td><td>4.20E-5</td><td>4.21E-5</td><td>7.21E-4</td></tr><tr><td>peak mutation (RGP)</td><td>1.71E-2</td><td>4.27E-2</td><td>4.08E-2</td><td>1.21E-2</td><td>8.96E-3</td><td>1.02E-2</td></tr><tr><td>peak mutation (RJ)</td><td>1.56E-2</td><td>3.04E-2</td><td>4.90E-2</td><td>8.51E-3</td><td>6.38E-3</td><td>1.41E-2</td></tr></table>
ee7433d8eb80567c828b2d9880eca8a14ed7898fff33bc9760c6ecaabeef7919.png	complex	<table><tr><td></td><td colspan="2">Cause of hospitalization</td><td colspan="2">Cause of death</td></tr><tr><td>Event</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>WHO stage 2 events</td><td>1</td><td>0.65</td><td>0</td><td>0</td></tr><tr><td>WHO 3 non-specific events</td><td>10</td><td>6.45</td><td>0</td><td>0</td></tr><tr><td>WHO 3 severe events</td><td>58</td><td>37.42</td><td>11</td><td>44</td></tr><tr><td>WHO stage 4 events</td><td>29</td><td>18.71</td><td>10</td><td>40</td></tr><tr><td>WHO stage 4 cachexia</td><td>9</td><td>5.81</td><td>0</td><td>0</td></tr><tr><td>Non-AIDS-defining infection</td><td>42</td><td>27.10</td><td>4</td><td>16</td></tr><tr><td>Non-AIDS-defining disease</td><td>3</td><td>1.94</td><td>0</td><td>0</td></tr><tr><td>Secondary effects to treatment</td><td>2</td><td>1.29</td><td>0</td><td>0</td></tr><tr><td>Uncategorised</td><td>1</td><td>0.65</td><td>0</td><td>0</td></tr><tr><td>Total</td><td>155</td><td>100.00</td><td>25</td><td>100</td></tr></table>
5af0831cd86822835fe3f27beb9056f48f7d5868f90c81d20811e0e426e761ca.png	complex	<table><tr><td colspan="2">Microscopy</td><td colspan="8">PCR</td></tr><tr><td></td><td>N</td><td>Pf</td><td>Pv</td><td>Pm</td><td>Po</td><td>Pf/Pv</td><td>Pf/Pm</td><td>Pv/Po</td><td>Negative</td></tr><tr><td>Pf</td><td>135</td><td>117</td><td>2</td><td>0</td><td>0</td><td>13</td><td>3</td><td>0</td><td>0</td></tr><tr><td>Pv</td><td>94</td><td>0</td><td>82</td><td>0</td><td>2</td><td>9</td><td>0</td><td>1</td><td>0</td></tr><tr><td>Pm</td><td>1</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Pf/Pv</td><td>31</td><td>0</td><td>0</td><td>0</td><td>0</td><td>30</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Negative</td><td>864</td><td>23</td><td>15</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>826</td></tr><tr><td>Total</td><td>1125</td><td>140</td><td>99</td><td>1</td><td>2</td><td>52</td><td>4</td><td>1</td><td>826</td></tr></table>
56ecfc0332493b2eecaa64ee7588e6157ad691e7d5e4c369c7b4ecf339f7815e.png	complex	<table><tr><td></td><td colspan="5">Patient N°</td></tr><tr><td></td><td>1.</td><td>2.</td><td>3.</td><td>4.</td><td>5.</td></tr><tr><td>Duration of tube feeding (days)</td><td>7</td><td>15</td><td>8</td><td>6</td><td>9</td></tr><tr><td>Parenteral nutritional support</td><td>none</td><td>none</td><td>12 kcal/kg/day (9 days)</td><td>none</td><td>none</td></tr><tr><td>The start of liquid diet <i>per os</i></td><td>4</td><td>7</td><td>7</td><td>6</td><td>6</td></tr><tr><td>Cumulative nitrogen balance during first 7 days after surgery</td><td>-6 grams</td><td>-18 grams</td><td>4 grams</td><td>0 gram</td><td>-8 grams</td></tr><tr><td>ICU free days</td><td>9</td><td>23</td><td>12</td><td>9</td><td>9</td></tr><tr><td>Length of hospital stay</td><td>10</td><td>28</td><td>12</td><td>9</td><td>12</td></tr><tr><td>Complications</td><td>none</td><td>myocardial infarction</td><td>urinary infection</td><td>none</td><td>wound infection</td></tr><tr><td>Outcome</td><td>discharged</td><td>died in 28<sup>th </sup>post day</td><td>discharged</td><td>discharged</td><td>discharged</td></tr></table>
b41e5eb1b95cbbf07c4963ea6e8d0df467a6e654aeb8de65a2e6d0253b7d8b11.png	complex	<table><tr><td></td><td colspan="2">Age < 30 years (n =3148)</td><td colspan="2">Age 30-39 years (n = 9310)</td><td colspan="2">Age 40-49 years (n = 13747)</td><td colspan="2">Age ≥ 50 years (n = 3520)</td></tr><tr><td></td><td>Patients</td><td>Controls</td><td>Patients</td><td>Controls</td><td>Patients</td><td>Controls</td><td>Patients</td><td>Controls</td></tr><tr><td>Diagnosis of EOC</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>2</td><td>3</td><td>10</td><td>4</td><td>18</td><td>22</td><td>9</td><td>7</td></tr><tr><td> No</td><td>571</td><td>2572</td><td>1781</td><td>7515</td><td>3005</td><td>10702</td><td>549</td><td>2955</td></tr><tr><td>IR</td><td>4.99</td><td>1.78</td><td>9.89</td><td>0.96</td><td>10.66</td><td>3.38</td><td>35.81</td><td>5.80</td></tr><tr><td>Crude HR (95% CI)</td><td>2.80 (0.47-16.74)</td><td>1.00</td><td>13.80 (3.80-50.11)<sup>*</sup></td><td>1.00</td><td>3.03 (1.62-5.64)<sup></sup></td><td>1.00</td><td>6.74 (2.51-18.10)<sup></sup></td><td>1.00</td></tr><tr><td>Adjusted HR (95% CI)</td><td>3.34 (0.54-20.60)</td><td>1.00</td><td>19.41 (5.02-75.10)<sup></sup></td><td>1.00</td><td>3.41 (1.76-6.61)<sup></sup></td><td>1.00</td><td>9.63 (3.27-28.37)<sup>**</sup></td><td>1.00</td></tr></table>
f75fee465f3ccfca0c1c52085adb175ee044531ec521feeb401794482dfff01f.png	complex	<table><tr><td>Aged parental clone</td><td>Origin</td><td>Overall haematopoietic chimerism (%±s.d.)</td><td>Overall relative chimerism (%±s.d.)</td><td colspan="3">Lineage distribution of test cells in 1°transplants, iPS chimeras and 2° transplants (%±s.d.)</td><td colspan="3">Lineage distribution of young cells (blastocyst/morula-derived; %±s.d.)</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td><i>T cell</i></td><td><i>B cell</i></td><td><i>Myeloid</i></td><td><i>T cell</i></td><td><i>B cell</i></td><td><i>Myeloid</i></td></tr><tr><td>M/E clone 1 (myeloid only)</td><td>1° Transplant</td><td>NA</td><td>NA</td><td>0</td><td>0</td><td>100</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td> </td><td>iPS chimera</td><td>26.9</td><td>100</td><td>11.2</td><td>60.6</td><td>28.2</td><td>45.5</td><td>32.3</td><td>22.2</td></tr><tr><td> </td><td>2° Transplant, iPS origin (<i>n</i>=4)</td><td>25.8±3.6</td><td>113.9±45.4</td><td>8.7±4.9</td><td>75.4±10.9</td><td>15.9±8.9</td><td>22.7±9.5</td><td>62±6.2</td><td>15.3±3.5</td></tr><tr><td>M/E clone 2 (myeloid only)</td><td>1° Transplant</td><td>NA</td><td>NA</td><td>0</td><td>0</td><td>100</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td> </td><td>iPS chimera</td><td>25.5</td><td>100</td><td>20.1</td><td>60.9</td><td>19</td><td>58.5</td><td>26.1</td><td>15.3</td></tr><tr><td> </td><td>2° Transplant, iPS origin (<i>n</i>=4)</td><td>18.6±3.3</td><td>73.1±12.8</td><td>10.1±1.7</td><td>76.9±6.1</td><td>13.1±6.8</td><td>26±4.4</td><td>61.5±3.6</td><td>12.5±4.2</td></tr><tr><td>M/E clone 3 (myeloid only)</td><td>1° Transplant</td><td>NA</td><td>NA</td><td>0</td><td>0</td><td>100</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td> </td><td>iPS chimera</td><td>55.4</td><td>100</td><td>32.9</td><td>36.8</td><td>30.3</td><td>55.8</td><td>27.2</td><td>17</td></tr><tr><td> </td><td>2° Transplant, iPS origin (<i>n</i>=4)</td><td>60.9±10.4</td><td>109.9±18.7</td><td>22.3±6</td><td>60.9±1.1</td><td>16.8±6.4</td><td>42.7±5.2</td><td>41±7.2</td><td>16.3±6.3</td></tr><tr><td>M/B/E clone 1 (T-cell deficient)</td><td>1° Transplant</td><td>NA</td><td>NA</td><td>0</td><td>16.5</td><td>83.5</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td> </td><td>iPS chimera</td><td>33.7</td><td>100</td><td>11.5</td><td>69.2</td><td>19.3</td><td>36.9</td><td>51.8</td><td>11.3</td></tr><tr><td> </td><td>2° Transplant, iPS origin (<i>n</i>=5)</td><td>27.6±9.7</td><td>79.7±32.8</td><td>22.4±6.2</td><td>64.7±10.1</td><td>13±5.9</td><td>43.7±6.1</td><td>40.7±7.8</td><td>15.6±2.3</td></tr><tr><td>M/B/E clone 2 (T-cell deficient)</td><td>1° Transplant</td><td>NA</td><td>NA</td><td>0</td><td>24.5</td><td>75.5</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td> </td><td>iPS chimera</td><td>22.4</td><td>100</td><td>29.5</td><td>31.7</td><td>38.8</td><td>62.3</td><td>22.3</td><td>15.4</td></tr><tr><td> </td><td>2° Transplant, iPS origin (<i>n</i>=5)</td><td>21.4±4.1</td><td>71.9±31.5</td><td>12.8±3.7</td><td>78.8±3.3</td><td>8.3±2.6</td><td>29.8±5.3</td><td>54.3±1.7</td><td>15.9±6.3</td></tr></table>
34acd5a8e364790efb3004f0b489212a829d5dfba77a9ea26f2c4b7af38b4f05.png	complex	<table><tr><td colspan="5">Training Dataset : Protein {:Chain}{:Domain Boundaries}</td></tr><tr><td>1a6q:297–368</td><td>1lok:A</td><td>1etx:A</td><td>1nj4:A:263–355</td><td>1egw:A</td></tr><tr><td>1ako</td><td>1lqp:A</td><td>1ew4:A</td><td>1nls</td><td>1erz:A</td></tr><tr><td>1ayl:228–540</td><td>1ltz:A</td><td>1eyq:A</td><td>1nzi:A:1–117</td><td>1ftr:A:1–148</td></tr><tr><td>1ayo:A</td><td>1m1n:A</td><td>1eyv:A</td><td>1o08:A</td><td>1gpr</td></tr><tr><td>1bx4:A</td><td>1mf7:A</td><td>1f60:A:241–334</td><td>1o1x:A</td><td>1gxu:A</td></tr><tr><td>1byq:A</td><td>1mgp:A</td><td>1g61:A</td><td>1oi7:A:122–288</td><td>1h16:A</td></tr><tr><td>1c5k:A:35–162</td><td>1mn8:A</td><td>1gs9:A</td><td>1qnf:205–475</td><td>1h4x:A</td></tr><tr><td>1c97:A:2–528</td><td>1mv8:A:203–300</td><td>1gso:A:-2–103</td><td>1qre:A</td><td>1hqs:A</td></tr><tr><td>1cip:A:61–181</td><td>1nf9:A</td><td>1hbn:A:2–269</td><td>1qtn:A</td><td>1hs6:A:1–208</td></tr><tr><td>1cuk:156–203</td><td>1nvm:A:291–341</td><td>1hx0:A:404–496</td><td>1who</td><td>1hz4:A</td></tr><tr><td>1d8c:A</td><td>1o98:A:77–310</td><td>1i1w:A</td><td>2pth</td><td>1jid:A</td></tr><tr><td>1ejx:A</td><td>1oo0:A</td><td>1iom:A</td><td>2uag:A:298–437</td><td>1k4g:A</td></tr><tr><td>1evl:A:533–642</td><td>1orv:A:39–508</td><td>1j3a:A</td><td>3grs:364–478</td><td>1kj9:A:113–318</td></tr><tr><td>1f46:A</td><td>1p3d:A:107–321</td><td>1jat:A</td><td>4eug:A</td><td>1kq1:A</td></tr><tr><td>1fye:A</td><td>1qhp:A:577–686</td><td>1jhf:A:73–198</td><td>16pk</td><td>1kqf:A:34–850</td></tr><tr><td>1g8l:A:327–409</td><td>1qna:A:17–115</td><td>1jkx:A</td><td>1bkr:A</td><td>1dfu:P</td></tr><tr><td>1gdn:A</td><td>1rl6:A:7–81</td><td>1k3x:A:125–213</td><td>1c8z:A</td><td>1mwx:A:139–327</td></tr><tr><td>1gpj:A:303–404</td><td>1tfe</td><td>1k3y:A:81–222</td><td>1cs0:B:2–152</td><td>1p5u:A:148–234</td></tr><tr><td>1h4a:X:1–85</td><td>4ubp:B</td><td>1k7k:A</td><td>1dg6:A</td><td>1qop:A</td></tr><tr><td>1heu:A:164–339</td><td>1af7:11–91</td><td>1kbl:A:377–509</td><td>1di6:A</td><td>1whi</td></tr><tr><td>1hp1:A:363–550</td><td>1aie</td><td>1kmt:A</td><td>1dmh:A</td><td>1xxa:A</td></tr><tr><td>1hqk:A</td><td>1bd8</td><td>1lam:1–159</td><td>1dqe:A</td><td>2ilk</td></tr><tr><td>1ir1:S</td><td>1cqm:A</td><td>1ld8:A</td><td>1duv:G:1–150</td><td>2sns</td></tr><tr><td>1kb0:A:1–573</td><td>1dl2:A</td><td>1m15:A:2–95</td><td>1dw9:A:87–156</td><td>2spc:A</td></tr><tr><td>1kqp:A</td><td>1dto:A</td><td>1me4:A</td><td>1dy5:A</td><td>3nul</td></tr><tr><td>1l8a:A:701–886</td><td>1e39:A:360–505</td><td>1me8:A:2–101</td><td>1e58:A</td><td>8ruc:A:9–147</td></tr><tr><td>1l8b:A</td><td>1e4c:P</td><td>1mg4:A</td><td>1eaz:A</td><td>1a77:209–316</td></tr><tr><td>1ldg:164–329</td><td>1ekr:A</td><td>1moo:A</td><td>1ez3:A</td><td>1a8o</td></tr><tr><td>1lkk:A</td><td>1elk:A</td><td>1muw:A</td><td>1f8n:A:6–149</td><td>1c1d:A:1–148</td></tr><tr><td>1lqt:A:2–108</td><td>1exm:A:313–405</td><td>1mvl:A</td><td>1fdr:101–248</td><td>1crz:A:141–409</td></tr><tr><td>1m1g:A:132–190</td><td>1fwx:A:8–451</td><td>1n55:A</td><td>1fsg:A</td><td>1czp:A</td></tr><tr><td>1m26:A</td><td>1gmi:A</td><td>1n60:B:7–146</td><td>1fx2:A</td><td>1dci:A</td></tr><tr><td>1mj4:A</td><td>1gs5:A</td><td>1n61:C:1–177</td><td>1g8m:A:4–200</td><td>1mfm:A</td></tr><tr><td>1n1b:A:271–598</td><td>1gtk:A:220–313</td><td>1n8k:A:1–163</td><td>1gkm:A</td><td>1g7s:A:329–459</td></tr><tr><td>1n3l:A</td><td>1hf8:A</td><td>1nm8:A:9–385</td><td>1gmx:A</td><td>1gkp:A:2–54</td></tr><tr><td>1n62:A:82–163</td><td>1hlr:A:311–907</td><td>1o26:A</td><td>1got:G</td><td>1gxr:A</td></tr><tr><td>1ns5:A</td><td>1hq1:A</td><td>1ofd:A:1240–1507</td><td>1gqz:A:1–130</td><td>1hxk:A:31–411</td></tr><tr><td>1nxj:A</td><td>1ijy:A</td><td>1oht:A</td><td>1gvo:A</td><td>1i9c:A</td></tr><tr><td>1oe1:A:1–159</td><td>1ix9:A:1–90</td><td>1or7:A:-1–111</td><td>1h05:A</td><td>1iu7:A:212–628</td></tr><tr><td>1p5v:A:7–147</td><td>1iz5:A:2–120</td><td>1ox0:A:-5–251</td><td>1h3n:A:226–417</td><td>1j8b:A</td></tr><tr><td>1qhv:A</td><td>1jos:A</td><td>1qcz:A</td><td>1hb6:A</td><td>1jp3:A</td></tr><tr><td>1qqf:A</td><td>1k0r:A:184–262</td><td>1qh4:A:103–381</td><td>1i2t:A</td><td>1jsd:A</td></tr><tr><td>1qsa:A:1–450</td><td>1khb:A:10–259</td><td>1qnx:A</td><td>1i4j:A</td><td>1jw9:B</td></tr><tr><td>1rss</td><td>1khd:A:12–80</td><td>1d0c:A</td><td>1ikt:A</td><td>1k8y:B</td></tr><tr><td>1tig</td><td>1kp8:A:2–136</td><td>1dd3:A:1–57</td><td>1ixb:A:91–205</td><td>1kek:A:416–668</td></tr><tr><td>1yge:150–839</td><td>1krh:A:106–205</td><td>1dj0:A:7–114</td><td>1ixh</td><td>1kpf</td></tr><tr><td>2tps:A</td><td>1kwm:A:1A-95A</td><td>1dow:A</td><td>1j6z:A:4–146</td><td>1ku1:A</td></tr><tr><td>7odc:A:44–283</td><td>1kyp:A</td><td>1dqi:A</td><td>1jke:A</td><td>1mc2:A</td></tr><tr><td>1awq:A</td><td>1l6p:A</td><td>1e6i:A</td><td>1k4i:A</td><td>1lb3:A</td></tr><tr><td>1bd0:A:2–11</td><td>1mix:A:195–308</td><td>1ei5:A:336–417</td><td>1k6d:A</td><td>1m9n:A:201–593</td></tr><tr><td>1bxy:A</td><td>1mla:198–307</td><td>1f86:A</td><td>1knl:A</td><td>1mgt:A:89–169</td></tr><tr><td>1byi</td><td>1n5u:A:2–196</td><td>1f9y:A</td><td>1l2h:A</td><td>1nkp:A</td></tr><tr><td>1chd</td><td>1np7:A:1–204</td><td>1fhu:A:1–99</td><td>1l5o:A</td><td>1npk</td></tr><tr><td>1cxq:A</td><td>1o8b:A:199–218</td><td>1fjj:A</td><td>1lm4:A</td><td>1pcf:A</td></tr><tr><td>1d5t:A:292–388</td><td>1oew:A</td><td>1fmt:A:207–314</td><td>1m6y:A:115–215</td><td>1qqq:A</td></tr><tr><td>1sei:A</td><td>2aop:149–345</td><td>1a8d:248–452</td><td>1bkf</td><td>1kwf:A</td></tr><tr><td>1uro:A</td><td>4uag:A:1–93</td><td>1b8z:A</td><td>1chm:A:2–156</td><td>1dl5:A:214–317</td></tr></table>
ed6a2741cf315841672c4d89914a1ec6eb3a31f9093b8bd6781af1d8e67e761d.png	simple	<table><tr><td>Variable name</td><td>ICC (95 % CI)<sup>a,b</sup></td></tr><tr><td>Maternal information</td><td></td></tr><tr><td> Pre-pregnancy weight</td><td>0.97 (0.96 –0.97)</td></tr><tr><td> Admission weight</td><td>0.94 (0.94 –0.95)</td></tr><tr><td> Height</td><td>0.90 (0.89 –0.92)</td></tr><tr><td>Antenatal information</td><td></td></tr><tr><td> Gravida</td><td>0.76 (0.73 –0.78)</td></tr><tr><td> Previous term deliveries</td><td>0.99 (0.98 –0.99)</td></tr><tr><td> Previous preterm deliveries</td><td>0.86 (0.85 –0.88)</td></tr><tr><td> Previous spontaneous abortions</td><td>0.92 (0.91 –0.93)</td></tr><tr><td> Previous therapeutic abortions</td><td>0.90 (0.88 –0.91)</td></tr><tr><td> Previous cesarean deliveries</td><td>0.99 (0.99 –0.99)</td></tr><tr><td> Previous vaginal deliveries</td><td>0.99 (0.99 –0.99)</td></tr><tr><td> Number of living children</td><td>0.98 (0.98 –0.99)</td></tr><tr><td> Third trimester hemoglobin</td><td>0.85 (0.83 –0.87)</td></tr><tr><td> Gestational age at first ultrasound, in weeks</td><td>0.92 (0.90 –0.93)</td></tr><tr><td> Gestational age at first ultrasound, in days</td><td>0.90 (0.89 –0.92)</td></tr><tr><td> Total prior admissions this pregnancy</td><td>0.59 (0.55 –0.63)</td></tr><tr><td> School years completed</td><td>0.92 (0.90 –0.94)</td></tr><tr><td> Number of antenatal visits</td><td>0.91 (0.90 –0.92)</td></tr><tr><td>Labour and delivery information</td><td></td></tr><tr><td> Cervical dilation on admission</td><td>0.88 (0.86 –0.90)</td></tr><tr><td> Cervical dilation prior to cesarean delivery</td><td>0.96 (0.95 –0.97)</td></tr><tr><td> Postpartum hemoglobin value</td><td>0.98 (0.98 –0.98)</td></tr></table>
3da0fa9ebec3160f1c3b98ebb5df97a9a4d732a74c33e063eabc9d35421e16d3.png	complex	<table><tr><td rowspan="3">Antimicrobial agent</td><td colspan="3">No. (%) of <i>H. pylori</i>-resistant strains</td></tr><tr><td>2006–2008 [13]</td><td>2009–2011</td><td rowspan="2"><i>P</i> value<sup>(1)</sup></td></tr><tr><td><i>n</i> = 115</td><td><i>n</i> = 51</td></tr><tr><td>CLA<sup>(2)</sup></td><td>39 (34%)</td><td>11 (22%)</td><td>0,16 NS<sup>(3)</sup></td></tr><tr><td>LEV<sup>(2)</sup></td><td>6 (5%)</td><td>8 (16%)</td><td>0,05<sup>(4)</sup></td></tr></table>
5acc420a4ea0e1f1aced36eae65f615689b84107c31e405bcd61f1e492e56d39.png	simple	<table><tr><td>Age</td><td>0.025</td><td>0.05</td><td>0.10</td><td>0.90</td><td>0.95</td><td>0.975</td></tr><tr><td>0.4</td><td>0.2</td><td>0.3</td><td>0.5</td><td>1.8</td><td>2.0</td><td>2.2</td></tr><tr><td>1.0</td><td>0.3</td><td>0.4</td><td>0.6</td><td>1.9</td><td>2.0</td><td>2.2</td></tr><tr><td>2.0</td><td>0.4</td><td>0.6</td><td>0.7</td><td>1.9</td><td>2.1</td><td>2.2</td></tr><tr><td>3.0</td><td>0.6</td><td>0.7</td><td>0.8</td><td>1.9</td><td>2.1</td><td>2.2</td></tr><tr><td>4.0</td><td>0.7</td><td>0.8</td><td>0.9</td><td>2.0</td><td>2.1</td><td>2.2</td></tr><tr><td>5.0</td><td>0.8</td><td>0.9</td><td>1.0</td><td>2.0</td><td>2.1</td><td>2.2</td></tr><tr><td>6.0</td><td>0.9</td><td>1.0</td><td>1.1</td><td>2.0</td><td>2.1</td><td>2.2</td></tr><tr><td>7.0</td><td>0.9</td><td>1.0</td><td>1.2</td><td>2.0</td><td>2.1</td><td>2.2</td></tr><tr><td>8.0</td><td>1.0</td><td>1.1</td><td>1.2</td><td>2.0</td><td>2.1</td><td>2.2</td></tr><tr><td>9.0</td><td>1.0</td><td>1.1</td><td>1.2</td><td>2.0</td><td>2.1</td><td>2.2</td></tr><tr><td>10.0</td><td>1.1</td><td>1.1</td><td>1.2</td><td>2.0</td><td>2.1</td><td>2.2</td></tr><tr><td>11.0</td><td>1.1</td><td>1.1</td><td>1.2</td><td>2.0</td><td>2.1</td><td>2.1</td></tr><tr><td>12.0</td><td>1.1</td><td>1.1</td><td>1.2</td><td>1.9</td><td>2.0</td><td>2.1</td></tr><tr><td>13.0</td><td>1.0</td><td>1.1</td><td>1.2</td><td>1.9</td><td>2.0</td><td>2.1</td></tr><tr><td>14.0</td><td>1.0</td><td>1.1</td><td>1.2</td><td>1.9</td><td>2.0</td><td>2.1</td></tr><tr><td>15.0</td><td>0.9</td><td>1.0</td><td>1.1</td><td>1.8</td><td>1.9</td><td>2.0</td></tr><tr><td>16.0</td><td>0.9</td><td>1.0</td><td>1.1</td><td>1.8</td><td>1.9</td><td>2.0</td></tr><tr><td>17.0</td><td>0.8</td><td>0.9</td><td>1.0</td><td>1.7</td><td>1.8</td><td>1.9</td></tr><tr><td>17.8</td><td>0.7</td><td>0.8</td><td>0.9</td><td>1.7</td><td>1.8</td><td>1.9</td></tr></table>
fa540625927dd336793dde074916b3830f1e453c29db21c99e4aa57518e457fc.png	complex	<table><tr><td></td><td>Crude OR (95% CI)</td><td>Adjusted OR (95% CI)</td></tr><tr><td>Female gender (vs male)</td><td>0.9 (0.5–1.5)</td><td></td></tr><tr><td>Zhuang ethnicity (vs Han and others)</td><td>0.8 (0.5–1.5)</td><td></td></tr><tr><td colspan="3">Age group (years): ref. = < 30</td></tr><tr><td> 30–39</td><td>0.8 (0.4–1.6)</td><td></td></tr><tr><td> 40–49</td><td>0.9 (0.4–1.8)</td><td></td></tr><tr><td> ≥ 50</td><td>0.7 (0.3–1.5)</td><td></td></tr><tr><td colspan="3">Education level: ref. = Illiterate</td></tr><tr><td> Elementary school</td><td>4.2 (1.4–12.2)</td><td></td></tr><tr><td> Junior high school</td><td>3.2 (1.1–9.5)</td><td></td></tr><tr><td> High school or higher</td><td>4.1 (1.1–15.1)</td><td></td></tr><tr><td colspan="3">Marital status: ref. = unmarried</td></tr><tr><td> Married</td><td>0.8 (0.5–1.4)</td><td></td></tr><tr><td> Divorced or widowed</td><td>0.6 (0.2–1.9)</td><td></td></tr><tr><td colspan="3">Occupation: ref. = unemployed</td></tr><tr><td> Farmer</td><td>1.5 (0.8–2.7)</td><td></td></tr><tr><td> Other</td><td>1.1 (0.3–3.5)</td><td></td></tr><tr><td colspan="3">Annual family income level: ref. = low</td></tr><tr><td> Middle</td><td>0.7 (0.4–1.3)</td><td></td></tr><tr><td> High</td><td>1.0 (0.5–2.1)</td><td></td></tr><tr><td colspan="3">Cause of disease</td></tr><tr><td> Other non-organic severe mental disorders (vs organic psychoses)</td><td>11.5 (1.6–84.6)</td><td>11.6 (1.6–86.0)</td></tr><tr><td>Disease duration (years)</td><td>1.0 (0.9–1.0)</td><td></td></tr><tr><td colspan="3">PANSS score</td></tr><tr><td> Positive scale</td><td>1.0 (0.9–1.0)</td><td></td></tr><tr><td> Negative scale</td><td>1.0 (0.9–1.0)</td><td></td></tr><tr><td> General psychopathology</td><td>1.0 (0.9–1.0)</td><td></td></tr><tr><td colspan="3">Caregiver</td></tr><tr><td> Yes (vs no)</td><td>6.2 (2.0–18.3)</td><td>3.21 (1.2–8.3)</td></tr><tr><td colspan="3">Caregiver’s gender</td></tr><tr><td> Female (vs male)</td><td>1.3 (0.6–2.4)</td><td></td></tr></table>
a1ccb6a34e32066f718b89c3c73e38f3187493a07c622423651e2801881d8d46.png	simple	<table><tr><td>R di Pearson p<.05</td><td>PF</td><td>PRF</td><td>BP</td><td>GHP</td><td>V</td><td>SRF</td><td>ERF</td><td>MH</td></tr><tr><td>Depression</td><td>-0.16</td><td>-0.21</td><td>-0.49*</td><td>-0.19</td><td>-0.21</td><td>-0.2</td><td>-0.14</td><td>-0.17</td></tr></table>
e1c72ddcb53b5b58f382606efb3e73c083a09a13e1d300d144c4d34754e70167.png	simple	<table><tr><td>Date</td><td>WWTP 1</td><td>WWTP 2</td><td>WWTP 3</td><td>WWTP 4</td><td>WWTP 5</td></tr><tr><td>Jan</td><td><0.006473</td><td><0.006473</td><td><0.006473</td><td>0.43</td><td><0.006473</td></tr><tr><td>Feb</td><td><0.006473</td><td>1.74</td><td><0.006473</td><td>0.49</td><td>0.43</td></tr><tr><td>Mar</td><td><0.006473</td><td>3.72</td><td>NP</td><td><0.006473</td><td><0.006473</td></tr><tr><td>Apr</td><td><0.006473</td><td>6.03</td><td><0.006473</td><td>0.21</td><td><0.006473</td></tr><tr><td>May</td><td><0.006473</td><td>4.81</td><td><0.006473</td><td><0.006473</td><td><0.006473</td></tr><tr><td>Jun</td><td><0.006473</td><td>5.63</td><td><0.006473</td><td>NP</td><td><0.006473</td></tr><tr><td>Jul</td><td><0.006473</td><td>2.28</td><td>NP</td><td>1.32</td><td><0.006473</td></tr><tr><td>Aug</td><td><0.006473</td><td>12.20</td><td>NP</td><td><0.006473</td><td><0.006473</td></tr><tr><td>Sep</td><td><0.006473</td><td>3.29</td><td>NP</td><td>0.69</td><td><0.006473</td></tr><tr><td>Oct</td><td><0.006473</td><td>1.66</td><td><0.006473</td><td>0.76</td><td><0.006473</td></tr><tr><td>Nov</td><td>0.75</td><td>5.74</td><td>NP</td><td>0.85</td><td><0.006473</td></tr><tr><td>Dec</td><td><0.006473</td><td>4.45</td><td><0.006473</td><td>1.86</td><td><0.006473</td></tr></table>
db263997212c077797427451b1e14349e3ea9308abc54f1a0aa7d46d539cd786.png	complex	<table><tr><td rowspan="2">Evaluation criteria</td><td rowspan="2">Description</td><td colspan="2">Temperature and duration</td><td rowspan="2">Reference</td></tr><tr><td>Treatment</td><td>Recovery</td></tr><tr><td>Germination stage</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Vigor of germination</td><td>Vigor of germination (%) = Number of germinated grains/Number of total grains × 100</td><td>14°C/7-17 d</td><td>-</td><td>(Han et al. [2006])</td></tr><tr><td>Seedling survival rate</td><td>Seedling survival rate (%) = Surviving seedlings/Sprouting seeds × 100, determined when shoots are about 5 mm long.</td><td>2°C/3 d</td><td>20°C/7 d</td><td>(Zhou et al. [2012])</td></tr><tr><td>Seedling stage</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Fresh weight (FW)</td><td>Changes in FW of plants after cold treatment can be used as an indicator of cold damage.</td><td>10°C/1-48 h</td><td>-</td><td>(Bonnecarrère et al. [2011])</td></tr><tr><td>Survival rate</td><td>Survival rate (%) after cold treatment is calculated as the Number of surviving plants/Total number plants treated × 100</td><td>4°C/6 d</td><td>26°C/6 d</td><td>(Zhang et al. [2011b])</td></tr><tr><td>Leaf emergence</td><td>New leaf emergence demonstrates maintained vigor and increased growth.</td><td>4°C/7 d</td><td>25°C/10 d</td><td>(Xie et al. [2012])</td></tr><tr><td>Seedling growth</td><td>1 = dark green seedlings, 3 = light green seedlings, 5 = yellow seedlings, 7 = brown seedlings, 9 = seedlings dead.</td><td>9°C/8-14 d</td><td>-</td><td>(Kim and Tai [2011]; IRRI [2002]; Andaya and Tai [2006])</td></tr><tr><td>Leaf growth</td><td>A score of 1–3 (tolerant, all leaves normal, no apparent visual injury), or 4–9 (susceptible, all leaves wilted, seedlings apparently dead).</td><td>10°C/7 d</td><td>25°C/7 d</td><td>(Suh et al. [2012])</td></tr><tr><td>Metabolic assessments</td><td>Metabolites include EL, proline, MDA, and AsA, and GSH.</td><td>9°C/1-14 d</td><td>-</td><td>(Tian et al. [2011]; Zhang et al. [2011a]; Kim and Tai [2011]; Yang et al. [2012])</td></tr><tr><td>Enzyme activities</td><td>Enzymes include POD, SOD, and CAT, and APX.</td><td>4°C/0-4 d</td><td>25°C/7 d</td><td>(Bonnecarrère et al. [2011]; Huang et al. [2009]; Sato et al. [2001])</td></tr><tr><td>Reproductive stage</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Spikelet fertility (CGC)</td><td>Spikelet fertility is calculated as the ratio of filled grains to the total number of florets, basing on cold greenhouse cultivation.</td><td>12°C/6 d</td><td>Until maturation</td><td>(Sato et al. [2011])</td></tr><tr><td>Spikelet fertility (CDWI)</td><td>Spikelet fertility is calculated as the same as spikelet fertility (CGC), but the cold treatment is based on cold deep-water irrigation.</td><td>18-19°C/~60 d</td><td>-</td><td>(Shirasawa et al. [2012])</td></tr></table>
0cb2738b21581a875ee247ce9f4a5754c2831f555e6dfc26e68de6692df9c4e6.png	simple	<table><tr><td>Algorithm</td><td>Proposed</td><td>No Preprocessing</td><td>No Verification</td></tr><tr><td>Recognition rate</td><td>97.8%</td><td>98.1%</td><td>68.0%</td></tr><tr><td>Computation time</td><td>1018</td><td>4951</td><td>736</td></tr></table>
647177729026b539bf2eccf3541d2e64f7af1ea46854bc0f7e187e836f211971.png	complex	<table><tr><td>Case</td><td colspan="3">Response time to deviation</td><td colspan="3">Response time to math</td></tr><tr><td></td><td>Mean</td><td>Standarddeviation</td><td>Difference(dual-single)</td><td>Mean</td><td>Standarddeviation</td><td>Difference(dual-single)</td></tr><tr><td>Case 1</td><td>0.9480</td><td>0.1314</td><td><i>p < 0.01</i></td><td>1.1479</td><td>0.3061</td><td><i>p < 0.01</i></td></tr><tr><td>Case 2</td><td>0.9856</td><td>0.1269</td><td><i>p > 0.01</i></td><td>1.1277</td><td>0.2724</td><td><i>p < 0.01</i></td></tr><tr><td>Case 3</td><td>0.9865</td><td>0.1231</td><td><i>p > 0.01</i></td><td>1.0975</td><td>0.2727</td><td><i>p < 0.01</i></td></tr><tr><td>Single (baseline)</td><td>1</td><td>0.1553</td><td></td><td>1</td><td>0.2168</td><td></td></tr></table>
4a4542b06edadbed8f825cecb26dfad5220638c15bc7fe60747057d0164a214b.png	simple	<table><tr><td>Year</td><td>Tumor type</td><td>No. of cases</td><td>Culture condition</td><td>Authors</td></tr><tr><td>1999</td><td>Renal cell carcinoma Colorectal carcinoma Lymphoma</td><td>10</td><td>IFN-γ, anti-CD3, IL2 plus IL-2 transgene</td><td>Schmidt-Wolf IG et al. [33]</td></tr><tr><td>2005</td><td>Lymphoma</td><td>9</td><td>IFN-γ, anti-CD3, and IL2</td><td>Leemhuis T et al. [14]</td></tr><tr><td>2006</td><td>Gastric carcinoma</td><td>57</td><td>IFN-γ, anti-CD3, IL2 and IL-1alpha</td><td>Jiang JT et al. [34]</td></tr><tr><td>2007</td><td>Leukemia</td><td>11</td><td>IFN-γ, anti-CD3 and IL2</td><td>Introna M et al. [35]</td></tr><tr><td>2008</td><td>Non-small cell lung cancer</td><td>59</td><td>IFN-γ, anti-CD3, IL2 and IL-1alpha</td><td>Wu CP et al. [36]</td></tr><tr><td>2009</td><td>Hepatocellular carcinoma</td><td>127</td><td>IFN-γ, anti-CD3, IL2 and IL-1lalpha</td><td>Hui D et al. [37]</td></tr><tr><td>2009</td><td>Renal cell carcinoma and lymphoma</td><td>6</td><td>IFN-γ, anti-CD3, and IL2</td><td>Olioso P et al. [38]</td></tr><tr><td>2010</td><td>Gastric carcinoma</td><td>156</td><td>IFN-γ, anti-CD3, IL2, and IL-1alpha</td><td>Jiang JT et al. [39]</td></tr><tr><td>2011</td><td>relapsed hematologic malignancies</td><td>18</td><td>IFN-γ, anti-CD3, and IL2</td><td>Laport GG et al. [40]</td></tr><tr><td>2012</td><td>Renal cell carcinoma</td><td>74</td><td>IFN-γ, anti-CD3, IL2, IL-1beta</td><td>Liu L et al. [41]</td></tr></table>
e33bde01c1620fa96d1a8b05bfa248499717a02c905224eba0a8b44c5122ad65.png	complex	<table><tr><td></td><td>Baseline (T0)</td><td>T1</td><td>T2</td><td>T3</td></tr><tr><td colspan="5">Mean arterial pressure (mmHg)</td></tr><tr><td> Control</td><td>91.5 ± 4.2</td><td>93 ± 4.1</td><td>94 ± 4.8</td><td>76.1 ± 2.3</td></tr><tr><td> LPS</td><td>88.7 ± 1.3</td><td>49 ± 5.1<sup>##</sup></td><td>54.9 ± 6.2<sup>##</sup></td><td>42.2 ± 4.4<sup>###</sup></td></tr><tr><td> LPS + FR</td><td>90.8 ± 1.3</td><td>53.5 ± 3.2<sup>##</sup></td><td>82.7 ± 2.1</td><td>56.6 ± 2.1<sup>,##</sup></td></tr><tr><td> LPS + BT</td><td>89.5 ± 2.2</td><td>54.1 ± 1.7<sup>##</sup></td><td>86.8 ± 1.7</td><td>61.1 ± 3.2</td></tr><tr><td colspan="5">Heart rate (beats per minute)</td></tr><tr><td> Control</td><td>232.9 ± 8.5</td><td>247.7 ± 7.7</td><td>248 ± 6.4</td><td>249.9 ± 13.4</td></tr><tr><td> LPS</td><td>236.3 ± 11.9</td><td>225.6 ± 5.2</td><td>226.9 ± 5.9</td><td>221 ± 8.5</td></tr><tr><td> LPS + FR</td><td>227.9 ± 8.7</td><td>219 ± 5.1</td><td>259 ± 7.7</td><td>258 ± 4.3</td></tr><tr><td> LPS + BT</td><td>255.3 ± 7.7</td><td>252.1 ± 5.6</td><td>258 ± 5.3</td><td>254.6 ± 6.5</td></tr><tr><td colspan="5">Renal blood flow (ml/min)</td></tr><tr><td> Control</td><td>7.5 ± 0.8</td><td>5.1 ± 0.2</td><td>5.2 ± 0.3</td><td>4.3 ± 0.2</td></tr><tr><td> LPS</td><td>7.1 ± 0.5</td><td>0.8 ± 0.3<sup>#</sup></td><td>0.9 ± 0.3<sup>###</sup></td><td>0.6 ± 0.3<sup>###</sup></td></tr><tr><td> LPS + FR</td><td>6.3 ± 0.2</td><td>0.4 ± 0.1<sup>##</sup></td><td>5.4 ± 0.9*</td><td>1.6 ± 0.3<sup>#</sup></td></tr><tr><td> LPS + BT</td><td>6.6 ± 0.7</td><td>0.8 ± 0.3<sup>#</sup></td><td>3.2 ± 0.4</td><td>1.8 ± 0.3<sup>#</sup></td></tr><tr><td colspan="5">Renal vascular resistances (dynes·s·cm<sup>–5</sup>)</td></tr><tr><td> Control</td><td>1291.9 ± 128.2</td><td>1823.2 ± 88.2</td><td>1844.4 ± 155.9</td><td>1784.3 ± 96.4</td></tr><tr><td> LPS</td><td>1275.2 ± 77.6</td><td>17,820 ± 7905.5</td><td>18,631.9 ± 11,394.9</td><td>20,237.7 ± 7939.2</td></tr><tr><td> LPS + FR</td><td>1449.9 ± 61.8</td><td>18,860.5 ± 6758.4</td><td>1853.3 ± 336.2</td><td>4390.5 ± 920.3</td></tr><tr><td> LPS + BT</td><td>1431.3 ± 124.1</td><td>12,133.9 ± 3493.6</td><td>2919.9 ± 388.8</td><td>4860.7 ± 1828.1</td></tr></table>
adc5729930f15565c2233d9fd949a600b9a0394b8f0b4eb9af1cd016c55d74fd.png	simple	<table><tr><td>Bacterial name</td><td>Inhibitory effects<sup>*</sup></td></tr><tr><td><i>Acetic bacteria</i></td><td>-</td></tr><tr><td><i>Bacillus subtilis</i></td><td>+</td></tr><tr><td><i>E. coli</i></td><td>+++</td></tr><tr><td><i>Lactobacillus fermenti</i></td><td>-</td></tr><tr><td><i>Lactobacillus plantarum ZJ316</i></td><td>-</td></tr><tr><td><i>Lactococcus lactis</i></td><td>-</td></tr><tr><td><i>Listeria monocytogenes</i></td><td>++</td></tr><tr><td><i>Micrococcus luteus</i></td><td>+</td></tr><tr><td><i>Pseudomonas aeruginosa</i></td><td>+</td></tr><tr><td><i>Pseudomonas putida</i></td><td>++++</td></tr><tr><td><i>Shigella flexneri</i></td><td>++</td></tr><tr><td><i>Saccharomyces cerevisiae</i></td><td>-</td></tr><tr><td><i>Salmonella</i></td><td>++</td></tr><tr><td><i>Shigella dysenteriae</i></td><td>+</td></tr><tr><td><i>Staphylococcus aureus</i></td><td>+</td></tr><tr><td><i>Staphylococcus citreus</i></td><td>+</td></tr><tr><td><i>Vibrio parahaemolyticus</i></td><td>-</td></tr></table>
52c8e9ec9b12135354827f22dc173d5023ac6b585cf452a47eeab2da698226d2.png	complex	<table><tr><td></td><td colspan="2">Second versus first tertile</td><td colspan="2">Third versus first tertile</td></tr><tr><td>Group</td><td>β ± SE</td><td><i>p</i>-Value</td><td>β ± SE</td><td><i>p</i>-Value</td></tr><tr><td colspan="5">Full (wet weight)</td></tr><tr><td> Systolic</td><td>0.023 ± 0.09</td><td>0.0088</td><td>0.028 ± 0.10</td><td>0.0092</td></tr><tr><td> Diastolic</td><td>0.034 ± 0.09</td><td>0.0002</td><td>0.035 ± 0.10</td><td>0.0011</td></tr><tr><td colspan="5">Full (lipid adjusted)</td></tr><tr><td> Systolic</td><td>0.030 ± 0.008</td><td>0.01</td><td>0.032 ± 0.01</td><td>0.006</td></tr><tr><td> Diastolic</td><td>0.033 ± 0.008</td><td>0.0002</td><td>0.037 ± 0.10</td><td>0.0005</td></tr><tr><td colspan="5">Normotensive (wet weight)</td></tr><tr><td> Systolic</td><td>0.007 ± 0.006</td><td>0.57</td><td>0.020 ± 0.007</td><td>0.035</td></tr><tr><td> Diastolic</td><td>0.013 ± 0.007</td><td>0.06</td><td>0.020 ± 0.008</td><td>0.04</td></tr><tr><td colspan="5">Normotensive (lipid adjusted)</td></tr><tr><td> Systolic</td><td>0.011 ± 0.006</td><td>0.075</td><td>0.023 ± 0.007</td><td>0.002</td></tr><tr><td> Diastolic</td><td>0.018 ± 0.007</td><td>0.012</td><td>0.026 ± 0.008</td><td>0.003</td></tr></table>
c30e6b7feca8303fdfdfba5f9ddd06269c875501bc907958e2c1a056a1f71eba.png	simple	<table><tr><td>Parameters</td><td>AZT</td><td>AZT + NAR</td><td>AZT + VITE</td><td>d4T</td><td>d4T + NAR</td><td>d4T + VITE</td><td>Control</td></tr><tr><td>Final body weight (g)</td><td>307.2 ± 3.7 <sup>a</sup></td><td>316.8 ± 1.99 <sup>#</sup></td><td>303.2 ± 4.2</td><td>303.8 ± 4.1 <sup>a</sup></td><td>304.2 ± 5.2</td><td>315.7 ± 7.5 </td><td>316.6 ± 3.4</td></tr><tr><td>Wet liver weight (g)</td><td>7.87 ± 0.24 <sup>aaa</sup></td><td>6.65 ± 0.17 <sup>###</sup></td><td>6.92 ± 0.20 <sup>##</sup></td><td>7.134 ± 0.20 <sup>a</sup></td><td>6.45 ± 0.17 </td><td>6.68 ± 0.21 </td><td>6.57 ± 0.20</td></tr><tr><td>Liver index (%)</td><td>2.30 ± 0.05 <sup>a</sup></td><td>2.19 ± 0.02 <sup>#</sup></td><td>2.44 ± 0.06 <sup>#</sup></td><td>2.35 ± 0.03 <sup>a</sup></td><td>2.11 ± 0.07 </td><td>2.31 ± 0.01 </td><td>2.27 ± 0.03</td></tr><tr><td>Bax/Bcl-2 ratio</td><td>7.20 ± 0.46 <sup>aaa</sup></td><td>1.18 ± 0.11 <sup>###</sup></td><td>1.14 ± 0.12 <sup>###</sup></td><td>5.42 ± 0.23 <sup>aaa</sup></td><td>1.02 ± 0.05 *</td><td>0.76 ± 0.1 *</td><td>3.18 ± 0.27</td></tr></table>
44432383d9edae872cbca9afb6d3359ad2d174270d7a21083bbe31ff45189263.png	simple	<table><tr><td>Insertions of transgenes</td><td>Relative levels of mRNA*</td></tr><tr><td><i>P{hsp83-AtSPO11-1 </i>cDNA, <i>A5-1}</i></td><td>3.40 ± 0.40</td></tr><tr><td><i>P{hsp83-AtSPO11-2 </i>cDNA, <i>2M3-1}</i></td><td>9.22 ± 2.72</td></tr><tr><td><i>P{hsp83-OsSPO11A cDNA, 3M2-3}</i></td><td>13.88 ± 3.59</td></tr><tr><td><i>P{hsp83-OsSPO11B cDNA, M6-2}</i></td><td>19.85 ± 4.50</td></tr><tr><td><i>P{hsp83-OsSPO11B cDNA, F3-2}</i></td><td>14.57 ± 6.32</td></tr><tr><td><i>P{hsp83-OsSPO11D cDNA, F2-1}</i></td><td>3.17 ± 0.36</td></tr><tr><td><i>P{hsp83-OsSPO11D<sup>Y213F</sup>, F22-F2}</i></td><td>4.22 ± 0.84</td></tr><tr><td><i>P{hsp83-OsSPO11D<sup>Y213F</sup>, M33-F1}</i></td><td>3.76 ± 1.39</td></tr></table>
9387f6bdeef7ed55aadf442ee371d889ca8690c438d3a36dc076b0cfb9f77a90.png	complex	<table><tr><td>Parameter</td><td colspan="2">c-MYC Nuclear Expression</td><td colspan="2">Significance</td></tr><tr><td>ADA3 Nuclear Expression</td><td>Low No (%)</td><td>High No.(%)</td><td><i>x</i><sup>2</sup></td><td>p value</td></tr><tr><td>Low No(%)</td><td>172 (49.1)</td><td>178 (50.9)</td><td rowspan="2">23.79</td><td rowspan="2"><0.0001</td></tr><tr><td>High No(%)</td><td>69 (29.0)</td><td>169 (71.3)</td></tr></table>
a221c381f7f9ff3a0379601d780dc25b8ed9388a0fe8b38700c65bb25ed4d0b2.png	simple	<table><tr><td><i>Mycobacterium smegmatis</i></td><td>Fold change</td><td>P-value</td><td>Gene name</td><td>Ortholog in <i>Mtb</i></td><td>Annotated function</td></tr><tr><td><i>MSMEG_5576</i></td><td>3.4</td><td>2.2E-02</td><td>–</td><td><i>–</i></td><td>d-mannonate oxidoreductase</td></tr><tr><td><i>MSMEG_4920</i></td><td>4.9</td><td>7.9E-04</td><td><i>fadA4</i></td><td><i>Rv1323</i></td><td>Acetyl-CoA acetyltransferase</td></tr><tr><td><i>MSMEG_4718</i></td><td>−1.8</td><td>4.8E-01</td><td><i>bkaR</i></td><td><i>Rv2506</i></td><td>TetR transcriptional regulator (<i>bkaR</i>)</td></tr><tr><td><i>MSMEG_4717</i></td><td>9.0</td><td>3.7E-05</td><td><i>accD1</i></td><td><i>Rv2502c</i></td><td>Acetyl/propionyl-coenzyme A carboxylase (β subunit)</td></tr><tr><td><i>MSMEG_4716</i></td><td>15.0</td><td>1.5E-05</td><td><i>accA1</i></td><td><i>Rv2501c</i></td><td>Acetyl/propionyl-coenzyme A carboxylase (α subunit)</td></tr><tr><td><i>MSMEG_4715</i></td><td>13.7</td><td>5.8E-06</td><td><i>fadE19</i></td><td><i>Rv2500c</i></td><td>Acyl-CoA dehydrogenase</td></tr><tr><td><i>MSMEG_4714</i></td><td>9.5</td><td>1.1E-04</td><td><i>Rv2499c</i></td><td><i>Rv2499c</i></td><td>Hydratase</td></tr><tr><td><i>MSMEG_4713</i></td><td>16.5</td><td>4.6E-06</td><td><i>citE</i></td><td><i>Rv2498c</i></td><td>HpcH/HpaI aldolase/citrate lyase family protein</td></tr><tr><td><i>MSMEG_4712</i></td><td>8.4</td><td>1.1E-04</td><td><i>bkdA</i></td><td><i>Rv2497c</i></td><td>Part of branched-chain keto-acid dehydrogenase complex†</td></tr><tr><td><i>MSMEG_4711</i></td><td>3.3</td><td>3.3E-02</td><td><i>bkdB</i></td><td><i>Rv2496c</i></td><td>Part of branched-chain keto-acid dehydrogenase complex</td></tr><tr><td><i>MSMEG_4710</i></td><td>1.8</td><td>4.9E-01</td><td><i>bkdC</i></td><td><i>Rv2495c</i></td><td>Part of branched-chain keto-acid dehydrogenase complex</td></tr><tr><td><i>MSMEG_4005</i></td><td>−3.2</td><td>2.5E-02</td><td><i>–</i></td><td><i>–</i></td><td>Calcium-binding protein</td></tr><tr><td><i>MSMEG_2080</i></td><td>3.1</td><td>3.3E-02</td><td><i>fadE23</i></td><td><i>Rv3140</i></td><td>Putative acyl-CoA dehydrogenase</td></tr><tr><td><i>MSMEG_1885</i></td><td>3.3</td><td>2.2E-02</td><td><i>Rv3230c</i></td><td><i>Rv3230c</i></td><td>Iron–sulphur cluster binding domain protein</td></tr><tr><td><i>MSMEG_1548</i></td><td>3.0</td><td>4.3E-02</td><td><i>–</i></td><td><i>–</i></td><td>Dehydratase (propanediol utilization)</td></tr><tr><td><i>MSMEG_1543</i></td><td>3.2</td><td>2.3E-02</td><td><i>Rv0458</i></td><td><i>Rv0458</i></td><td>EPTC-Inducible aldehyde dehydrogenase</td></tr><tr><td><i>MSMEG_0881</i></td><td>−3.4</td><td>2.2E-02</td><td><i>–</i></td><td><i>–</i></td><td>Hypothetical protein</td></tr><tr><td><i>MSMEG_0066</i></td><td>3.3</td><td>2.2E-02</td><td><i>esxA</i></td><td><i>Rv3875</i></td><td>Early secretory antigenic target</td></tr></table>
c4050b0f73e87df24840dc40d60f84d425cdf75febc77febcc6a4e88c2bb3529.png	simple	<table><tr><td></td><td>Microwave biosensor [42]</td><td>Terahertz biosensor [48]</td><td>Plasmonic biosensor [55]</td></tr><tr><td>Unit size</td><td>mm</td><td>um</td><td>nm</td></tr><tr><td>Operating frequency</td><td>GHz</td><td>THz</td><td>100–800 THz</td></tr><tr><td>Application field</td><td>Detect binding of biomolecules</td><td>Detect biomolecular composition</td><td>Detect refractive index of biomolecules</td></tr><tr><td>Sensitivity</td><td>20 MHz</td><td>4 GHz</td><td>32,000 nm per RIU</td></tr><tr><td>Advantages</td><td>Low cost</td><td>High concentration of electric field</td><td>High sensitivity</td></tr><tr><td>Drawbacks</td><td>Large area</td><td>Higher cost</td><td>High cost, complicated fabricated process</td></tr></table>
9218657afc02033380e2f5b6240ae8dc4393af2c5311cb77e48ca8fc1a622a40.png	complex	<table><tr><td> </td><td colspan="3">Men (n = 371)</td><td colspan="3">Women (n = 438)</td><td colspan="3">Total (n = 809)</td></tr><tr><td> </td><td>Healthy (n = 300)</td><td>Controlled asthma (n = 59)</td><td>Uncontrolled asthma (n = 12)</td><td>Healthy (n = 306)</td><td>Controlled asthma (n = 66)</td><td>Uncontrolled asthma (n = 66)</td><td>Healthy (n = 606)</td><td>Controlled asthma (n = 125)</td><td>Uncontrolled asthma (n = 78)</td></tr><tr><td>Age, years , median (IQR)</td><td>50.0 (28.0)</td><td>36.0 (25.0)</td><td>56.5 (15.0)</td><td>55.00 (20)</td><td>50.00 (28)</td><td>53.50 (22)</td><td>53.0 (24)</td><td>43.0 (28.0)</td><td>54.0 (21.5)</td></tr><tr><td>BMI, median (IQR)</td><td>25.4 (5.0)</td><td>24.7 (4.0)</td><td>27.6 (4.0)</td><td>24.67 (6)</td><td>24.98 (7)</td><td>26.26 (8)</td><td>25.1 (5)</td><td>24.9 (5.1)</td><td>26.6 (6.6)</td></tr><tr><td>SES, n (%)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> High</td><td>26 (8.8)</td><td>10 (16.9)</td><td>2 (16.7)</td><td>15 (5.0)</td><td>4 (6.1)</td><td>1 (1.5)</td><td>41 (6.8)</td><td>14 (11.2)</td><td>3 (3.9)</td></tr><tr><td> Medium</td><td>238 (80.4)</td><td>45 (76.3)</td><td>7 (58.3)</td><td>224 (73.9)</td><td>56 (84.8)</td><td>49 (75.4)</td><td>462 (77.1)</td><td>101 (80.8)</td><td>56 (72.7)</td></tr><tr><td> Low</td><td>32 (10.8)</td><td>4 (6.8)</td><td>3 (25.0)</td><td>64 (21.1)</td><td>6 (9.1)</td><td>15 (23.1)</td><td>96 (16.0)</td><td>10 (8.0)</td><td>18 (23.4)</td></tr><tr><td>Smoking, n (%)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Never</td><td>147 (49.0)</td><td>30 (50.8)</td><td>5 (41.7)</td><td>259 (84.6)</td><td>50 (75.8)</td><td>51 (77.3)</td><td>406 (67–0)</td><td>80 (64.0)</td><td>56 (71.8)</td></tr><tr><td> Ever</td><td>153 (51.0)</td><td>29 (49.2)</td><td>7 (58.3)</td><td>47 (15.4)</td><td>16 (24.2)</td><td>15 (22.7)</td><td>200 (33.0)</td><td>45 (36.0)</td><td>22 (28.2)</td></tr><tr><td>Daily sitting time, min, median (IQR)</td><td>240.0 (240.0)<sup>,§</sup></td><td>300.0 (330.0)<sup>, §</sup></td><td>180.0 (195.0)</td><td>180.00 (180)</td><td>180.00 (180)</td><td>180.00 (210)</td><td>180.0 (180.0)</td><td>240.0 (300.0)</td><td>180.0 (187.5)</td></tr><tr><td>VPA, MET-min/week, median (IQR)</td><td>340.0 (1920.0)<sup>§</sup></td><td>960.0 (2880.0)<sup>§</sup></td><td>960.0 (5130.0)</td><td>0.00 (560)<sup>, §§</sup></td><td>0.00 (960)</td><td>0.00 (1380)*<sup>, §§</sup></td><td>0.0 (960.0)</td><td>240.0 (1440.0)</td><td>0.0 (1920.0)</td></tr><tr><td>MPA, MET-min/week, median (IQR)</td><td>60.0 (720.0)<sup>§</sup></td><td>280.0 (960.0)<sup>§</sup></td><td>120.0 (720.0)</td><td>280.00 (3360)</td><td>280.00 (3360)</td><td>450.00 (3360)</td><td>280.0 (1680.0)</td><td>280.0 (1680.0)</td><td>360.0 (3360.0)</td></tr><tr><td>WPA, MET-min/week, median (IQR)</td><td>346.5 (693.0)</td><td>594.0 (941.0)</td><td>577.5 (1361.0)</td><td>429.00 (759)</td><td>346.50 (743)</td><td>346.50 (594)</td><td>396.0 (742.5)</td><td>462.0 (1089.0)</td><td>371.3 (594.0)</td></tr><tr><td>Total PA, MET-min/week, median (IQR)</td><td>1657.5 (3627.0)</td><td>2000.0 (4194.0)</td><td>2253.0 (6373.0)</td><td>1680.00 (4347)</td><td>1732.50 (5993)</td><td>2273.00 (4499)</td><td>16660. (3861.6)</td><td>1878.0 (5579.5)</td><td>2273.0 (4499.3)</td></tr><tr><td>Overall PA level, n(%)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Low</td><td>91 (30.3)</td><td>18 (25.0)</td><td>3 (25.0)</td><td>83 (27.1)</td><td>22 (33.3)</td><td>17 (25.8)</td><td>174 (28.7)</td><td>40 (32.0)</td><td>20 (25.6)</td></tr><tr><td> Moderate</td><td>114 (38.0)</td><td>24 (40.7)</td><td>5 (41.7)</td><td>114 (37.3)</td><td>21 (31.8)</td><td>23 (34.8)</td><td>228 (37.6)</td><td>45 (36.0)</td><td>28 (35.9)</td></tr><tr><td> HEPA</td><td>95 (31.7)</td><td>17 (28.8)</td><td>4 (33.3)</td><td>109 (35.6)</td><td>23 (34.8)</td><td>29 (39.4)</td><td>204 (33.7)</td><td>40 (32.0)</td><td>30 (38.5)</td></tr><tr><td>2007 PA recommendation, n(%)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>161 (53.7)</td><td>27 (45.8)</td><td>5 (41.7)</td><td>151 (49.3)</td><td>31 (47.0)</td><td>29 (43.9)</td><td>312 (51.5)</td><td>58 (46.4)</td><td>34 (43.6)</td></tr><tr><td> Yes</td><td>139 (46.3)</td><td>32 (54.2)</td><td>7 (58.3)</td><td>155 (50.7)</td><td>35 (53.0)</td><td>37 (56.1)</td><td>294 (48.5)</td><td>67 (53.6)</td><td>44 (56.4)</td></tr></table>
93d8136be125af434dd5f958f3bb76cc59fed65aa6876c7e410f8bba4cf36ceb.png	complex	<table><tr><td></td><td></td><td colspan="7">EGFR-IHC result</td><td colspan="6">EGFR-FISH result</td></tr><tr><td></td><td></td><td colspan="4">System 1</td><td colspan="3">System 4</td><td colspan="3">FISH Positive</td><td colspan="3">Amplification</td></tr><tr><td></td><td>N</td><td>L</td><td>M</td><td>H</td><td><i>P</i></td><td>L</td><td>H</td><td><i>P</i></td><td>No</td><td>Yes</td><td><i>P</i></td><td>No</td><td>Yes</td><td><i>P</i></td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Male</td><td>80</td><td>42</td><td>32</td><td>6</td><td>0.724</td><td>74</td><td>6</td><td>0.509</td><td>52</td><td>28</td><td>0.022</td><td>74</td><td>6</td><td>0.861</td></tr><tr><td> Female</td><td>16</td><td>7</td><td>7</td><td>2</td><td></td><td>14</td><td>2</td><td></td><td>15</td><td>1</td><td></td><td>15</td><td>1</td><td></td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> <60</td><td>34</td><td>24</td><td>8</td><td>2</td><td>0.017</td><td>22</td><td>12</td><td>0.422</td><td>22</td><td>12</td><td>0.422</td><td>32</td><td>2</td><td>0.694</td></tr><tr><td> >60</td><td>62</td><td>25</td><td>31</td><td>6</td><td></td><td>45</td><td>17</td><td></td><td>45</td><td>17</td><td></td><td>57</td><td>5</td><td></td></tr><tr><td>Tumor site</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Upper</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0.181</td><td>1</td><td>0</td><td>0.607</td><td>1</td><td>0</td><td>0.313</td><td>1</td><td>0</td><td>0.413</td></tr><tr><td> Middle</td><td>33</td><td>12</td><td>17</td><td>4</td><td></td><td>29</td><td>4</td><td></td><td>20</td><td>13</td><td></td><td>29</td><td>4</td><td></td></tr><tr><td> Lower</td><td>62</td><td>37</td><td>21</td><td>4</td><td></td><td>58</td><td>4</td><td></td><td>46</td><td>16</td><td></td><td>59</td><td>3</td><td></td></tr><tr><td>T-stage</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> T1</td><td>5</td><td>2</td><td>3</td><td>0</td><td>0.889</td><td>5</td><td>0</td><td>0.499</td><td>3</td><td>2</td><td>0.552</td><td>5</td><td>0</td><td>0.602</td></tr><tr><td> T2</td><td>24</td><td>13</td><td>9</td><td>2</td><td></td><td>23</td><td>1</td><td></td><td>15</td><td>9</td><td></td><td>23</td><td>1</td><td></td></tr><tr><td> T3</td><td>67</td><td>34</td><td>27</td><td>6</td><td></td><td>60</td><td>7</td><td></td><td>49</td><td>18</td><td></td><td>61</td><td>6</td><td></td></tr><tr><td>Vaso invasion</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>77</td><td>34</td><td>35</td><td>8</td><td>0.020</td><td>69</td><td>8</td><td>0.142</td><td>54</td><td>23</td><td>0.884</td><td>70</td><td>7</td><td>0.172</td></tr><tr><td> Yes</td><td>19</td><td>15</td><td>4</td><td>0</td><td></td><td>19</td><td>0</td><td></td><td>13</td><td>6</td><td></td><td>19</td><td>0</td><td></td></tr><tr><td>Nerve invasion</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>62</td><td>34</td><td>24</td><td>4</td><td>0.497</td><td>59</td><td>3</td><td>0.094</td><td>44</td><td>18</td><td>0.735</td><td>59</td><td>3</td><td>0.212</td></tr><tr><td> Yes</td><td>34</td><td>15</td><td>15</td><td>4</td><td></td><td>29</td><td>5</td><td></td><td>23</td><td>11</td><td></td><td>30</td><td>4</td><td></td></tr><tr><td>LN metastases</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>52</td><td>29</td><td>22</td><td>1</td><td>0.046</td><td>51</td><td>1</td><td>0.013</td><td>39</td><td>13</td><td>0.227</td><td>51</td><td>1</td><td>0.028</td></tr><tr><td> Yes</td><td>44</td><td>20</td><td>17</td><td>7</td><td></td><td>37</td><td>7</td><td></td><td>28</td><td>16</td><td></td><td>38</td><td>6</td><td></td></tr><tr><td>Necrosis</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>38</td><td>21</td><td>16</td><td>1</td><td>0.258</td><td>36</td><td>2</td><td>0.378</td><td>27</td><td>11</td><td>0.828</td><td>37</td><td>1</td><td>0.155</td></tr><tr><td> Yes</td><td>58</td><td>28</td><td>23</td><td>7</td><td></td><td>52</td><td>6</td><td></td><td>40</td><td>18</td><td></td><td>52</td><td>6</td><td></td></tr><tr><td>Mitoses (/10HPF)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> ≤20</td><td>29</td><td>12</td><td>15</td><td>2</td><td>0.645</td><td>27</td><td>2</td><td>0.307</td><td>18</td><td>11</td><td>0.06</td><td>27</td><td>2</td><td>0.768</td></tr><tr><td> 20~50</td><td>37</td><td>20</td><td>13</td><td>4</td><td></td><td>32</td><td>5</td><td></td><td>31</td><td>6</td><td></td><td>35</td><td>2</td><td></td></tr><tr><td> ≥50</td><td>30</td><td>17</td><td>11</td><td>2</td><td></td><td>29</td><td>1</td><td></td><td>18</td><td>12</td><td></td><td>27</td><td>3</td><td></td></tr><tr><td>Tumour differentiation</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> G2</td><td>61</td><td>33</td><td>26</td><td>2</td><td>0.061</td><td>43</td><td>18</td><td>0.844</td><td>43</td><td>18</td><td>0.844</td><td>57</td><td>4</td><td>0.715</td></tr><tr><td> G3</td><td>35</td><td>16</td><td>13</td><td>6</td><td></td><td>24</td><td>11</td><td></td><td>24</td><td>11</td><td></td><td>32</td><td>3</td><td></td></tr></table>
2861699e197bb50546e56be5c1b65f7729f273ff5dda3f70118581fec1063421.png	simple	<table><tr><td>Location</td><td>Number of HC‐markers (Table S2)</td><td>Estimated proteome size</td><td>Proteome coverage (%)</td><td>GFP localization (%)</td><td>Correct GFP localization (%)</td></tr><tr><td>CYT</td><td>2512</td><td>5587</td><td>45</td><td>15</td><td>74</td></tr><tr><td>ER</td><td>323</td><td>716</td><td>45</td><td>40</td><td>82</td></tr><tr><td>EXC</td><td>1495</td><td>3320</td><td>45</td><td>5</td><td>40</td></tr><tr><td>GLG</td><td>239</td><td>524</td><td>45</td><td>41</td><td>92</td></tr><tr><td>MT</td><td>1073</td><td>2383</td><td>45</td><td>22</td><td>83</td></tr><tr><td>NCL</td><td>3274</td><td>7274</td><td>45</td><td>14</td><td>87</td></tr><tr><td>PRX</td><td>135</td><td>295</td><td>45</td><td>61</td><td>85</td></tr><tr><td>PLTD</td><td>1437</td><td>3192</td><td>45</td><td>20</td><td>80</td></tr><tr><td>PM</td><td>1193</td><td>2649</td><td>45</td><td>22</td><td>85</td></tr><tr><td>VAC</td><td>213</td><td>469</td><td>45</td><td>46</td><td>84</td></tr></table>
2cb37a04d95dfc002d6e1e2b0098c69fc422bb7d8c7c5ad5a933e761a10d51da.png	simple	<table><tr><td>Amino Acid Pattern</td><td>T1</td><td>T2</td><td>T3</td><td><i>p</i> for Trend</td></tr><tr><td>Pattern 1</td><td></td><td></td><td></td><td></td></tr><tr><td>Crude</td><td>1.00</td><td>0.97 (0.79–1.20)</td><td>1.07 (0.87–1.31)</td><td>0.61</td></tr><tr><td>Model 1</td><td>1.00</td><td>0.97 (0.78–1.19)</td><td>1.06 (0.86–1.29)</td><td>0.67</td></tr><tr><td>Model 2</td><td>1.00</td><td>0.97 (0.85–1.30)</td><td>1.05 (0.78–1.19)</td><td>0.85</td></tr><tr><td>Pattern 2</td><td></td><td></td><td></td><td></td></tr><tr><td>Crude</td><td>1.00</td><td>1.00 (0.82–1.22)</td><td>0.87 (0.71–1.07)</td><td>0.33</td></tr><tr><td>Model 1</td><td>1.00</td><td>0.92 (0.76–1.13)</td><td>0.83 (0.68–1.03)</td><td>0.24</td></tr><tr><td>Model 2</td><td>1.00</td><td>0.91 (0.74–1.11)</td><td>0.81 (0.65–1.01)</td><td>0.17</td></tr><tr><td>Pattern 3</td><td></td><td></td><td></td><td></td></tr><tr><td>Crude</td><td>1.00</td><td>0.95 (0.77–1.17)</td><td>1.30 (1.07–1.58)</td><td>0.003</td></tr><tr><td>Model 1</td><td>1.00</td><td>1.00 (0.81–1.24)</td><td>1.24 (1.01–1.51)</td><td>0.04</td></tr><tr><td>Model 2</td><td>1.00</td><td>1.00 (0.81–1.24)</td><td>1.24 (1.02–1.52)</td><td>0.05</td></tr></table>
7c66980a3bc856db6e0a80fea8f199a799fadbcca87fa515698b4e10d3fbc641.png	complex	<table><tr><td></td><td colspan="4"><i>Trend percentage at T3 per T1-T2 risk state</i></td></tr><tr><td><i>T1-T2 risk state </i>(N = 180,767)</td><td><i>(0)</i></td><td><i>(1)</i></td><td><i>Comparison of order</i></td><td><i>Trend statistic (Z)</i></td></tr><tr><td>Low-Low<sup>a</sup></td><td>82.4<sup>(1)</sup></td><td>17.6</td><td>Vs. d</td><td>-68.2</td></tr><tr><td>Low-Medium<sup>b</sup></td><td>52.5<sup>(3)</sup></td><td>47.5</td><td>Vs. g</td><td>-11.4</td></tr><tr><td>Low-High<sup>c</sup></td><td>35.8<sup>(5)</sup></td><td>64.2</td><td>Vs. e</td><td>-44.7</td></tr><tr><td>Medium-Low<sup>d</sup></td><td>58.6<sup>(2)</sup></td><td>41.4</td><td>Vs. b</td><td>-11.2</td></tr><tr><td>Medium-Medium<sup>e</sup></td><td>34.0<sup>(6)</sup></td><td>66.0</td><td>Vs. h</td><td>-18.0</td></tr><tr><td>Medium-High<sup>f</sup></td><td>21.5<sup>(8)</sup></td><td>78.5</td><td>Vs. i</td><td>-27.7</td></tr><tr><td>High-Low<sup>g</sup></td><td>43.5<sup>(4)</sup></td><td>56.5</td><td>Vs. c</td><td>-26.2</td></tr><tr><td>High-Medium<sup>h</sup></td><td>22.6<sup>(7)</sup></td><td>77.4</td><td>Vs. f</td><td>-43.8</td></tr><tr><td>High-High<sup>i</sup></td><td>11.7<sup>(9)</sup></td><td>88.3</td><td>-</td><td>-</td></tr></table>
8fe0b30619822434160b423ad4d57b589803a2f57a6f26b7e004466a0bf3a620.png	simple	<table><tr><td>Characteristics</td><td>Scabies infected cases, <i>n</i></td><td>%</td></tr><tr><td>No. of cases</td><td>14 883 (100.0%)</td><td></td></tr><tr><td>Age (mean ± SD, years)</td><td>52.4 ± 21.0</td><td></td></tr><tr><td> 20–29</td><td>2831</td><td>19.0</td></tr><tr><td> 30–39</td><td>2190</td><td>14.7</td></tr><tr><td> 40–49</td><td>2259</td><td>15.2</td></tr><tr><td> 50–59</td><td>2065</td><td>13.9</td></tr><tr><td> 60–69</td><td>1537</td><td>10.3</td></tr><tr><td> ≥70</td><td>4001</td><td>26.9</td></tr><tr><td>Sex</td><td></td><td></td></tr><tr><td> Female</td><td>7026</td><td>47.2</td></tr><tr><td> Male</td><td>7857</td><td>52.8</td></tr><tr><td>Comorbidity disease*</td><td></td><td></td></tr><tr><td> Chronic pulmonary disease</td><td>3054</td><td>20.5</td></tr><tr><td> Diabetes</td><td>2396</td><td>16.1</td></tr><tr><td> Hypertension</td><td>4905</td><td>33.0</td></tr><tr><td> Peptic ulcer disease</td><td>2502</td><td>16.8</td></tr><tr><td> Mild liver disease</td><td>1113</td><td>7.5</td></tr><tr><td> Congestive heart failure</td><td>808</td><td>5.4</td></tr><tr><td> Rheumatologic disease</td><td>667</td><td>4.5</td></tr><tr><td> Cerebrovascular disease</td><td>2773</td><td>18.6</td></tr><tr><td> Malignancy</td><td>572</td><td>3.8</td></tr><tr><td> Parkinson disease</td><td>808</td><td>5.4</td></tr><tr><td> Tuberculosis</td><td>522</td><td>3.5</td></tr><tr><td> Chronic kidney disease</td><td>223</td><td>1.5</td></tr><tr><td> Liver cirrhosis</td><td>1294</td><td>8.7</td></tr><tr><td> Hyperlipidemia</td><td>901</td><td>6.1</td></tr><tr><td> Heart disease</td><td>3672</td><td>24.7</td></tr><tr><td> Anemia</td><td>1169</td><td>7.9</td></tr><tr><td> Epilepsy</td><td>420</td><td>2.8</td></tr><tr><td>Insured amount (NTD)</td><td></td><td></td></tr><tr><td> <20,000</td><td>4385</td><td>29.5</td></tr><tr><td> 20,000–40,000</td><td>7656</td><td>51.4</td></tr><tr><td> 40,000–60,000</td><td>2012</td><td>13.5</td></tr><tr><td> ≧60,000</td><td>830</td><td>5.6</td></tr><tr><td>Insured region in Taiwan</td><td></td><td></td></tr><tr><td> Northern</td><td>6569</td><td>44.1</td></tr><tr><td> Middle</td><td>3374</td><td>22.7</td></tr><tr><td> Southern</td><td>4363</td><td>29.3</td></tr><tr><td> Eastern and outlying islands</td><td>577</td><td>3.9</td></tr></table>
d852c4f75ced6026a99f5a13f3f7cf47035852a84b5bcd9663154795e2bfe331.png	simple	<table><tr><td>Variable</td><td>Total (<i>n</i> = 240) (%)</td></tr><tr><td>Teaching years </td><td> </td></tr><tr><td> (1) (1–<10)</td><td>116 (48.3%)</td></tr><tr><td> (2) (10–<20)</td><td>86 (35.8%)</td></tr><tr><td> (3) (20–<30)</td><td>38 (15.8%)</td></tr><tr><td>Classes per day </td><td> </td></tr><tr><td> (1) (1–4)</td><td>184 (76.7%)</td></tr><tr><td> (2) (5–7)</td><td>56 (23.3%) </td></tr><tr><td>Classes per week </td><td> </td></tr><tr><td> (1) (1–9)</td><td>15 (6.2%)</td></tr><tr><td> (2) (10–19)</td><td>142 (59.2%)</td></tr><tr><td> (3) (20–30)</td><td> 83 (34.6%) </td></tr><tr><td>Daily hours </td><td> </td></tr><tr><td> (1) (3–6)</td><td>27 (11.2%)</td></tr><tr><td> (2) (7–9)</td><td>213 (88.8%)</td></tr><tr><td>Students per class </td><td> </td></tr><tr><td> (1) (5–19)</td><td>16 (6.7%)</td></tr><tr><td> (2) (20–34)</td><td>151 (62.9%)</td></tr><tr><td> (3) (35–50)</td><td>73 (30.4%) </td></tr></table>
e830c079c9b5d23f4748448d03cf736a91ff85cf8ff7bb82360610cc56609d2c.png	simple	<table><tr><td>MIGS ID</td><td>Property</td><td>Term</td><td>Evidence code<sup>a</sup></td></tr><tr><td></td><td>Classification</td><td>Domain <i>Bacteria</i></td><td>TAS [70]</td></tr><tr><td></td><td></td><td>Phylum <i>Cyanobacteria</i></td><td>TAS [71, 72]</td></tr><tr><td></td><td></td><td>Class <i>Oscillatoriophycideae</i></td><td>TAS [73]</td></tr><tr><td></td><td></td><td>Order <i>Chroococcales</i></td><td>TAS [73, 74]</td></tr><tr><td></td><td></td><td>Family <i>Microcystaceae</i></td><td>TAS [74]</td></tr><tr><td></td><td></td><td>Genus <i>Microcystis</i></td><td>TAS [71, 75]</td></tr><tr><td></td><td></td><td>Species <i>M. panniformis</i></td><td>TAS [15, 31]</td></tr><tr><td></td><td></td><td>Strain: <i>M. panniformis</i> FACHB1757</td><td>TAS [26]</td></tr><tr><td></td><td>Gram stain</td><td>Gram-negative</td><td>TAS [76]</td></tr><tr><td></td><td>Cell shape</td><td>Spherical cells</td><td>TAS [15]</td></tr><tr><td></td><td>Motility</td><td>Non-motile</td><td>NAS</td></tr><tr><td></td><td>Sporulation</td><td>None</td><td>TAS [76]</td></tr><tr><td></td><td>Temperature range</td><td>Mesophile</td><td>NAS</td></tr><tr><td></td><td>Optimum temperature</td><td>29.5 °C</td><td>IDA</td></tr><tr><td></td><td>pH range; Optimum</td><td>pH 7.50-9.21; pH 8.33</td><td>IDA</td></tr><tr><td></td><td>Carbon source</td><td>Autotroph, heterotroph</td><td>NAS</td></tr><tr><td>MIGS-6</td><td>Habitat</td><td>Fresh water</td><td>NAS</td></tr><tr><td>MIGS-6.3</td><td>Salinity</td><td>1.0 % (maximum)</td><td>IDA</td></tr><tr><td>MIGS-22</td><td>Oxygen requirement</td><td>Aerobic</td><td>NAS</td></tr><tr><td>MIGS-15</td><td>Biotic relationship</td><td>Free-living</td><td>NAS</td></tr><tr><td>MIGS-14</td><td>Pathogenicity</td><td>Microcystins (MCY) </td><td>TAS [25, 77]</td></tr><tr><td>MIGS-4</td><td>Geographic location</td><td>Isolated Lake Taihu, China</td><td>IDA</td></tr><tr><td>MIGS-5</td><td>Sample collection</td><td>August, 2015</td><td>IDA</td></tr><tr><td>MIGS-4.1</td><td>Latitude</td><td>31.421 N</td><td>IDA</td></tr><tr><td>MIGS-4.2</td><td>Longitude</td><td>120.201E</td><td>IDA</td></tr><tr><td>MIGS-4.3</td><td>Depth</td><td>Surface 0.5 m</td><td>IDA</td></tr><tr><td>MIGS-4.3</td><td>Altitude</td><td>11 m</td><td>IDA</td></tr></table>
dbd4cc112b691a18360b1ed532f1afcabd26272af98f8954296b2f2699c28711.png	simple	<table><tr><td>Recipient vessels</td><td>Venous number (%)</td><td>Arterial number (%)</td></tr><tr><td>Retrograde IM vessel</td><td>11 (44)</td><td>16 (64)</td></tr><tr><td>Anterograde IM vessel</td><td>6 (24)</td><td>0 (0)</td></tr><tr><td>Superior pedicle continuity</td><td>5 (20)</td><td>5 (20)</td></tr><tr><td>Inferior pedicle continuity</td><td>3 (12)</td><td>3 (12)</td></tr><tr><td>Thoracodorsal vessel</td><td>1 (4)</td><td>1 (4)</td></tr><tr><td>Intercostal perforator</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td>Pectoral vein</td><td>0 (0)</td><td>0 (0)</td></tr></table>
17bb0d70a569095ec3c30ebdfd87a0d9a7bf14478cd1f0b3eef555e25c342c22.png	simple	<table><tr><td>Variables</td><td><i>ρ</i></td><td><i>P</i></td></tr><tr><td>Diagnosis of ANbp</td><td>0.525</td><td>0.017</td></tr><tr><td>Age</td><td>0.345</td><td>0.136</td></tr><tr><td>Body mass index</td><td>0.168</td><td>0.479</td></tr><tr><td>Duration of illness</td><td>0.536</td><td>0.015</td></tr><tr><td>Current menstruation</td><td>0.281</td><td>0.230</td></tr><tr><td>Use of sedative drugs</td><td>0.332</td><td>0.152</td></tr><tr><td>CES-D</td><td>0.318</td><td>0.172</td></tr><tr><td>Vomiting</td><td>0.561</td><td>0.010*</td></tr><tr><td>Chewing</td><td>-0.061</td><td>0.798</td></tr><tr><td>Laxative overuse</td><td>0.407</td><td>0.075</td></tr><tr><td>Uretic misuse</td><td>0.280</td><td>0.232</td></tr></table>
f2884cf8ee545f7e88c552dd98f0f35d96a99df4e209086f8df656b6ea6eb398.png	simple	<table><tr><td>#1</td><td>Rheumatic Heart Disease or Disease, Rheumatic Heart or Diseases, Rheumatic Heart or Heart Disease, Rheumatic or Bouillaud Disease or Disease, Bouillaud</td></tr><tr><td>#2</td><td>IL 10-1082</td></tr><tr><td>#3</td><td>mutation</td></tr><tr><td>#4</td><td>polymorphism</td></tr><tr><td>#5</td><td>variant</td></tr><tr><td>#6</td><td>#1 AND #2 AND (#3 OR #4 OR #5)</td></tr></table>
fe92b5f5da5d97623eb32e802b3cc956bca2fad4280f0ad912dd20a890e19ba2.png	simple	<table><tr><td>Dosimetric Criteria</td><td>Treatment planning system</td><td>Knowledge based engineering tool</td></tr><tr><td>Spinal Cord Maximum Dose (Gy)</td><td>40 ± 2</td><td>44 ± 2</td></tr><tr><td>Esophagus Maximum Dose (Gy)</td><td>68 ± 3</td><td>75 ± 2</td></tr><tr><td>Heart V<sub>30 Gy</sub> (%)</td><td>16 ± 4</td><td>15 ± 3</td></tr><tr><td>Heart V<sub>45 Gy</sub> (%)</td><td>10 ± 3</td><td>9 ± 2</td></tr><tr><td>Lung V<sub>20Gy</sub> (%)</td><td>27 ± 2</td><td>29 ± 2</td></tr><tr><td>Lung mean dose (Gy)</td><td>17 ± 1</td><td>18 ± 2</td></tr></table>
5573a9a772f8186aa42c3298a63a0fe56319c59a4cf12f371bfaeb4b528d1a1a.png	complex	<table><tr><td>Residential</td><td>Time</td><td>Sunlight Intensity (lux)</td><td>Temperature (°C)</td><td>Humidity (%)</td></tr><tr><td rowspan="3">Tebet Barat</td><td>08.00</td><td>44,900</td><td>28.7</td><td>79.4</td></tr><tr><td>12.00</td><td>64,700</td><td>32.7</td><td>63.4</td></tr><tr><td>16.00</td><td>24,400</td><td>27.4</td><td>57.7</td></tr><tr><td rowspan="3">Jagakarsa</td><td>08.00</td><td>26,800</td><td>31.4</td><td>72.6</td></tr><tr><td>12.00</td><td>57,900</td><td>29.7</td><td>60.1</td></tr><tr><td>16.00</td><td>43,400</td><td>33.2</td><td>57.9</td></tr><tr><td rowspan="3">Pasar Minggu</td><td>08.00</td><td>64,800</td><td>26.2</td><td>71.6</td></tr><tr><td>12.00</td><td>62,300</td><td>34.7</td><td>55.9</td></tr><tr><td>16.00</td><td>26,100</td><td>32.5</td><td>61.2</td></tr><tr><td rowspan="3">Cipulir</td><td>08.00</td><td>29,900</td><td>31.5</td><td>71.8</td></tr><tr><td>12.00</td><td>77,900</td><td>33.9</td><td>54.5</td></tr><tr><td>16.00</td><td>23,000</td><td>32.7</td><td>67.1</td></tr></table>
b377444c7dd236474a14d4b08d9cce48a8cebedfc4349c2c38ae415ee2c70fc0.png	simple	<table><tr><td></td><td>FOV (mm)</td><td>Res (mm)</td><td>TR (ms)</td><td>TE (ms)</td><td>FA (deg)</td><td>BW (Hz/px)</td><td>Scan time (s)</td><td># views</td></tr><tr><td>UTE T1</td><td>160×160×160</td><td>1.0×1.0×1.0</td><td>11</td><td>0.05</td><td>8, 36</td><td>1008</td><td>167</td><td>15000</td></tr><tr><td>UTE T2*</td><td>160×160×160</td><td>1.0×1.0×1.0</td><td>6</td><td>0.05, 0.09, 0.13, 0.17, 0.25</td><td>15</td><td>1008</td><td>122</td><td>20000</td></tr></table>
48fbf25cbc0443c4747fb1db7b3952f42b239c659452d432451f256382f6164f.png	simple	<table><tr><td>Marker name</td><td>Position (galGal3 assembly)</td><td>Upper primer</td><td>Lower primer</td><td>PCR annealing T°</td></tr><tr><td>SEQALL0348</td><td><underline>chr1:135392697-135392876</underline></td><td>GCTCAGCACCTCCTCCTC</td><td>AGAAAGCAGCCTCACAAAGC</td><td>55°C</td></tr><tr><td>SEQALL0349</td><td><underline>chr1:135543677-135543882</underline></td><td>AGGGTTTCCAAGTGGTGTTG</td><td>ACCTTGCCTGAGACTGGTG</td><td>55°C</td></tr><tr><td>SEQALL0350</td><td><underline>chr1:135576325-135576564</underline></td><td>CGACAGATGGTCAAGAATGG</td><td>ACACAGTTCTTCGCTGTACG</td><td>55°C</td></tr><tr><td>SEQALL0468</td><td><underline>chr1:64162253-64162451</underline></td><td>TTGCCATTCGAAACATCAAC</td><td>GGACTCTGCTGTGCCAAATAC</td><td>50°C</td></tr><tr><td>SEQALL0469</td><td><underline>chr1:64480773-64480997</underline></td><td>TGAGATGATGAATGGCTTGG</td><td>ATATGCAGCAGGGCTCATTC</td><td>58°C</td></tr><tr><td>SEQALL0470</td><td><underline>chr1:72300927-72301126</underline></td><td>CACAGGTCCACGAGAAAAGG</td><td>TGCAGTCCTTCACATTCTGC</td><td>58°C</td></tr><tr><td>SEQALL0471</td><td><underline>chr1:78494600-78494914</underline></td><td>AGCATCATGACAGTCCAACC</td><td>AGGCCAAATTGTCTCACTCG</td><td>58°C</td></tr><tr><td>SEQALL0472</td><td><underline>chr6:24021693-24022070</underline></td><td>ATCATGCGGCAGAAAAAGAG</td><td>AAATCCATCAGCCTGACAGC</td><td>50°C</td></tr><tr><td>SEQALL0473</td><td><underline>chr6:24772426-24772628</underline></td><td>GAGAGGGAGGGAGATGAAGG</td><td>GAAGAGCTCGTGCAAAAAGC</td><td>58°C</td></tr><tr><td>SEQALL0474</td><td><underline>chr6:25154425-25154640</underline></td><td>TAGGGTTTGGCTGTTGTCTG</td><td>CATTTGGAAACCCAGAGCAG</td><td>58°C</td></tr><tr><td>SEQALL0475</td><td><underline>chr15:4463535-4463868</underline></td><td>ACAGGATGCTGCTGCTCAC</td><td>AATGTTTCCCTTTCCCAACC</td><td>58°C</td></tr><tr><td>SEQALL0476</td><td><underline>chr15:8651118-8651325</underline></td><td>AGCCAAATCCTGTTTCATGC</td><td>TGTCCTTTCTGGGAGAGACG</td><td>58°C</td></tr><tr><td>SEQALL0477</td><td><underline>chr15:9172235-9172553</underline></td><td>CATCCAAGTAACCCCACCTG</td><td>TGTAAGGTGTAGGGCGTTGG</td><td>58°C</td></tr><tr><td>SEQALL0478</td><td><underline>chr1:72181285-72181516</underline></td><td>TGGCTTATGGCAACAAAAATC</td><td>TGGCCGGTAGTGGATAAAAG</td><td>58°C</td></tr><tr><td>SEQALL0479</td><td><underline>chr1:68536797-68537124</underline></td><td>GATGTTCCTGGCACTTATAGGG</td><td>TTTCCCTTTGTTTCTGCATCC</td><td>58°C</td></tr><tr><td>SEQALL0481</td><td><underline>chr1:142664771-142665102</underline></td><td>GCAGCTGCTGTTCCACAAG</td><td>GCTCATTGCATTTTTGCTTTC</td><td>58°C</td></tr><tr><td>SEQALL0482</td><td><underline>chr2:88572048-88572376</underline></td><td>GGAAGTGTGTGTTATGGACTGG</td><td>CTAGGCTGGAACTGGCAGTAG</td><td>58°C</td></tr><tr><td>SEQALL0483</td><td><underline>chr2:90911596-90911826</underline></td><td>TCTTGGAGATCACGGGAAAG</td><td>TGCAACATCAGGACAAGAGG</td><td>58°C</td></tr><tr><td>SEQALL0484</td><td><underline>chr6:5752041-5752395</underline></td><td>CGAGTCTGCTGAATGGACAC</td><td>GCGCAATTAATTCAGGAAGG</td><td>58°C</td></tr><tr><td>SEQALL0485</td><td><underline>chr6:6245960-6246304</underline></td><td>GACCACACAGTCACACGTCAG</td><td>TCTGGAGGAAGCAATAAGAAGTG</td><td>58°C</td></tr><tr><td>SEQALL0486</td><td><underline>chr6:25680338-25680656</underline></td><td>TTCCCCAGGTGCTCTATCAG</td><td>ACCATCGTCTCCTGCCATAG</td><td>58°C</td></tr></table>
1d7afcc6cda46f28cb657e33831c2c4925617d1ac31b238cb915009a7f3f2921.png	simple	<table><tr><td>Characteristics</td><td>n (%)</td><td>Mean ± S.D</td></tr><tr><td><underline>Socio-demography</underline></td><td></td><td></td></tr><tr><td>Age (years)</td><td></td><td>49.7 ± 14.1</td></tr><tr><td>24 – 34</td><td>14 (15.6)</td><td></td></tr><tr><td>35 – 49</td><td>30 (33.3)</td><td></td></tr><tr><td>50 – 64</td><td>28 (31.1)</td><td></td></tr><tr><td>≥ 65</td><td>18 (20.0)</td><td></td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td>Males</td><td>44 (48.9)</td><td></td></tr><tr><td>Females</td><td>46 (51.1)</td><td></td></tr><tr><td>Ethnicity</td><td></td><td></td></tr><tr><td>Chinese</td><td>62 (68.9)</td><td></td></tr><tr><td>Malay</td><td>19 (21.1)</td><td></td></tr><tr><td>Others</td><td>9 (10.0)</td><td></td></tr><tr><td>Educational Level</td><td></td><td></td></tr><tr><td>No formal education</td><td>10 (11.1)</td><td></td></tr><tr><td>Primary school</td><td>33 (36.7)</td><td></td></tr><tr><td>Secondary School </td><td>40 (44.4)</td><td></td></tr><tr><td>Tertiary education </td><td>7 (7.8)</td><td></td></tr><tr><td>Current employment status</td><td></td><td></td></tr><tr><td>Unemployed</td><td>64 (71.1)</td><td></td></tr><tr><td>Government</td><td>2 (2.2)</td><td></td></tr><tr><td>Private</td><td>14 (15.6)</td><td></td></tr><tr><td>Part time</td><td>10 (11.1)</td><td></td></tr><tr><td>Current estimated household income (monthly)</td><td></td><td></td></tr><tr><td><RM 1000</td><td>22 (24.5)</td><td></td></tr><tr><td>RM 1000 - RM 2000</td><td>28 (31.1)</td><td></td></tr><tr><td>RM 2001 - RM 3000</td><td>19 (21.1)</td><td></td></tr><tr><td>> RM 3000</td><td>21 (23.3)</td><td></td></tr><tr><td><underline>Medical History</underline></td><td></td><td></td></tr><tr><td>Primary renal diagnosis</td><td></td><td></td></tr><tr><td>Unknown cause</td><td>30 (33.3)</td><td></td></tr><tr><td>Diabetes mellitus</td><td>20 (22.2)</td><td></td></tr><tr><td>Glomerulonephritis</td><td>7 (7.8)</td><td></td></tr><tr><td>Hypertensive nephrosclerosis</td><td>7 (7.8)</td><td></td></tr><tr><td>Systemic Lupus Erythaematosus (SLE)</td><td>6 (6.7)</td><td></td></tr><tr><td>Others*</td><td>10 (11.1)</td><td></td></tr><tr><td>Presence of co-morbidities</td><td></td><td></td></tr><tr><td>Hypertension</td><td>62 (68.9)</td><td></td></tr><tr><td>Diabetes mellitus</td><td>23 (25.6)</td><td></td></tr><tr><td>Cardiovascular disease </td><td>7 (7.8)</td><td></td></tr><tr><td>Number of prescribed medications</td><td></td><td></td></tr><tr><td>Vitamin and mineral supplements</td><td>85 (94.4)</td><td></td></tr><tr><td>Calcium carbonate</td><td>79 (87.8)</td><td></td></tr><tr><td>Erythropoietin (EPO)</td><td>45 (50.0)</td><td></td></tr><tr><td>Hypercholesterolaemia drugs</td><td>41 (45.6)</td><td></td></tr><tr><td>Antihypertensive drug</td><td>35 (38.9)</td><td></td></tr><tr><td>Oral diabetic agent (ODA)</td><td>18 (20.0)</td><td></td></tr><tr><td>Insulin</td><td>5 (5.6)</td><td></td></tr><tr><td><underline>HD treatment</underline></td><td></td><td></td></tr><tr><td>Duration of dialysis (months) </td><td>90</td><td>55.2 ± 39.0</td></tr><tr><td>Blood flow (ml/minute)</td><td>90</td><td>297 ± 39</td></tr><tr><td>Kt/V</td><td>90</td><td>1.6 ± 0.5</td></tr><tr><td>nPCR (g/kg/day)</td><td>56</td><td>1.1 ± 0.3</td></tr></table>
ba00c957b032f345a138111d2a191246886a4501f8c26db86de36697e2077d28.png	simple	<table><tr><td>Glycerol Content (%)</td><td>Elastic Modulus (MPa)</td><td>Elongation at Break (%)</td><td>Tensile Strength (MPa)</td></tr><tr><td>0</td><td>0.64 ±0.09</td><td>53.58 ±8.69</td><td>0.21 ±0.05</td></tr><tr><td>10</td><td>4.08 ±0.53</td><td>130.37 ±29.67</td><td>0.73 ±0.09</td></tr><tr><td>20</td><td>3.70 ±0.45</td><td>168.24 ±31.47</td><td>1.15 ±0.07</td></tr><tr><td>30</td><td>2.68 ±0.32</td><td>244.67 ±51.70</td><td>1.12 ±0.08</td></tr><tr><td>40</td><td>2.26 ±0.26</td><td>271.33 ±42.51</td><td>1.18 ±0.08</td></tr></table>
2d98bcaf57aec4a11f26b138e9a09c80a94393f4e33d8084a276cd45c9a82cb7.png	simple	<table><tr><td>Variable</td><td>GlavonoidTM Pre(n = 11)</td><td>GlavonoidTM Post(n = 11)</td><td>PlaceboPre(n = 11)</td><td>PlaceboPost(n = 11)</td></tr><tr><td>Insulin (μU·mL<sup>-1</sup>)</td><td>7.9 ± 1.3</td><td>9.2 ± 1.5</td><td>9.1 ± 0.5</td><td>8.4 ± 1.2</td></tr><tr><td>HOMA-IR</td><td>1.6 ± 0.3</td><td>2.0 ± 0.4</td><td>1.9 ± 0.1</td><td>1.9 ± 0.3</td></tr><tr><td>Adiponectin (μg·mL<sup>-1</sup>)</td><td>17.8 ± 1.7</td><td>19.0 ± 2.7</td><td>15.3 ± 3.4</td><td>15.3 ± 3.2</td></tr><tr><td>Resistin (ng·mL<sup>-1</sup>)</td><td>5.7 ± 0.4</td><td>5.9 ± 0.6</td><td>5.1 ± 0.7</td><td>4.8 ± 0.5</td></tr><tr><td>Glucose (mg·dL<sup>-1</sup>)</td><td>84.4 ± 1.9</td><td>85.7 ± 2.9</td><td>83.4 ± 2.7</td><td>88.0 ± 4.2</td></tr><tr><td>BUN (mg·dL<sup>-1</sup>)</td><td>13.6 ± 1.2</td><td>12.6 ± 1.3</td><td>12.7 ± 1.0</td><td>13.8 ± 1.3</td></tr><tr><td>Creatinine (mg·dL<sup>-1</sup>)</td><td>1.0 ± 0.1</td><td>1.0 ± 0.1</td><td>0.9 ± 0.0</td><td>0.9 ± 0.0</td></tr><tr><td>BUN:Creatinine</td><td>14.2 ± 0.8</td><td>13.1 ± 0.6</td><td>14.3 ± 1.5</td><td>15.0 ± 1.6</td></tr><tr><td>Sodium (mmol·L<sup>-1</sup>)†</td><td>137.5 ± 0.4</td><td>139.0 ± 0.5</td><td>138.9 ± 0.5</td><td>139.0 ± 0.5</td></tr><tr><td>Potassium (mmol·L<sup>-1</sup>)</td><td>4.1 ± 0.1</td><td>4.2 ± 0.1</td><td>4.3 ± 0.1</td><td>4.5 ± 0.2</td></tr><tr><td>Chloride (mmol·L<sup>-1</sup>)</td><td>102.5 ± 1.1</td><td>102.1 ± 0.7</td><td>102.7 ± 0.6</td><td>103.1 ± 0.5</td></tr><tr><td>CO<sub>2 </sub>(mmol·L<sup>-1</sup>)</td><td>24.0 ± 0.9</td><td>26.0 ± 0.8</td><td>24.3 ± 0.7</td><td>25.3 ± 0.7</td></tr><tr><td>Calcium (mg·dL<sup>-1</sup>)</td><td>9.4 ± 0.1</td><td>9.2 ± 0.1</td><td>9.4 ± 0.2</td><td>9.1 ± 0.1</td></tr><tr><td>Protein (g·dL<sup>-1</sup>)</td><td>6.9 ± 0.1</td><td>6.9 ± 0.1</td><td>6.9 ± 0.1</td><td>7.0 ± 0.1</td></tr><tr><td>Albumin (g·dL<sup>-1</sup>)</td><td>4.3 ± 0.1</td><td>4.3 ± 0.1</td><td>4.3 ± 0.1</td><td>4.3 ± 0.1</td></tr><tr><td>Globulin (g·dL<sup>-1</sup>)</td><td>2.6 ± 0.1</td><td>2.6 ± 0.1</td><td>2.6 ± 0.1</td><td>2.7 ± 0.1</td></tr><tr><td>A:G</td><td>1.7 ± 0.1</td><td>1.7 ± 0.1</td><td>1.7 ± 0.1</td><td>1.7 ± 0.1</td></tr><tr><td>Bilirubin (mg·dL<sup>-1</sup>)</td><td>0.5 ± 0.1</td><td>0.4 ± 0.1</td><td>0.6 ± 0.1</td><td>0.5 ± 0.1</td></tr><tr><td>Alk Phos (IU·L<sup>-1</sup>)</td><td>67.5 ± 6.8</td><td>65.3 ± 6.5</td><td>72.6 ± 6.3</td><td>70.9 ± 7.4</td></tr><tr><td>AST (SGOT) (IU·L<sup>-1</sup>)*</td><td>23.7 ± 2.5</td><td>26.7 ± 2.3</td><td>21.2 ± 2.1</td><td>19.9 ± 0.9</td></tr><tr><td>ALT (SGPT) (IU·L<sup>-1</sup>)</td><td>23.5 ± 4.0</td><td>28.9 ± 5.2</td><td>20.5 ± 3.9</td><td>21.2 ± 4.9</td></tr></table>
2b5c80c04f12a63b8f72d1860b5748bc1f3194b28fa7032e2b66eba6db732224.png	complex	<table><tr><td rowspan="3">HCV seropositivity status groups(number of subjects)</td><td rowspan="3">group AHCV Ab(−)<i>n</i> = 968</td><td rowspan="3">group B and CHCV Ab(+)<i>n</i> = 109</td><td>group B</td><td>group C</td><td rowspan="3">All subjects<i>n</i> = 1077</td></tr><tr><td>HCV Ab(+) Ag(−)<i>n</i> = 39</td><td>HCV Ab(+) Ag(+)<i>n</i> = 70</td></tr><tr><td>all-cause death (crude mortality)</td><td>356 (92.7)</td><td>50 (127)</td><td>14 (94.0)</td><td>36 (147)</td><td>406 (95.9)</td></tr><tr><td> adjusted mortality (95% CI)</td><td>71.9 (62.6–81.3)</td><td>123 (88.6–158)</td><td>80.4 (37.9–123)</td><td>156 (104–207)</td><td>96.5 (75.5–118)</td></tr><tr><td> RR (95% CI)</td><td>REF</td><td>1.71 (1.27–2.30)</td><td>1.12 (0.66–1.91)</td><td>2.16 (1.53–3.07)</td><td> </td></tr><tr><td>cardiovascular (crude mortality)</td><td>173 (45.1)</td><td>21 (53.4)</td><td>4 (26.9)</td><td>17 (69.5)</td><td>194 (45.8)</td></tr><tr><td> adjusted mortality (95% CI)</td><td>37.2 (30.5–43.9)</td><td>53.0 (30.0–76.0)</td><td>24.3 (0.40–48.2)</td><td>73.5 (38.0–109)</td><td>40.5 (25.3–55.7)</td></tr><tr><td> RR (95% CI)</td><td>REF</td><td>1.42 (0.90–2.44)</td><td>0.65 (0.24–1.76)</td><td>1.98 (1.19–3.28)</td><td> </td></tr><tr><td>infectious disease-related (crude mortality)</td><td>97 (25.3)</td><td>15 (38.1)</td><td>5 (33.6)</td><td>10 (40.9)</td><td>112 (26.5)</td></tr><tr><td> adjusted mortality (95% CI)</td><td>17.8 (13.1–22.5)</td><td>35.6 (17.1–54.1)</td><td>25.7 (2.70–48.7)</td><td>43.6 (16.3–71.0)</td><td>27.1 (16.5–37.7)</td></tr><tr><td> RR (95% CI)</td><td>REF</td><td>1.99 (1.15–3.43)</td><td>1.45 (0.50–3.56)</td><td>2.46 (1.27–4.76)</td><td> </td></tr><tr><td>liver disease-related (crude mortality)</td><td>2 (0.52)</td><td>5 (12.7)</td><td>1 (6.71)</td><td>4 (16.4)</td><td>7 (1.65)</td></tr><tr><td> adjusted mortality (95% CI)</td><td>0.40 (0.00–1.10)</td><td>9.80 (0.00–21.5)</td><td>5.70 (0.00–17.4)</td><td>12.8 (0.00–29.6)</td><td>3.10 (0.00–6.60)</td></tr><tr><td> RR (95% CI)</td><td>REF</td><td>24.2 (4.56–128)</td><td>13.7 (1.24–152)</td><td>30.8 (5.34–178)</td><td> </td></tr></table>
faa0a0bde10fede158d5c8678dbddc455c79c200882f89af1360a2575ce30832.png	complex	<table><tr><td></td><td colspan="4">Off-treatment analysis</td><td></td><td></td></tr><tr><td></td><td colspan="2">Included</td><td colspan="2">Excluded</td><td colspan="2">FREEDOM25</td></tr><tr><td></td><td>Placebo (<i>N</i>1 = 470)</td><td>Denosumab (<i>N</i>1 = 327)</td><td>Placebo (<i>N</i>2 = 520)</td><td>Denosumab (<i>N</i>2 = 466)</td><td>Placebo (<i>N</i>3 = 3906)</td><td>Denosumab (<i>N</i>3 = 3902)</td></tr><tr><td>Baseline characteristics</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Age, years (mean ± SD)</td><td>73 ± 5</td><td>73 ± 5</td><td>74 ± 5</td><td>73 ± 5</td><td>72 ± 5</td><td>72 ± 5</td></tr><tr><td> Prevalent fracture, <i>n</i> (%)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Vertebral</td><td>122 (26)</td><td>89 (27)</td><td>155 (30)</td><td>107 (23)</td><td>915 (23)</td><td>929 (24)</td></tr><tr><td>Nonvertebral</td><td>149 (32)</td><td>107 (33)</td><td>168 (32)</td><td>149 (32)</td><td>1177 (30)</td><td>1163 (30)</td></tr><tr><td> BMD <i>T</i>-score (mean ± SD)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Lumbar spine</td><td>−2.8 ± 0.7</td><td>−2.8 ± 0.8</td><td>−2.8 ± 0.7</td><td>−2.8 ± 0.7</td><td>−2.8 ± 0.7</td><td>−2.8 ± 0.7</td></tr><tr><td>Total hip</td><td>−2.1 ± 0.9</td><td>−2.0 ± 0.9</td><td>−2.1 ± 0.8</td><td>−2.0 ± 0.8</td><td>−1.9 ± 0.8</td><td>−1.9 ± 0.8</td></tr><tr><td> Prior bisphosphonate use, <i>n</i> (%)</td><td>62 (13)</td><td>46 (14)</td><td>66 (13)</td><td>61 (13)</td><td>521 (13)</td><td>472 (12)</td></tr><tr><td>Duration, years</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>n</i>1</td><td>54</td><td>41</td><td>56</td><td>54</td><td>460</td><td>415</td></tr><tr><td>Mean</td><td>1.0</td><td>1.0</td><td>0.9</td><td>0.9</td><td>0.9</td><td>0.9</td></tr><tr><td>Median (Q1, Q3)</td><td>0.8 (0.3, 1.4)</td><td>1.0 (0.1, 2.0)</td><td>0.5 (0.2, 1.0)</td><td>1.0 (0.2, 1.5)</td><td>0.5 (0.2, 1.6)</td><td>0.8 (0.2, 1.3)</td></tr><tr><td>Per-subject follow-up, yearsa</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mean</td><td>0.8</td><td>0.8</td><td>0.3</td><td>0.3</td><td>2.8</td><td>2.8</td></tr><tr><td>Median (Q1, Q3)</td><td>0.5 (0.3, 1.4)</td><td>0.5 (0.2, 1.4)</td><td>0 (0,0)</td><td>0 (0, 0)</td><td>3.0 (3.0, 3.0)</td><td>3.0 (3.0, 3.0)</td></tr></table>
748a88d641cfabea340e2e62f5ab6cca6829e8931319ad198d0807c2d21736db.png	simple	<table><tr><td></td><td>Apoptotic cells sub-G1</td><td>G1</td><td>S</td><td>G2/M</td></tr><tr><td>FemX</td><td></td><td></td><td></td><td></td></tr><tr><td>Control</td><td>0.30</td><td>58.19</td><td>15.42</td><td>22.87</td></tr><tr><td><i>T. candida</i></td><td>5.34</td><td>47.64</td><td>15.09</td><td>31.93</td></tr><tr><td><i>U. barbata</i></td><td>6.90</td><td>46.65</td><td>9.36</td><td>37.09</td></tr><tr><td>Norstictic acid</td><td>18.20</td><td>43.81</td><td>15.30</td><td>18.62</td></tr><tr><td>Usnic acid</td><td>10.18</td><td>54.38</td><td>14.64</td><td>20.37</td></tr><tr><td>LS 174</td><td></td><td></td><td></td><td></td></tr><tr><td>Control</td><td>2.55</td><td>49.53</td><td>12.06</td><td>32.21</td></tr><tr><td><i>T. candida</i></td><td>15.83</td><td>47.35</td><td>15.89</td><td>20.66</td></tr><tr><td><i>U. barbata</i></td><td>13.87</td><td>46.47</td><td>16.82</td><td>22.85</td></tr><tr><td>Norstictic acid</td><td>16.92</td><td>52.34</td><td>15.28</td><td>16.49</td></tr><tr><td>Usnic acid</td><td>12.89</td><td>52.77</td><td>15.06</td><td>19.28</td></tr></table>
2cf3fb31fa5295ed7a6698722d04fd7e4446dd0842cedc9a5fffeb5595a6edd2.png	simple	<table><tr><td>Characteristic</td><td>Total cohort(<i>n</i> = 63)</td><td>Yoga group(<i>n</i> = 29)</td><td>Control group(<i>n</i> = 34)</td></tr><tr><td>Age (y)</td><td>37.2 ± 10.8</td><td>38.2 ± 10.1</td><td>36.3 ± 11.4</td></tr><tr><td>Women (n; %)</td><td>50; 79%</td><td>23; 79%</td><td>27; 79%</td></tr><tr><td>Body weight (kg)</td><td>88.5 ± 21.0</td><td>86.4 ± 21.2</td><td>90.4 ± 21.0</td></tr><tr><td>Body mass index (BMI) (kg/m<sup>2</sup>)</td><td>30.5 ± 6.2</td><td>29.9 ± 6.2</td><td>30.9 ± 6.3</td></tr><tr><td>Obese (BMI 30+) (n; %)</td><td>27; 43%</td><td>11; 38%</td><td>16; 47%</td></tr><tr><td>Waist circumference (cm)</td><td>94.7 ± 14.7</td><td>93.9 ± 14.5</td><td>95.3 ± 15.1</td></tr><tr><td>Stress score (DASS-21)</td><td>23.8 ± 6.0</td><td>23.3 ± 6.0</td><td>24.3 ± 6.1</td></tr><tr><td>Current smoker or quit in last 6 months (n; %)</td><td>3; 5%</td><td>1; 3%</td><td>2; 6%</td></tr></table>
5bfdd8bdc42284d5f71a821a0f1b5770adcf0e068da4f4321f57757c41f5f3e5.png	simple	<table><tr><td>Source</td><td>d.f.</td><td>MS</td><td>F</td><td>P</td></tr><tr><td>Line</td><td>3</td><td>0.006</td><td>2.119</td><td>0.269</td></tr><tr><td>Cactus</td><td>1</td><td>0.004</td><td>1.145</td><td>0.365</td></tr><tr><td>Line × Cactus</td><td>3</td><td>0.003</td><td>2.623</td><td>0.067</td></tr><tr><td>Wing Length</td><td>1</td><td>0.001</td><td>1.048</td><td>0.309</td></tr><tr><td>Error</td><td>71</td><td>0.001</td><td></td><td></td></tr></table>
0d05e5dee333c428d251b430202df482b6e23a10809351bfa3a40d2d4edc7c70.png	complex	<table><tr><td>Characteristic</td><td>All Countries</td><td>South Africa</td><td>Tanzania</td><td>Zimbabwe</td></tr><tr><td>Qualitative FGDs (parents)</td><td>N = 192</td><td>n = 59</td><td>n = 60</td><td>n = 73</td></tr><tr><td> Mean age, y (SD)</td><td>39.9 (11.5)</td><td>40.5 (10.1)</td><td>36.1 (10.1)</td><td>42.5 (12.8)</td></tr><tr><td colspan="5"> Gender</td></tr><tr><td>Female</td><td>97 (50.5)</td><td>30 (50.8)</td><td>31 (51.7)</td><td>36 (49.3)</td></tr><tr><td>Male</td><td>95 (49.5)</td><td>29 (49.2)</td><td>29 (48.3)</td><td>37 (50.7)</td></tr><tr><td colspan="5"> Setting</td></tr><tr><td>Urban</td><td>89 (46.4)</td><td>18 (30.5)</td><td>16 (26.7)</td><td>55 (75.3)</td></tr><tr><td>Periurban</td><td>43 (22.4)</td><td>13 (22.0)</td><td>30 (50.0)</td><td>0 (0.0)</td></tr><tr><td>Rural</td><td>60 (31.3)</td><td>28 (47.5)</td><td>14 (23.3)</td><td>18 (24.7)</td></tr><tr><td colspan="5"> Completed primary education</td></tr><tr><td>No</td><td>31 (16.2)</td><td>18 (30.5)</td><td>5 (8.3)</td><td>8 (11.0)</td></tr><tr><td>Yes</td><td>161 (83.9)</td><td>41 (69.5)</td><td>55 (91.7)</td><td>65 (89.0)</td></tr><tr><td>Quantitative survey (adolescents)</td><td>N = 1293</td><td>n = 299</td><td>n = 498</td><td>n = 496</td></tr><tr><td> Mean age, y (SD)</td><td>13.5 (3.1)</td><td>13.8 (3.0)</td><td>12.0 (2.6)</td><td>14.7 (3.0)</td></tr><tr><td colspan="5"> Age group, y</td></tr><tr><td>10–14</td><td>836 (64.7)</td><td>187 (62.5)</td><td>413 (82.9)</td><td>236 (47.6)</td></tr><tr><td>15–19</td><td>457 (35.3)</td><td>112 (37.5)</td><td>85 (17.1)</td><td>260 (52.4)</td></tr><tr><td colspan="5"> Setting</td></tr><tr><td>Urban</td><td>696 (53.8)</td><td>107 (35.8)</td><td>233 (46.8)</td><td>356 (71.8)</td></tr><tr><td>Periurban</td><td>192 (14.9)</td><td>50 (16.7)</td><td>142 (28.5)</td><td>0 (0.0)</td></tr><tr><td>Rural</td><td>405 (31.3)</td><td>142 (47.5)</td><td>123 (24.7)</td><td>140 (28.2)</td></tr><tr><td colspan="5"> SES wealth score<sup>a</sup></td></tr><tr><td>Low</td><td>443 (34.3)</td><td>15 (5.0)</td><td>333 (66.9)</td><td>95 (19.2)</td></tr><tr><td>Moderate</td><td>419 (32.4)</td><td>94 (31.4)</td><td>151 (30.3)</td><td>174 (35.1)</td></tr><tr><td>High</td><td>424 (32.8)</td><td>183 (61.2)</td><td>14 (2.8)</td><td>227 (45.8)</td></tr><tr><td colspan="5"> Religion</td></tr><tr><td>Christian</td><td>1231 (95.2)</td><td>269 (90.0)</td><td>480 (96.4)</td><td>482 (97.2)</td></tr><tr><td>Muslim</td><td>20 (1.6)</td><td>2 (0.7)</td><td>13 (2.6)</td><td>5 (1.0)</td></tr><tr><td>Traditional</td><td>13 (1.0)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>13 (4.4)</td></tr><tr><td>Agnostic/other</td><td>25 (1.9)</td><td>4 (0.8)</td><td>9 (1.8)</td><td>12 (4.0)</td></tr><tr><td colspan="5"> Ever had sex</td></tr><tr><td>No</td><td>1073 (83.0)</td><td>231 (77.3)</td><td>410 (82.3)</td><td>432 (87.1)</td></tr><tr><td>Yes</td><td>219 (16.9)</td><td>67 (22.4)</td><td>88 (17.7)</td><td>64 (12.9)</td></tr><tr><td colspan="5"> Most talked-to adult with personal matters<sup>b</sup></td></tr><tr><td>Mother</td><td>411 (31.9)</td><td>150 (50.8)</td><td>124 (25.0)</td><td>137 (27.6)</td></tr><tr><td>Father</td><td>301 (23.4)</td><td>42 (14.2)</td><td>113 (22.8)</td><td>146 (29.4)</td></tr><tr><td>Brother</td><td>199 (15.5)</td><td>37 (12.5)</td><td>71 (14.3)</td><td>91 (18.3)</td></tr><tr><td>Other family member<sup>c</sup></td><td>198 (15.4)</td><td>48 (16.3)</td><td>56 (11.3)</td><td>94 (19.0)</td></tr><tr><td>Other adult<sup>d</sup></td><td>30 (2.3)</td><td>11 (3.7)</td><td>8 (1.6)</td><td>11 (2.2)</td></tr><tr><td>Does not talk with adultsabout personal matters</td><td>148 (11.5)</td><td>7 (2.4)</td><td>124 (25.0)</td><td>17 (3.4)</td></tr></table>
0bb0dddbb2e682352c75a3cd4acbdc72a35465479d6f78d8225ce60daf81c9f7.png	simple	<table><tr><td>Patients code</td><td>Sex</td><td>Infection status</td><td>CD4</td><td>HIV load</td><td>HCV load</td></tr><tr><td>H1</td><td>F</td><td>HIV</td><td>288</td><td>140222</td><td>NUL</td></tr><tr><td>H2</td><td>M</td><td>HIV</td><td>56</td><td>373429</td><td>NUL</td></tr><tr><td>H3</td><td>F</td><td>HIV</td><td>400</td><td>46189</td><td>NUL</td></tr><tr><td>H4</td><td>M</td><td>HIV</td><td>218</td><td>95726</td><td>NUL</td></tr><tr><td>H5</td><td>M</td><td>HIV</td><td>508</td><td>1665</td><td>NUL</td></tr><tr><td>HC1</td><td>F</td><td>HIV/HCV</td><td>325</td><td><75</td><td>79000</td></tr><tr><td>HC2</td><td>M</td><td>HIV/HCV</td><td>422</td><td><74</td><td>63999</td></tr><tr><td>HC3</td><td>M</td><td>HIV/HCV</td><td>590</td><td><75</td><td>216000</td></tr><tr><td>HC4</td><td>F</td><td>HIV/HCV</td><td>399</td><td><75</td><td>1200000</td></tr><tr><td>HC5</td><td>F</td><td>HIV/HCV</td><td>331</td><td>123</td><td>5,070,000</td></tr><tr><td>C1</td><td>F</td><td>HCV</td><td>517</td><td>NUL</td><td>85426</td></tr><tr><td>C2</td><td>F</td><td>HCV</td><td>397</td><td>NUL</td><td>>1000000</td></tr><tr><td>C3</td><td>F</td><td>HCV</td><td>354</td><td>NUL</td><td>>1000000</td></tr><tr><td>C4</td><td>M</td><td>HCV</td><td>516</td><td>NUL</td><td>417070</td></tr><tr><td>C5</td><td>M</td><td>HCV</td><td>389</td><td>NUL</td><td>>1000000</td></tr><tr><td>N1</td><td>F</td><td>Negative</td><td>N/A</td><td>NUL</td><td>NUL</td></tr><tr><td>N2</td><td>F</td><td>Negative</td><td>N/A</td><td>NUL</td><td>NUL</td></tr><tr><td>N3</td><td>M</td><td>Negative</td><td>N/A</td><td>NUL</td><td>NUL</td></tr><tr><td>N4</td><td>M</td><td>Negative</td><td>N/A</td><td>NUL</td><td>NUL</td></tr><tr><td>N5</td><td>M</td><td>Negative</td><td>N/A</td><td>NUL</td><td>NUL</td></tr></table>
36a8739e480639272a058b820be132321f00d0f690c7a0c6d00b2bb1429b47ee.png	complex	<table><tr><td></td><td colspan="3">Percentage cilia</td><td colspan="3">Length, μm</td></tr><tr><td></td><td>Cycling</td><td>Assemb</td><td>Disassemb</td><td>Cycling</td><td>Assemb</td><td>Disassemb</td></tr><tr><td>Empty</td><td>1.7 ± 0.8</td><td>42.1 ± 3.7</td><td>12.6 ± 1.4</td><td>1.7 ± 0.4</td><td>4.1 ± 0.1</td><td>2.9 ± 0.1</td></tr><tr><td>AurA</td><td>0</td><td>26.5 ± 2.8</td><td>8.8 ± 0.9</td><td>0</td><td>4.1 ± 0.1</td><td>3.1 ± 0.2</td></tr><tr><td>Nek2</td><td>0.5 ± 0.5</td><td>27.8 ± 2.3</td><td>7.2 ± 1.9</td><td>0.9 ± 0.5</td><td>4.2 ± 0.1</td><td>3.0 ± 0.1</td></tr><tr><td>AurA/Nek2</td><td>ND</td><td>13.3 ± 1.0</td><td>15.5 ± 1.6</td><td>ND</td><td>7.2 ± 0.2</td><td>7.0 ± 0.3</td></tr><tr><td>AurAKD</td><td>ND</td><td>31.7 ± 1.8</td><td>13.6 ± 1.3</td><td>ND</td><td>4.5 ± 0.2</td><td>4.0 ± 0.1</td></tr><tr><td>Nek2KD</td><td>ND</td><td>32.2 ± 1.2</td><td>16.8 ± 1.8</td><td>ND</td><td>5.3 ± 0.2</td><td>3.2 ± 0.2</td></tr><tr><td>AurAKD/Nek2KD</td><td>ND</td><td>34.5 ± 2.7</td><td>25.6 ± 1.5</td><td>ND</td><td>14.0 ± 0.8</td><td>10.1 ± 0.3</td></tr><tr><td>AurA/Nek2KD</td><td>ND</td><td>12 ± 1.3</td><td>18 ± 2.0</td><td>ND</td><td>3.9 ± 0.1</td><td>3.3 ± 0.1</td></tr><tr><td>AurAKD/Nek2</td><td>ND</td><td>11 ± 1.0</td><td>19.6 ± 2.0</td><td>ND</td><td>3.4 ± 0.2</td><td>3.0 ± 0.1</td></tr><tr><td>R42</td><td>9.1 ± 1.3</td><td>47.2 ± 2.9</td><td>22.3 ± 3.0</td><td>4.2 ± 0.3</td><td>4.3 ± 0.1</td><td>3.4 ± 0.2</td></tr><tr><td>R42/AurA</td><td>1 ± 0.4</td><td>24.8 ± 2.1</td><td>7.2 ± 1.0</td><td>2.6 ± 0.7</td><td>4.3 ± 0.1</td><td>2.7 ± 0.1</td></tr><tr><td>R42/Nek2</td><td>0.8 ± 0.4</td><td>18.4 ± 2.6</td><td>12.5 ± 2.6</td><td>2.2 ± 0.8</td><td>4.0 ± 0.1</td><td>3.0 ± 0.1</td></tr><tr><td>OT siRNA</td><td>4.8 ± 1.3</td><td>46 ± 4.6</td><td>26.3 ± 8.6</td><td>2.6 ± 0.2</td><td>4.0 ± 0.1</td><td>2.9 ± 0.1</td></tr><tr><td>R42 siRNA</td><td>3.4 ± 0.7</td><td>41 ± 2.2</td><td>24 ± 4.0</td><td>2.7 ± 0.2</td><td>3.6 ± 0.1</td><td>3.4 ± 0.2</td></tr><tr><td>Empty-MLN</td><td>ND</td><td>26.4 ± 3.1</td><td>13.2 ± 1.3</td><td>ND</td><td>6.4 ± 0.4</td><td>5.3 ± 0.4</td></tr><tr><td>Empty + MLN</td><td>ND</td><td>33.4 ± 1.7</td><td>18.3 ± 3.3</td><td>ND</td><td>6.8 ± 0.4</td><td>4.8 ± 0.4</td></tr><tr><td>Nek2-MLN</td><td>ND</td><td>25.2 ± 2.3</td><td>10.6 ± 1.5</td><td>ND</td><td>5.9 ± 0.4</td><td>4.8 ± 0.4</td></tr><tr><td>Nek2 + MLN</td><td>ND</td><td>36.2 ± 2.0</td><td>17.5 ± 1.4</td><td>ND</td><td>6.3 ± 0.3</td><td>4.8 ± 0.4</td></tr><tr><td>Empty-rac</td><td>ND</td><td>46 ± 3.7</td><td>17.6 ± 2.0</td><td>ND</td><td>4.6 ± 4.7</td><td>5.3 ± 0.6</td></tr><tr><td>Empty + rac</td><td>ND</td><td>43 ± 5.8</td><td>27.7 ± 2.3</td><td>ND</td><td>10.8 ± 1.2</td><td>6.4 ± 0.6</td></tr><tr><td>AurA-rac</td><td>ND</td><td>33 ± 4.4</td><td>14.3 ± 2.3</td><td>ND</td><td>5.3 ± 0.7</td><td>3.8 ± 0.3</td></tr><tr><td>AurA + rac</td><td>ND</td><td>48.4 ± 5.6</td><td>28 ± 5.0 l</td><td>ND</td><td>7.4 ± 0.9</td><td>11.8 ± 1.3</td></tr></table>
efea6fe8d29b405b0d6d0a33d210d1dd535d91038895e2857a0f0213f8b7c246.png	complex	<table><tr><td>Contig</td><td>Accession number<sup>a</sup></td><td>Name and/or putative function</td><td>Organism</td><td><i>E</i> -value</td></tr><tr><td colspan="5">Cell wall degradation</td></tr><tr><td>Contig 27 – SS_024</td><td>SS1G_01493</td><td>β-xylosidase<sup>b</sup></td><td><i>S. sclerotiorum</i></td><td>3e-15</td></tr><tr><td>Contig 45 – SS_041</td><td>SS1G_13255.3</td><td>β-1,4-glucanase<sup>b</sup></td><td><i>S. sclerotiorum</i></td><td>6e-73</td></tr><tr><td>Contig 57 – SS_052</td><td>SS1G_08474</td><td>β-1,3-glucanase precursor</td><td><i>S. sclerotiorum</i></td><td>6e-05</td></tr><tr><td>Contig 98 – SS_091</td><td>SS1G_07146.3</td><td>Cellobiohydrolase<sup>b</sup></td><td><i>S. sclerotiorum</i></td><td>2e-40</td></tr><tr><td>Contig 124 – SS_116</td><td>SS1G_12937</td><td>Glycosyl hydrolase</td><td><i>S. sclerotiorum</i></td><td>2e-32</td></tr><tr><td>Contig 145 – SS_136</td><td>SS1G_07393</td><td>β-1,3-glucanase</td><td><i>S. sclerotiorum</i></td><td>1e-64</td></tr><tr><td>Contig 42 – SS_038</td><td>SS1G_02789</td><td>Glucan endo-1,3-β-glucosidase<sup>b</sup></td><td><i>S. sclerotiorum</i></td><td>3e-22</td></tr><tr><td>Contig 33 – SS_029</td><td>SS1G_01005</td><td>α-glucosidaseputative</td><td><i>S. sclerotiorum</i></td><td>3e-40</td></tr><tr><td>Contig 18 – SS_016</td><td>SS1G_12021</td><td>β-1,6-glucanase putative</td><td><i>S. sclerotiorum</i></td><td>5e-18</td></tr><tr><td colspan="5">Protein degradation</td></tr><tr><td>Contig 25 – SS_022</td><td>SS1G_0336</td><td>Serine peptidase putative</td><td><i>S. sclerotiorum</i></td><td>3e-43</td></tr><tr><td>Contig 26 – SS_023</td><td>SS1G_06534</td><td>Serin endopeptidase</td><td><i>S. sclerotiorum</i></td><td>2e-53</td></tr><tr><td>Contig 16 – SS_014</td><td>SS1G_03181</td><td>Aspartyl protease<sup>b</sup></td><td><i>S. sclerotiorum</i></td><td>2e-20</td></tr><tr><td>Contig 13 – SS_011</td><td>SS1G_00624</td><td>Acid protease<sup>b</sup></td><td><i>S. sclerotiorum</i></td><td>8e-15</td></tr><tr><td>Contig 62 – SS_057</td><td>SS1G_11818</td><td>Vacuolar protease A</td><td><i>S. sclerotiorum</i></td><td>4e-53</td></tr><tr><td>Contig 74 – SS_068</td><td>SS1G_00477</td><td>Ubiquitin homeostasis protein lub1 (phospholipase)</td><td><i>S. sclerotiorum</i></td><td>1e-12</td></tr><tr><td>Contig 63 – SS_058</td><td>SS1G_0770</td><td>Proteasome component PRE6</td><td><i>S. sclerotiorum</i></td><td>3e-47</td></tr><tr><td>Contig 61 – SS_056</td><td>SS1G_01331</td><td>Translocation protein Sec62 putative</td><td><i>S. sclerotiorum</i></td><td>1e-22</td></tr><tr><td colspan="5">Intracellular transport</td></tr><tr><td>Contig 40 – SS_036</td><td>SS1G_07860</td><td>Protein SEY1</td><td><i>S. sclerotiorum</i></td><td>6e-42</td></tr><tr><td>Contig 77 – SS_071</td><td>SS1G_09620</td><td>Hypothetical protein (GTPase)</td><td><i>S. sclerotiorum</i></td><td>2e-04</td></tr><tr><td>Contig 103 – SS_096</td><td>SS1G_10229</td><td>GTP-binding protein EsdC</td><td><i>S. sclerotiorum</i></td><td>1e-51</td></tr><tr><td>Contig 160 – SS_150</td><td>SS1G_08784</td><td>GTP-binding protein</td><td><i>S. sclerotiorum</i></td><td>6e-33</td></tr><tr><td>Contig 148 – SS_139</td><td>SS1G_11149</td><td>SEC24 related gene family (GTPase)</td><td><i>S. sclerotiorum</i></td><td>3e-31</td></tr><tr><td>Contig 9 – SS_007</td><td>SS1G_02490</td><td>DENN domain-containing protein</td><td><i>S. sclerotiorum</i></td><td>2e-32</td></tr><tr><td>Contig 86 – SS_080</td><td>SS1G_09635</td><td>Geranylgeranyl pyrophosphate synthetase (biosynthesis of secondary metabolites)</td><td><i>S. sclerotiorum</i></td><td>5e-25</td></tr><tr><td colspan="5">Oxidative stress</td></tr><tr><td>Contig 53 – SS_048</td><td>SS1G_14466</td><td>Oxidoreductase, 2-nitropropane dioxygenase family</td><td><i>S. sclerotiorum</i></td><td>9e-19</td></tr><tr><td>Contig 44 – SS_040</td><td>SS1G_12928</td><td>Peroxidase/catalase</td><td><i>S. sclerotiorum</i></td><td>2e-38</td></tr><tr><td>Contig 88 – SS_082</td><td>SS1G_10037</td><td>Cytochrome P450</td><td><i>S. sclerotiorum</i></td><td>4e-29</td></tr><tr><td>Contig 161 – SS_151</td><td>SS1G_06754</td><td>Zinc transcription factor</td><td><i>S. sclerotiorum</i></td><td>4e-42</td></tr><tr><td>Contig 153 – SS_143</td><td>SS1G_11235</td><td>2-nitropropane dioxygenase</td><td><i>S. sclerotiorum</i></td><td>2e-44</td></tr><tr><td colspan="5">Others</td></tr><tr><td>Contig 10 – SS_008</td><td>SS1G_06319</td><td>Perilipin MPL1- like protein CAP 20<sup>b</sup></td><td><i>S. sclerotiorum</i></td><td>1e-07</td></tr><tr><td>Contig 97 – SS_090</td><td>SS1G_03197</td><td>pH-response regulator protein</td><td><i>S. sclerotiorum</i></td><td>2e-09</td></tr><tr><td>Contig 75 – SS_069</td><td>SS1G_10538</td><td>Ceramidase</td><td><i>S. sclerotiorum</i></td><td>6e-20</td></tr><tr><td>Contig 142 – SS_133</td><td>SS1G_00477</td><td>Phospholipase</td><td><i>S. sclerotiorum</i></td><td>1e-12</td></tr></table>
6e0698733ade05cb8229fb83045ce99cb0e82f9156f7b4c8d39f8ddeca2aec43.png	simple	<table><tr><td><i>Group</i></td><td><i>Test group</i></td><td><i>Control group</i></td><td><i>t</i></td><td><i>P</i></td></tr><tr><td>Duration of operation (min)</td><td>180.4±48.9</td><td>179.7±66.4</td><td>1.513</td><td>>0.05</td></tr><tr><td>Intraoperative bleeding volume (mL)</td><td>390.5±90.3</td><td>384.6±89.5</td><td>0.023</td><td>>0.05</td></tr><tr><td>Length of hospital stay (d)</td><td>22.0±4.5</td><td>23.1±5.6</td><td>0.804</td><td>>0.05</td></tr><tr><td>VAS score (point)</td><td>1.76±1.09</td><td>5.22±2.90</td><td>8.196</td><td><0.05</td></tr><tr><td>Fracture healing time (week)</td><td>6.34±1.12</td><td>6.25±1.17</td><td>0.082</td><td>>0.05</td></tr></table>
47a7dcb7e5c4d78057eafaa5c0d779e1fa993a66c38f19ca0c991991abcbde9d.png	simple	<table><tr><td>MBSR sessions completed</td><td>Number of participants</td><td>Percentage (%)</td></tr><tr><td>All</td><td>3</td><td>12%</td></tr><tr><td>7</td><td>8</td><td>32%</td></tr><tr><td>6</td><td>3</td><td>12%</td></tr><tr><td>5</td><td>1</td><td>4%</td></tr><tr><td>4</td><td>0</td><td>0%</td></tr><tr><td>3</td><td>1</td><td>4%</td></tr><tr><td>2</td><td>1</td><td>4%</td></tr><tr><td>1</td><td>4</td><td>16%</td></tr><tr><td>0</td><td>4</td><td>16%</td></tr></table>
06f87b4f06c8e1e8b34d28a403872e3af4d1bb2c0632950eb73adc6083395145.png	simple	<table><tr><td>Variable</td><td>Hazard ratio (95% CI)</td><td><i>P</i></td></tr><tr><td>Age: ≥50 versus <50</td><td>0.63 (0.08–5.19)</td><td>0.67</td></tr><tr><td>Age: ≥60 versus <60</td><td>0.55 (0.13–2.32)</td><td>0.42</td></tr><tr><td>Tumor size: >2 cm versus ≤2 cm<sup>a</sup></td><td>2.20 (0.25–19.75)</td><td>0.48</td></tr><tr><td>Tumor type: ILC versus other</td><td>1.89 (0.23–15.41)</td><td>0.55</td></tr><tr><td>Tumor type: DCIS versus invasive cancer</td><td>1.61 (0.38–6.75)</td><td>0.52</td></tr><tr><td>ER status: negative versus positive<sup>a</sup></td><td>5.87 (0.97–35.34)</td><td>0.053</td></tr><tr><td>Margins: negative versus close/positive</td><td>7.63 (1.45–40.0)</td><td>0.016</td></tr><tr><td>Multifocality: yes versus no</td><td>2.36 (0.28–19.99)</td><td>0.43</td></tr><tr><td>LVI: present versus none<sup>a,b</sup></td><td>—</td><td>0.60</td></tr><tr><td>Nodal status: positive versus negative<sup>a,b</sup></td><td>—</td><td>1.0</td></tr></table>
895f69ac9bffb16acb6584d347c8c4b75ebc1d1efd157a0ebe060feea220bb3a.png	complex	<table><tr><td>Variable</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td colspan="5">RIGHT/FRONTAL QUADRANT</td></tr><tr><td>1. Congruence effect</td><td></td><td></td><td></td><td></td></tr><tr><td>2. Association effect</td><td>0.055</td><td></td><td></td><td></td></tr><tr><td>3. Stroop interference</td><td>0.037</td><td>0.099</td><td></td><td></td></tr><tr><td>4. Listening span</td><td>−0.486</td><td>0.001</td><td>0.094</td><td></td></tr><tr><td colspan="5">LEFT/FRONTAL QUADRANT</td></tr><tr><td>1. Congruence effect</td><td></td><td></td><td></td><td></td></tr><tr><td>2. Association effect</td><td>0.223</td><td></td><td></td><td></td></tr><tr><td>3. Stroop interference</td><td>−0.125</td><td>0.05</td><td></td><td></td></tr><tr><td>4. Listening span</td><td>−0.283</td><td>−0.044</td><td>0.094</td><td></td></tr><tr><td colspan="5">RIGHT/POSTERIOR QUADRANT</td></tr><tr><td>1. Congruence effect</td><td></td><td></td><td></td><td></td></tr><tr><td>2. Association effect</td><td>−0.225</td><td></td><td></td><td></td></tr><tr><td>3. Stroop interference</td><td>0.262</td><td>0.035</td><td></td><td></td></tr><tr><td>4. Listening span</td><td>−0.032</td><td>0.159</td><td>0.094</td><td></td></tr><tr><td colspan="5">LEFT/POSTERIOR QUADRANT</td></tr><tr><td>1. Congruence effect</td><td></td><td></td><td></td><td></td></tr><tr><td>2. Association effect</td><td>0.455</td><td></td><td></td><td></td></tr><tr><td>3. Stroop interference</td><td>−0.132</td><td>0.131</td><td></td><td></td></tr><tr><td>4. Listening span</td><td>0.516</td><td>0.622</td><td>0.094</td><td></td></tr></table>
73ea1245f83a44194112de7c192b51c5a48164487ff52fd73177d3873659afa6.png	simple	<table><tr><td><i>Species</i></td><td>Lot</td><td>Seeds/well</td><td>Linear regression</td><td>R<sup>2</sup></td></tr><tr><td><i>Phelipanche ramosa</i></td><td>St Martin de Fraigneau, France, 2005</td><td>120</td><td>A = 0.0023 gs + 0.011</td><td>0.976</td></tr><tr><td><i>Orobanche cumana</i></td><td>Longeville-sur-mer, France, 2009</td><td>110</td><td>A = 0.0019 gs + 0.009</td><td>0.965</td></tr><tr><td><i>Orobanche minor</i></td><td>Japan, 2010</td><td>80</td><td>A = 0.0043 gs + 0.032</td><td>0.977</td></tr><tr><td><i>Striga hermonthica</i></td><td>Gadarif, Soudan, 1999</td><td>90</td><td>A = 0.0127 gs + 0.016</td><td>0.920</td></tr></table>
203764a11f815b79d60ea79128dc30e289fc27ea87518ad8a6b48a9c30756c0c.png	complex	<table><tr><td></td><td colspan="4">1994–1999</td><td colspan="4">2000–2004</td><td colspan="4">2005–2009</td></tr><tr><td></td><td colspan="3">Empirical data</td><td>Spectrum estimate</td><td colspan="3">Empirical data</td><td>Spectrum estimate</td><td colspan="3">Empirical data</td><td>Spectrum estimate</td></tr><tr><td>Age group</td><td>Number of deaths</td><td>Number of person years</td><td>Mortality rate (95% CI)</td><td>Mortality rate</td><td>Number of deaths</td><td>Number of person years</td><td>Mortality rate (95% CI)</td><td>Mortality rate</td><td>Number of deaths</td><td>Number of person years</td><td>Mortality rate (95% CI)</td><td>Mortality rate</td></tr><tr><td>Men</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>15–19</td><td>19</td><td>6,064</td><td>3.13 (2–4.91)</td><td>3.06</td><td>19</td><td>6,275</td><td>3.03 (1.93–4.75)</td><td>2.69</td><td>15</td><td>7,654</td><td>1.96 (1.18–3.25)</td><td>2.31</td></tr><tr><td>20–24</td><td>19</td><td>4,716</td><td>4.03 (2.57–6.32)</td><td>4.86</td><td>17</td><td>5,029</td><td>3.38 (2.1–5.44)</td><td>4.23</td><td>20</td><td>5,229</td><td>3.82 (2.47–5.93)</td><td>3.58</td></tr><tr><td>25–29</td><td>25</td><td>3,615</td><td>6.91 (4.67–10.23)</td><td>7.51</td><td>24</td><td>4,089</td><td>5.87 (3.93–8.76)</td><td>6.81</td><td>31</td><td>4,165</td><td>7.44 (5.23–10.58)</td><td>5.60</td></tr><tr><td>30–34</td><td>49</td><td>3,312</td><td>14.80 (11.18–19.58)</td><td>10.24</td><td>32</td><td>3,344</td><td>9.57 (6.77–13.53)</td><td>10.09</td><td>28</td><td>4,096</td><td>6.84 (4.72–9.90)</td><td>8.07</td></tr><tr><td>35–39</td><td>45</td><td>2,654</td><td>16.96 (12.66–22.71)</td><td>13.95</td><td>33</td><td>2,922</td><td>11.30 (8.03–15.89)</td><td>14.60</td><td>37</td><td>3,249</td><td>11.39 (8.25–15.72)</td><td>11.85</td></tr><tr><td>40–44</td><td>21</td><td>1,903</td><td>11.04 (7.2–16.93)</td><td>15.02</td><td>49</td><td>2,425</td><td>20.21 (15.27–6.74)</td><td>16.14</td><td>31</td><td>2,744</td><td>11.30 (7.94–16.06)</td><td>13.10</td></tr><tr><td>45–49</td><td>31</td><td>1,609</td><td>19.26 (13.55–27.39)</td><td>15.38</td><td>31</td><td>1,688</td><td>18.36 (12.91–26.11)</td><td>16.09</td><td>25</td><td>2,254</td><td>11.09 (7.49–16.41)</td><td>13.55</td></tr><tr><td>50–54</td><td>25</td><td>1,333</td><td>18.76 (12.68–27.76)</td><td>15.29</td><td>25</td><td>1,290</td><td>19.39 (13.1–28.69)</td><td>14.90</td><td>31</td><td>1,563</td><td>19.83 (13.94–28.19)</td><td>12.73</td></tr><tr><td>55–59</td><td>23</td><td>1,005</td><td>22.89 (15.21–34.44)</td><td>25.15</td><td>24</td><td>1,093</td><td>21.95 (14.71–32.75)</td><td>23.61</td><td>21</td><td>1,147</td><td>18.31 (11.94–28.08)</td><td>19.97</td></tr><tr><td>60 +</td><td>126</td><td>2,387</td><td>52.79 (40.33–69.79)</td><td>62.28</td><td>138</td><td>2,500</td><td>55.20 (42.35–71.80)</td><td>59.95</td><td>135</td><td>2,801</td><td>48.20 (36.34–63.88)</td><td>56.86</td></tr><tr><td>Women</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>15–19</td><td>10</td><td>5,265</td><td>1.90 (1.02–3.53)</td><td>2.59</td><td>19</td><td>5,774</td><td>3.29 (2.1–5.16)</td><td>2.23</td><td>17</td><td>6,881</td><td>2.47 (1.54–3.97)</td><td>1.80</td></tr><tr><td>20–24</td><td>35</td><td>4,983</td><td>7.02 (5.04–9.78)</td><td>4.81</td><td>28</td><td>4,954</td><td>5.65 (3.9–8.19)</td><td>4.23</td><td>10</td><td>5,310</td><td>1.88 (1.01–3.5)</td><td>3.43</td></tr><tr><td>25–29</td><td>35</td><td>4,164</td><td>8.40 (6.03–11.71)</td><td>8.97</td><td>36</td><td>4,572</td><td>7.87 (5.68–10.92)</td><td>8.71</td><td>29</td><td>4,767</td><td>6.08 (4.23–8.75)</td><td>6.82</td></tr><tr><td>30–34</td><td>46</td><td>3,598</td><td>12.78 (9.58–17.07)</td><td>10.85</td><td>46</td><td>3,728</td><td>12.34 (9.24–16.47)</td><td>12.17</td><td>25</td><td>4,423</td><td>5.65 (3.82–8.37)</td><td>9.44</td></tr><tr><td>35–39</td><td>25</td><td>2,619</td><td>9.55 (6.45–14.13)</td><td>12.15</td><td>40</td><td>3,164</td><td>12.64 (9.27–17.24)</td><td>14.16</td><td>28</td><td>3,402</td><td>8.23 (5.68–11.92)</td><td>11.87</td></tr><tr><td>40–44</td><td>22</td><td>2,059</td><td>10.69 (7.04–16.23)</td><td>11.48</td><td>30</td><td>2,436</td><td>12.31 (8.61–17.61)</td><td>13.04</td><td>25</td><td>2,995</td><td>8.35 (5.64–12.35)</td><td>10.94</td></tr><tr><td>45–49</td><td>18</td><td>1,566</td><td>11.50 (7.24–18.25)</td><td>14.00</td><td>21</td><td>1,884</td><td>11.15 (7.27–17.1)</td><td>14.80</td><td>23</td><td>2,379</td><td>9.67 (6.42–14.55)</td><td>12.35</td></tr><tr><td>50–54</td><td>19</td><td>1,368</td><td>13.89 (8.86–21.78)</td><td>14.30</td><td>20</td><td>1,406</td><td>14.22 (9.18–22.04)</td><td>13.74</td><td>19</td><td>1,733</td><td>10.97 (6.99–17.19)</td><td>11.30</td></tr><tr><td>55–59</td><td>19</td><td>1,079</td><td>17.62 (11.24–27.62)</td><td>13.84</td><td>20</td><td>1,186</td><td>16.87 (10.88–26.14)</td><td>12.63</td><td>18</td><td>1,363</td><td>13.21 (8.32–20.97)</td><td>10.71</td></tr><tr><td>60+</td><td>151</td><td>2,866</td><td>52.69 (40.21–69.00)</td><td>55.60</td><td>132</td><td>3,113</td><td>42.40 (36.31–48.81)</td><td>53.60</td><td>139</td><td>3,612</td><td>38.48 (33.45–4497)</td><td>51.03</td></tr></table>
18c7ad7e6d55cfd122a6f99d7b904aacd3c0d45f1a9c8e2734fb1d23cae9499f.png	complex	<table><tr><td rowspan="2">Cutpoint</td><td rowspan="2">Method</td><td colspan="4">Level of burden</td></tr><tr><td>Heavy</td><td>Medium</td><td>Mild</td><td>None</td></tr><tr><td rowspan="3">0.9</td><td>PP</td><td>0.788</td><td>0.982</td><td>1.052</td><td>1.028</td></tr><tr><td>AT</td><td>0.749</td><td>0.983</td><td>1.052</td><td>1.017</td></tr><tr><td>IV</td><td>2.977</td><td>3.269</td><td>1.710</td><td>1.184</td></tr><tr><td rowspan="3">0.85</td><td>PP</td><td>0.776</td><td>0.950</td><td>1.019</td><td>1.028</td></tr><tr><td>AT</td><td>0.742</td><td>0.933</td><td>1.014</td><td>1.009</td></tr><tr><td>IV</td><td>2.647</td><td>2.629</td><td>1.531</td><td>1.175</td></tr><tr><td rowspan="3">0.8</td><td>PP</td><td>0.752</td><td>0.909</td><td>1.006</td><td>1.020</td></tr><tr><td>AT</td><td>0.711</td><td>0.886</td><td>0.994</td><td>1.009</td></tr><tr><td>IV</td><td>2.362</td><td>2.195</td><td>1.421</td><td>1.175</td></tr><tr><td rowspan="3">0.75</td><td>PP</td><td>0.729</td><td>0.905</td><td>1.000</td><td>1.028</td></tr><tr><td>AT</td><td>0.690</td><td>0.886</td><td>0.979</td><td>1.015</td></tr><tr><td>IV</td><td>2.110</td><td>1.894</td><td>1.347</td><td>1.167</td></tr><tr><td rowspan="3">0.7</td><td>PP</td><td>0.715</td><td>0.883</td><td>1.001</td><td>1.021</td></tr><tr><td>AT</td><td>0.679</td><td>0.865</td><td>0.984</td><td>1.015</td></tr><tr><td>IV</td><td>1.915</td><td>1.647</td><td>1.289</td><td>1.159</td></tr><tr><td rowspan="3">0.65</td><td>PP</td><td>0.694</td><td>0.870</td><td>0.996</td><td>1.021</td></tr><tr><td>AT</td><td>0.662</td><td>0.858</td><td>0.985</td><td>1.008</td></tr><tr><td>IV</td><td>1.728</td><td>1.468</td><td>1.243</td><td>1.152</td></tr><tr><td rowspan="3">0.6</td><td>PP</td><td>0.686</td><td>0.860</td><td>0.985</td><td>1.013</td></tr><tr><td>AT</td><td>0.656</td><td>0.852</td><td>0.970</td><td>1.008</td></tr><tr><td>IV</td><td>1.560</td><td>1.336</td><td>1.213</td><td>1.144</td></tr><tr><td rowspan="3">0.55</td><td>PP</td><td>0.669</td><td>0.859</td><td>0.981</td><td>1.014</td></tr><tr><td>AT</td><td>0.636</td><td>0.856</td><td>0.971</td><td>1.001</td></tr><tr><td>IV</td><td>1.413</td><td>1.235</td><td>1.179</td><td>1.144</td></tr><tr><td rowspan="3">0.5</td><td>PP</td><td>0.665</td><td>0.854</td><td>0.970</td><td>1.013</td></tr><tr><td>AT</td><td>0.629</td><td>0.842</td><td>0.957</td><td>1.000</td></tr><tr><td>IV</td><td>1.291</td><td>1.158</td><td>1.147</td><td>1.144</td></tr></table>
52d7f0f762d875492512473fb65eb013508a2bc1b074538115303de39c9ff361.png	simple	<table><tr><td>Age of onset</td><td>Study population</td><td>Annual reported non-fatal early cases</td><td>Annual reported non-fatal late cases</td><td>Annual reported deaths</td><td>Annual YLLs with 0% under-reporting (age weighted)</td><td>Annual YLLs with 0% under-reporting (non-age weighted)</td><td>Annual deaths with 69% under-reporting</td><td>Annual YLLs with 69% under-reporting (age weighted)</td><td>Annual YLLs with 69% under-reporting (non-age weighted)</td></tr><tr><td>0–4</td><td>7145</td><td>1.6 (0–3)</td><td>2.1 (0–4)</td><td>0.1 (0–1)</td><td>4 (0–28)</td><td>3.5 (0–24.8)</td><td>2.8 (0.5–5.5)</td><td>86.9 (17–170)</td><td>71.4 (13.9–140.1)</td></tr><tr><td>5–14</td><td>12432</td><td>5.7 (2–13)</td><td>11.4 (3–17)</td><td>1 (0–3)</td><td>33.2 (0–100.5)</td><td>24 (0–73.3)</td><td>12.7 (4.2–27)</td><td>423.2 (141.1–902.5)</td><td>308.7 (102.4–660.5)</td></tr><tr><td>15–29</td><td>12687</td><td>9.9 (3–16)</td><td>16.7 (9–23)</td><td>0.7 (0–2)</td><td>19.7 (0–52.8)</td><td>14.9 (0–40.4)</td><td>19 (7–34.8)</td><td>552.7 (199.1–1027.2)</td><td>406.3 (147.3–752.8)</td></tr><tr><td>30–44</td><td>6857</td><td>4.6 (1–8)</td><td>9.4 (4–18)</td><td>0.6 (0–1)</td><td>10.3 (0–18.7)</td><td>9.8 (0–18)</td><td>10.1 (4.4–21.8)</td><td>210.6 (90.6–444.7)</td><td>184.6 (79.8–391.8)</td></tr><tr><td>45–59</td><td>4668</td><td>2.4 (0–5)</td><td>6.7 (3–10)</td><td>0.1 (0–1)</td><td>1.9 (0–13.1)</td><td>2.1 (0–15)</td><td>6.5 (2.1–12.2)</td><td>83.4 (28.6–154.3)</td><td>93.3 (31.4–171.5)</td></tr><tr><td>60–69</td><td>1850</td><td>2.4 (0–5)</td><td>4.1 (3–7)</td><td>0.9 (0–2)</td><td>6.1 (0–16.4)</td><td>8.7 (0–22.6)</td><td>5.4 (1.6–10.4)</td><td>39.4 (10.4–74.3)</td><td>55.6 (15–105.9)</td></tr><tr><td>70–79</td><td>781</td><td>0.1 (0–1)</td><td>2.3 (0–4)</td><td>0.3 (0–1)</td><td>1.1 (0–4.4)</td><td>1.9 (0–7.5)</td><td>1.9 (0–4.6)</td><td>8 (0–19.2)</td><td>13.5 (0–32.5)</td></tr><tr><td>80+</td><td>235</td><td>0.6 (0–3)</td><td>0.4 (0–2)</td><td>0.1 (0–1)</td><td>0.2 (0–1.2)</td><td>0.4 (0–3)</td><td>0.8 (0–3.5)</td><td>1.6 (0–6.5)</td><td>3.5 (0–14.3)</td></tr><tr><td>Totals</td><td>46655</td><td>27.3 (7–48)</td><td>53.3 (24–73)</td><td>3.9 (1–8)</td><td>76.4 (17.3–160)</td><td>65.4 (16.2–132.1)</td><td>59.2 (25.2–109.1)</td><td>1405.8 (608.8–2657.2)</td><td>1136.8 (493–2132.2)</td></tr></table>
8d799da7d18e9e11ab993b7099cbbc6d914995fcca75df829d2a3bd5b0f36dc9.png	simple	<table><tr><td>Solvents</td><td>Possible replacement</td></tr><tr><td>benzonitrile</td><td>1,4-cineol</td></tr><tr><td>1-hexanol</td><td>N,N-diethylolcapramide</td></tr><tr><td>sulfolane</td><td>ethylene glycol</td></tr><tr><td>methyl tert-butyl ether</td><td>diethyl succinate</td></tr><tr><td>diethyl ether</td><td>ethylhexyllactate</td></tr><tr><td>2-pentanol</td><td>gamma-valerolactone</td></tr><tr><td>2-methyl-2-propanol</td><td>glycerol, cyclopentyl methyl ether</td></tr><tr><td>trifluoroethanol</td><td>methyl ricinoleate</td></tr><tr><td>diphenyl ether</td><td>isopropyl palmitate</td></tr><tr><td>n-propylamine</td><td>ricinoleic acid</td></tr><tr><td>propionitrile</td><td>1,4-cineol</td></tr><tr><td>ethylenediamine</td><td>diisobutyl adipate</td></tr><tr><td>2,6-dimethylpyridine</td><td>ethyl acetate</td></tr><tr><td>4-picoline</td><td>ethanol/water(80:20)vol</td></tr><tr><td>diethylamine</td><td>glycerol-1,2,3-triethyl ether, dihydromyrcenol</td></tr><tr><td>morpholine</td><td>ethanol/water(90:10)vol</td></tr><tr><td>diethylene glycol</td><td>glycerol-1-ethyl monoether</td></tr><tr><td>2-aminoethanol</td><td>glycerol-1-methyl monoether</td></tr><tr><td>3-pentanol</td><td>glycerol-2-methyl monoether</td></tr><tr><td>aniline</td><td>dimethyl phthalate</td></tr><tr><td>2-methyl-2-butanol</td><td>2-furfuraldehyde</td></tr><tr><td>nitroethane</td><td>butyl myristate</td></tr></table>
60e4d6d680062ac7c7d695c5adedf6b4692ca969bdbb4a41749e9c211a9da8f1.png	complex	<table><tr><td rowspan="2">Clinicopathologic Characteristic</td><td rowspan="2">Number</td><td colspan="2">Oct4</td><td rowspan="2">p value</td><td colspan="2">Sox2</td><td rowspan="2">p value</td></tr><tr><td>Negative N (%)</td><td>Positive N (%)</td><td>Negative N (%)</td><td>Positive N (%)</td></tr><tr><td>T stage</td><td></td><td></td><td></td><td>0.496</td><td></td><td></td><td>0.353</td></tr><tr><td> T1</td><td>44</td><td>33 (44.0)</td><td>11 (52.4)</td><td></td><td>40 (47.6)</td><td>4 (33.3)</td><td></td></tr><tr><td> T2-T4</td><td>52</td><td>42 (56.0)</td><td>10 (47.6)</td><td></td><td>44 (52.4)</td><td>8 (66.7)</td><td></td></tr><tr><td>N stage</td><td></td><td></td><td></td><td>0.208</td><td></td><td></td><td>0.749</td></tr><tr><td> N0</td><td>62</td><td>46 (61.3)</td><td>16 (76.2)</td><td></td><td>55 (65.5)</td><td>7 (58.3)</td><td></td></tr><tr><td> N1-N3</td><td>34</td><td>29 (38.7)</td><td>5 (23.8)</td><td></td><td>29 (34.5)</td><td>5 (41.7)</td><td></td></tr><tr><td>Histologic grade</td><td></td><td></td><td></td><td>0.201</td><td></td><td></td><td>0.641</td></tr><tr><td> I</td><td>1</td><td>0 (0.0)</td><td>1 (4.8)</td><td></td><td>1 (1.2)</td><td>0 (0.0)</td><td></td></tr><tr><td> II</td><td>8</td><td>6 (8.0)</td><td>2 (9.5)</td><td></td><td>8 (9.5)</td><td>0 (0.0)</td><td></td></tr><tr><td> III</td><td>87</td><td>69 (92.0)</td><td>18 (85.7)</td><td></td><td>75 (89.3)</td><td>12 (100.0)</td><td></td></tr><tr><td>LVI</td><td></td><td></td><td></td><td>0.508</td><td></td><td></td><td>1.000</td></tr><tr><td> Absent</td><td>58</td><td>44 (58.7)</td><td>14 (66.7)</td><td></td><td>51 (60.7)</td><td>7 (58.3)</td><td></td></tr><tr><td> Present</td><td>38</td><td>31 (41.3)</td><td>7 (33.3)</td><td></td><td>33 (39.3)</td><td>5 (41.7)</td><td></td></tr><tr><td>P53 overexpression</td><td></td><td></td><td></td><td>0.757</td><td></td><td></td><td>0.757</td></tr><tr><td> Negative</td><td>44</td><td>35 (46.7)</td><td>9 (42.9)</td><td></td><td>39 (46.4)</td><td>5 (41.7)</td><td></td></tr><tr><td> Positive</td><td>52</td><td>40 (53.3)</td><td>12 (57.1)</td><td></td><td>45 (53.6)</td><td>7 (58.3)</td><td></td></tr><tr><td>Ki-67</td><td></td><td></td><td></td><td>0.446</td><td></td><td></td><td>1.000</td></tr><tr><td> < 20%</td><td>11</td><td>10 (13.3)</td><td>1 (4.8)</td><td></td><td>10 (11.9)</td><td>1 (8.3)</td><td></td></tr><tr><td> ≥ 20%</td><td>85</td><td>65 (86.7)</td><td>20 (95.2)</td><td></td><td>74 (88.1)</td><td>11 (91.7)</td><td></td></tr><tr><td>HER2</td><td></td><td></td><td></td><td>0.531</td><td></td><td></td><td>0.531</td></tr><tr><td> Negative</td><td>56</td><td>45 (60.0)</td><td>11 (52.4)</td><td></td><td>48 (57.1)</td><td>8 (66.7)</td><td></td></tr><tr><td> Positive</td><td>40</td><td>30 (40.0)</td><td>10 (47.6)</td><td></td><td>36 (42.9)</td><td>4 (33.3)</td><td></td></tr><tr><td>CD44(+)CD24(−)</td><td></td><td></td><td></td><td>0.655</td><td></td><td> </td><td>0.526</td></tr><tr><td> < 10%</td><td>36</td><td>29 (38.7)</td><td>7 (33.3)</td><td></td><td>33 (39.3)</td><td>3 (25.0)</td><td></td></tr><tr><td> ≥ 10%</td><td>60</td><td>46 (61.3)</td><td>14 (66.7)</td><td></td><td>51 (60.7)</td><td>9 (75.0)</td><td></td></tr><tr><td>ALDH1</td><td></td><td></td><td></td><td>0.022</td><td></td><td></td><td>1.000</td></tr><tr><td> < 10%</td><td>73</td><td>61 (81.3)</td><td>12 (57.1)</td><td></td><td>64 (76.2)</td><td>9 (75.0)</td><td></td></tr><tr><td> ≥ 10%</td><td>23</td><td>14 (18.7)</td><td>9 (42.9)</td><td></td><td>20 (23.8)</td><td>3 (25.0)</td><td></td></tr><tr><td>Vimentin</td><td></td><td></td><td></td><td>0.458</td><td></td><td></td><td>0.107</td></tr><tr><td> < 10%</td><td>62</td><td>47 (62.7)</td><td>15 (71.4)</td><td></td><td>57 (67.9)</td><td>5 (41.7)</td><td></td></tr><tr><td> ≥ 10%</td><td>34</td><td>28 (37.3)</td><td>6 (28.6)</td><td></td><td>27 (32.1)</td><td>7 (58.3)</td><td></td></tr><tr><td>E-cadherin loss</td><td></td><td></td><td></td><td>0.555</td><td></td><td></td><td>0.437</td></tr><tr><td> < 50%</td><td>54</td><td>41 (54.7)</td><td>13 (61.9)</td><td></td><td>46 (54.8)</td><td>8 (66.7)</td><td></td></tr><tr><td> ≥ 50%</td><td>42</td><td>34 (45.3)</td><td>8 (38.1)</td><td></td><td>38 (45.2)</td><td>4 (33.3)</td><td></td></tr></table>
21582be8be40f309110c8cba907d5fdfa5195fff468be000555f72de8d369e97.png	complex	<table><tr><td>Item</td><td>Criteria</td><td>Assessment</td></tr><tr><td rowspan="2">Validity</td><td>a) Are findings presented objectively?• Clear rationale and justification• Findings presented and discussed within appropriate context• Similar to existing literature and if not, reasons explained• Conflict of interest statement</td><td>YesNoUnclearN/A</td></tr><tr><td>b) Are the authors conclusions justified?• Transparency• Results consistent with those described in discussion• Conclusions based on empirical findings</td><td>YesNoUnclearN/A</td></tr><tr><td rowspan="5">Reliability</td><td>a) Is the research methodology clearly described?• Study population and surveillance system described• Can identify the research design• Methods carried out in a rigorous and transparent manner</td><td>YesNoUnclearN/A</td></tr><tr><td>b) Is methodology appropriate for the scope of research?<sup>a</sup>• Comparison with an appropriate reference standard (i.e. a data source other than notification data)?o Is the sensitivity of the reference standard described? Are cases verified?o Is the population base for notifications and supplementary data sources drawn from same catchment area?o Is there an adequate description of case ascertainment?o Are cases ascertained for the same time period in both datasets?• Are the data sources to be compared clearly identified and described/referenced?• What case definition is used? Is the same definition applied to all data sources?• Are the methods for linkage described?o Were the identifiers unique and available?o How complete was the link? (% linked)o How accurate was the link? (i.e. were individuals linked who were not supposed to be or vice versa)o Were duplicate cases identified and removed?• How precise are results? (confidence interval width)• Were any statistical measures of agreement used (did authors express level of agreement using a statistic)?• For capture-recapture methods:o If dependency between data sources is suspected, are ≥3 or more data sources used, along with log linear modelling methods, to account for this dependency?</td><td>YesNoUnclearN/A</td></tr><tr><td>c) Is the research methodology free from bias?• Are there major sources of bias?• Can the study be reproduced?</td><td>YesNoUnclearN/A</td></tr><tr><td>d) Are ethics procedures described?• Approval from ethics review board• Individual consent</td><td>YesNoUnclearN/A</td></tr><tr><td>e) Can I be confident about findings?• Were sources of information quality assessed?• Any major methodological flaws?</td><td>YesNoUnclearN/A</td></tr><tr><td>Applicability</td><td>Can results be applied within the scope of public health?• Do the results of the study apply to the issue under consideration (i.e. are surveillance systems and supplementary data sources similar to Ontario?)?</td><td>YesNoUnclearN/A</td></tr></table>
b693f222569d87b3b4fdb94024faee280d147693c8bed634a4468fae2321884c.png	complex	<table><tr><td>Exposures</td><td>Low</td><td>High</td><td><i>P</i> for difference</td><td colspan="2">Odds ratios with 95% confidence interval for psychological impairment (High category is reference)</td></tr><tr><td colspan="5">MICRONUTRIENTS</td></tr><tr><td>Haemoglobin</td><td>28.7 (6.2)</td><td>28.5 (7.6)</td><td>0.92</td><td>1.43</td><td>(0.48, 4.21)</td></tr><tr><td>Ferritin</td><td>26.6 (8.0)</td><td>29.1 (7.0)</td><td>0.20</td><td>0.50</td><td>(0.16, 1.51)</td></tr><tr><td>Calcium</td><td>29.4 (6.9)</td><td>25.7 (7.7)</td><td>0.03</td><td>1.47</td><td>(1.21, 4.31)</td></tr><tr><td>Vitamin D</td><td>29.9 (10.2)</td><td>28.2 (6.2)</td><td>0.39</td><td>1.43</td><td>(0.48, 4,21)</td></tr><tr><td>Zinc</td><td>29.0 (9.2)</td><td>28.4 (6.7)</td><td>0.77</td><td>0.78</td><td>(0.26, 2.31)</td></tr><tr><td>Vitamin B<sub>1</sub></td><td>28.0 (6.6)</td><td>28.8 (7.7)</td><td>0.62</td><td>0.63</td><td>(0.24, 1.64)</td></tr><tr><td>Vitamin B2</td><td>27.4 (8.9)</td><td>28.9 (6.8)</td><td>0.47</td><td>1.23</td><td>(0.43, 3.55)</td></tr><tr><td>Vitamin B6</td><td>28.7 (7.7)</td><td>28.5 (7.2)</td><td>0.95</td><td>0.78</td><td>(0.26, 2.31)</td></tr><tr><td>Vitamin B12</td><td>28.2 (5.9)</td><td>28.6 (7.7)</td><td>0.85</td><td>1.43</td><td>(0.48, 4.21)</td></tr><tr><td>Folic acid</td><td>28.9 (7.6)</td><td>28.8 (7.3)</td><td>0.94</td><td>0.91</td><td>(0.21, 3.96)</td></tr><tr><td>Vitamin C</td><td>28.1 (7.4)</td><td>28.7 (7.3)</td><td>0.79</td><td>1.50</td><td>(0.20, 3.70)</td></tr><tr><td colspan="5">MACRONUTRIENTS</td></tr><tr><td>Energy</td><td>30.8 (8.3)</td><td>27.9 (6.9)</td><td>0.24</td><td>1.94</td><td>(0.65, 5.81)</td></tr><tr><td>Protein</td><td>30.4 (8.3)</td><td>28.0 (6.9)</td><td>0.48</td><td>1.68</td><td>(0.55, 5.11)</td></tr><tr><td>Fat</td><td>29.6 (8.0)</td><td>28.2 (7.1)</td><td>0.22</td><td>1.05</td><td>(0.36, 3.11)</td></tr><tr><td>Calcium</td><td>30.4 (8.8)</td><td>27.7 (6.6)</td><td>0.03</td><td>1.43</td><td>(1.08, 3.19)</td></tr><tr><td>Iron</td><td>31.4(8.8)</td><td>27.7 (6.6)</td><td>0.046</td><td>3.04</td><td>(1.02, 9.26)</td></tr></table>
0fd82c7539a8e89cb8718bfad6df9de9d8b149e0bb44abaf13b73000a8981bd0.png	simple	<table><tr><td>Name</td><td>Sequence (5′→3′)</td><td>Position from ATG</td><td>Experimental use</td></tr><tr><td>ChsV-1</td><td>CAAGGACGAAAAGAGAGTAAC</td><td>+ 2769 (s)</td><td>RT-PCR</td></tr><tr><td>ChsV-3</td><td>TGTTGGTAGTTGTGATAATCGT</td><td>+ 2985 (as)</td><td>RT-PCR</td></tr><tr><td>B2m-F</td><td>TTTTCATCTGTCTTCCCCTGT</td><td>+ 3105 (s)</td><td>RT-PCR</td></tr><tr><td>B2m-R</td><td>GTATGTATCAGTCTCAGTGGG</td><td>+ 3362 (as)</td><td>RT-PCR</td></tr><tr><td>pyrG-F2</td><td>TGCCTCAGCATTGGTACTTG</td><td>- 670 (s)</td><td>Deletion vector</td></tr><tr><td>pyrG-R2</td><td>GTACACTGGCCATGCTATCG</td><td>+ 1335 (as)</td><td>Deletion vector</td></tr><tr><td>112092-F1</td><td>TGAGTTCTGCTTCTTCGTCTG</td><td>- 970 (s)</td><td>Deletion vector and probe</td></tr><tr><td>112092-R1</td><td><i>caagtaccaatgctgaggca</i>GGGGCTTTCTGGATGATGAGT</td><td>- 19 (as)</td><td>Deletion vector and probe</td></tr><tr><td>112092-F2</td><td><i>cgatagcatggccagtgtac</i>GTAGTAGCGTTGAATAAAGAGT</td><td>+ 1327 (s)</td><td>Deletion vector</td></tr><tr><td>112092-R2</td><td>GTGAGTTTCTGCTTGAATTTGT</td><td>+ 2456 (as)</td><td>Deletion vector</td></tr><tr><td>112092-F3n</td><td>ACGAAGAATCAGCAATTACACA</td><td>- 917 (s)</td><td>Deletion vector</td></tr><tr><td>112092-R3n</td><td>ACTCCATCAACTTTTATAAGCC</td><td>+ 2398 (as)</td><td>Deletion vector</td></tr><tr><td>108920-F1</td><td>TTTTGCAGGCTTTTATTACATTT</td><td>- 1063 (s)</td><td>Deletion vector</td></tr><tr><td>108920-R2</td><td>ACCTATGCAATGCCTCCGATGCGA</td><td>- 791 (s)</td><td>Deletion vector</td></tr><tr><td>108920-F2</td><td><i>cgatagcatggccagtgtac</i>CCATTGGCATCACGGATCAGCA</td><td>+ 563 (as)</td><td>Deletion vector</td></tr><tr><td>108920-R1</td><td><i>caagtaccaatgctgaggca</i>TGCTGCTGCGTACTGACTGATGT</td><td>+ 2312 (s)</td><td>Deletion vector and probe</td></tr><tr><td>108920-F1</td><td>GATGCAGGTTGTGATGGAAC</td><td>+ 3123 (as)</td><td>Deletion vector and probe</td></tr></table>
5d68143495a6c8f36fc532f52039eadaf1f947aa1224c2dc0b891325ef7cceb7.png	simple	<table><tr><td>Classification (α-angle)</td><td>Number (%)</td></tr><tr><td>Pathologic (>57°)</td><td>64 (14.6)</td></tr><tr><td>Borderline (51–56°)</td><td>66 (15.1)</td></tr><tr><td>Subtle (46–50°)</td><td>64 (14.6)</td></tr><tr><td>Very subtle (43–45°)</td><td>88 (20.1)</td></tr><tr><td>Normal (≤42°)</td><td>156 (35.6)</td></tr></table>
90d86ab296580a02d9981d4269477e255c5c9e9300ae5a8fb8dea0530bbd5a6e.png	simple	<table><tr><td>Source</td><td>Age (months) sex</td><td>Time of sample colection</td><td>Symptoms<sup>a</sup>or signs</td><td>Clinical diagnosis</td><td>Comorbidity</td><td>Time in hospital (days)</td><td>Coinfecting viruses</td></tr><tr><td>infant</td><td>3/M</td><td>November 01, 2005</td><td>fever</td><td>bronchiolitis</td><td>/</td><td>3</td><td>hRV</td></tr><tr><td>infant</td><td>6/M</td><td>January 19, 2006</td><td>hypoxia, fever</td><td>asthmatic bronchitis</td><td>/</td><td>6</td><td>RSV, hRV</td></tr><tr><td>Transplanted adult</td><td> </td><td>February 2006, 180 days after transplantation</td><td>pharingodinia</td><td>pharingodinia</td><td> </td><td> </td><td>/</td></tr></table>
3d57463b181a01b1e22dd8320eae10d0cd8765c2a685d0bf866ae30d5aee0203.png	complex	<table><tr><td></td><td colspan="2">All women</td><td colspan="2">ZDV monotherapy</td><td colspan="2">Combination therapy</td></tr><tr><td><i>Parameter</i></td><td><i>2–6 months</i></td><td><i>6–12 months</i></td><td><i>2–6 months</i></td><td><i>Parameter</i></td><td><i>2–6 months</i></td><td><i>6–12 months</i></td></tr><tr><td>CD4 count</td><td>−12.2, <i>P</i> = .51</td><td>10.0, <i>P</i> = .46</td><td>−19.5, <i>P</i> = .52</td><td>CD4 count</td><td>−12.2, <i>P</i> = .51</td><td>10.0, <i>P</i> = .46</td></tr><tr><td>CD4+ %</td><td>−0.01, <i>P</i> = .96</td><td>−0.13, <i>P</i> = .46</td><td>0.06, <i>P</i> = .82</td><td>CD4+ %</td><td>−0.01, <i>P</i> = .96</td><td>−0.13, <i>P</i> = .46</td></tr><tr><td>Log10 HIV RNA</td><td>−0.07, <i>P</i> = .35</td><td>−0.04, <i>P</i> = .43</td><td>−0.10, <i>P</i> = .25</td><td>Log10 HIV RNA</td><td>−0.07, <i>P</i> = .35</td><td>−0.04, <i>P</i> = .43</td></tr></table>
46c5645fdcaf121326f3d4361a9ab9a481ddfcd62263f151f2f3138670616b9f.png	complex	<table><tr><td rowspan="2">Region</td><td>Disposable Income</td><td>FAS Index</td><td>Std. Deviation</td><td>Family Car</td><td>Own Bedroom</td><td>No. of Computers</td><td>No. of Bathrooms</td><td>Dishwasher in Home</td><td>Family Holidays</td></tr><tr><td>(CZK/Year)</td><td>Mean (0–13)</td><td></td><td>Mean (0–2)</td><td>Mean (0–1)</td><td>Mean (0–3)</td><td>Mean (0–3)</td><td>Mean (0–1)</td><td>Mean (0–3)</td></tr><tr><td>Prague</td><td>264,100</td><td>8.1090</td><td>2.3646</td><td>1.3873</td><td>0.5679</td><td>2.5261</td><td>1.3583</td><td>0.7496</td><td>1.7844</td></tr><tr><td>Central Bohemia</td><td>216,633</td><td>7.9662</td><td>2.3401</td><td>1.5832</td><td>0.6667</td><td>2.4073</td><td>1.4861</td><td>0.7063</td><td>1.6183</td></tr><tr><td>Plzeň</td><td>205,083</td><td>7.5646</td><td>2.4755</td><td>1.4984</td><td>0.5679</td><td>2.2411</td><td>1.3222</td><td>0.6605</td><td>1.6284</td></tr><tr><td>South Moravia</td><td>203,208</td><td>7.5845</td><td>2.3741</td><td>1.4306</td><td>0.616</td><td>2.4108</td><td>1.3778</td><td>0.6517</td><td>1.6713</td></tr><tr><td>Hradec Králové</td><td>198,052</td><td>7.3255</td><td>2.3201</td><td>1.4579</td><td>0.5941</td><td>2.2442</td><td>1.3954</td><td>0.6502</td><td>1.4634</td></tr><tr><td>Vysočina</td><td>195,304</td><td>7.1183</td><td>2.4678</td><td>1.5197</td><td>0.5759</td><td>2.2495</td><td>1.459</td><td>0.6434</td><td>1.5424</td></tr><tr><td>Pardubice</td><td>193,820</td><td>7.0297</td><td>2.3404</td><td>1.4406</td><td>0.5503</td><td>2.2585</td><td>1.3488</td><td>0.6431</td><td>1.4397</td></tr><tr><td>South Bohemia</td><td>193,653</td><td>7.3271</td><td>2.2867</td><td>1.4797</td><td>0.5871</td><td>2.2576</td><td>1.414</td><td>0.6645</td><td>1.5814</td></tr><tr><td>Zlin</td><td>189,825</td><td>7.2367</td><td>2.3199</td><td>1.4714</td><td>0.5994</td><td>2.3472</td><td>1.4548</td><td>0.6445</td><td>1.5503</td></tr><tr><td>Liberec</td><td>189,176</td><td>7.5447</td><td>2.2164</td><td>1.3525</td><td>0.5683</td><td>2.1903</td><td>1.2939</td><td>0.5992</td><td>1.5</td></tr><tr><td>Moravia-Silesia</td><td>184,014</td><td>7.7997</td><td>2.3226</td><td>1.3021</td><td>0.5205</td><td>2.31</td><td>1.3333</td><td>0.5837</td><td>1.5208</td></tr><tr><td>Olomouc</td><td>183,173</td><td>7.1465</td><td>2.3534</td><td>1.3548</td><td>0.5574</td><td>2.2951</td><td>1.361</td><td>0.563</td><td>1.5322</td></tr><tr><td>Karlovy Vary</td><td>181,819</td><td>7.8075</td><td>2.3894</td><td>1.3993</td><td>0.6269</td><td>2.2229</td><td>1.2607</td><td>0.5709</td><td>1.5635</td></tr><tr><td>Ústí nad Labem</td><td>174,662</td><td>7.3046</td><td>2.3696</td><td>1.2746</td><td>0.602</td><td>2.2266</td><td>1.2955</td><td>0.5706</td><td>1.577</td></tr></table>
2b7394a37178525ab6026b229c682b59f29171e7291355e3f69f76a326a5cec2.png	simple	<table><tr><td>Source</td><td>No. of samples analyzed</td><td>No. of samples positive (%)</td></tr><tr><td>Well (n = 45)</td><td>241</td><td>72 (29.9)</td></tr><tr><td>Tap (n = 8)</td><td>56</td><td>4 (7.1)</td></tr><tr><td>Stream (n = 1)</td><td>21</td><td>11 (52.4)</td></tr><tr><td>Total</td><td>318</td><td>87 (27.4)</td></tr></table>
271d7385737b9dd178ee96ca92b836678a08ad8b749074c989c20635ac244574.png	simple	<table><tr><td>#</td><td>Name</td><td>Sequence</td></tr><tr><td>F1</td><td>SpeI-KDM4C-F1</td><td>GTACTAGTATGGAGGTGGCCGAGGTGGAA</td></tr><tr><td>R1</td><td>XhoI-KDM4C-R2121</td><td>ACTTGTTCCATCCTCCTCGAGGAAGGCATTGGGTGGAG</td></tr><tr><td>F2</td><td>Eco47III-D2A-F</td><td>GAGCCTCAGCGCTATGGCTTCTGAGTCTGAAACTCTGAAT</td></tr><tr><td>R2</td><td>SalI-KDM4A-R2150</td><td>CTGCAGCCAGTCGACGTGAAGCACATTTCTGGAATC</td></tr><tr><td>F3</td><td>XhoI-KDM4A-F2181</td><td>TCTACTCCTTATCTCGAGGAGGATGGCACCAGCATAC</td></tr><tr><td>R3</td><td>SalI-D2A-R</td><td>CATGTCGACCGCTCCATGATGGCCCGGTATAGTGCAG</td></tr><tr><td>F4</td><td>SalI-KDM4C-F2083</td><td>GCGGTCGACCGAAGAAAATATAGAATATTCTCCACCCAATG</td></tr><tr><td>R4</td><td>XmaI-D2C-R</td><td>ATCCCGGGTCTGTCTCTTCTGGCACTTCTTCTGGAAA</td></tr><tr><td>F5</td><td>SalI-KDM4C-F2083</td><td>GCGGTCGACCGAAGAAAATATAGAATATTCTCCACCCAATG</td></tr><tr><td>R5</td><td>XhoI-KDM4C-R2595</td><td>GGCTCGAGCTTATGTCGAAAGCATGTAATGTTCACCAC</td></tr><tr><td>F6</td><td>XhoI-KDM4A-F2656</td><td>GACTCGAGATTCCTAATTTGGAGCGTGCC</td></tr><tr><td>R6</td><td>SalI-KDM4A-R2655</td><td>AGGGTCGACCTTGTGCCGAAAGCAGGTAATGAAG</td></tr><tr><td>F7</td><td>SalI-KDM4C-F2598</td><td>ACGGTCGACGACAACCCCAACGTGAAGTCCAAGG</td></tr><tr><td>R7</td><td>XhoI-KDM4C-R2802</td><td>GGCTCGAGCAGCTTCAGACAGTCTCGGCTCACGATATC</td></tr><tr><td>F8</td><td>XhoI-KDM4A-F2865</td><td>GACTCGAGACTCCTCCTGCTGAAGGGGAAGT</td></tr><tr><td>R8</td><td>SalI-KDM4A-R2862</td><td>AGGGTCGACAAACTGGAGACAGTCCTGGCTCACTA</td></tr><tr><td>F9</td><td>SalI-KDM4C-F2805</td><td>ACGGTCGACGACCCACCTGCTGAGGGAGAAGTCGTC</td></tr><tr><td>F10</td><td>BamHI-KDM4C-RDTF-DNLY-F</td><td>GTTTGATGATGGATCCTTTAGCGATAACTTATATCCTGAGGATATCGTG</td></tr><tr><td>R10</td><td>BamHI-KDM4C-RDTF-DNLY-R</td><td>CACGATATCCTCAGGATATAAGTTATCGCTAAAGGATCCATCATCAAAC</td></tr><tr><td>F11</td><td>BamHI-KDM4A-DNLY-RTDF-F</td><td>ACTTTGATGATGGATCCTTCAGCCGCGATACCTTTCCTGAGGACATAGT</td></tr><tr><td>R11</td><td>BamHI-KDM4A-DNLY-RTDF-R</td><td>ACTATGTCCTCAGGAAAGGTATCGCGGCTGAAGGATCCATCATCAAAGT</td></tr><tr><td>F12</td><td>BamHI-KDM4C-R919D-F</td><td>TGTTTGATGATGGATCCTTTAGCGACGACACATTTCCTGAGGAT</td></tr><tr><td>R12</td><td>BamHI-KDM4C-R919D-R</td><td>ATCCTCAGGAAATGTGTCGTCGCTAAAGGATCCATCATCAAACA</td></tr><tr><td>R13</td><td>EcoR571-KDM4C-S198M</td><td>GCATGGCACACTGAAGACATGGACCTCTATATGATTAATTATCTCCAC</td></tr></table>
16cc6ced69e527afa58f14c89a29aa52e21005a78d4cbb703529409af2fc3251.png	complex	<table><tr><td> </td><td> </td><td> </td><td colspan="2">0–6 months</td><td colspan="2">>6 months</td></tr><tr><td>Baseline characteristics</td><td> </td><td>n<sup>1</sup></td><td>Crude HR(95% CI)</td><td>Adjusted<sup>2</sup> HR(95% CI)n = 10 283</td><td>Crude HR(95% CI)</td><td>Adjusted<sup>2</sup> HR(95% CI)n = 10 283</td></tr><tr><td>Age</td><td>Per 10-year increase</td><td>14 633</td><td>1.5(1.3 to 1.7)</td><td>1.5(1.3 to 1.8)</td><td>1.4(1.1 to 1.7)</td><td>1.6(1.2 to 2.2)</td></tr><tr><td>eGFR (reference ≥60 mL/min)</td><td><60 mL/min</td><td>13 003</td><td>7.2(5.0 to 10.5)</td><td>4.6(2.9 to 7.2)</td><td>1.5(0.5 to 4.7)</td><td>1.3(0.4 to 4.3)</td></tr><tr><td>CD4 (reference ≥200 cells/μL)</td><td>100–199 cells/μL</td><td>11 686</td><td>1.8(1.1 to 2.9)</td><td>2.1(1.2 to 3.5)</td><td>0.8(0.4 to 1.5)</td><td>0.8(0.4 to 1.6)</td></tr><tr><td> </td><td>50–99 cells/μL</td><td> </td><td>3.7(2.2 to 6.0)</td><td>4.1(2.4 to 6.9)</td><td>1.3(0.6 to 2.9)</td><td>1.2(0.5 to 2.9)</td></tr><tr><td> </td><td><50 cells/μL</td><td> </td><td>6.2(4.0 to 9.7)</td><td>7.9(4.9 to 12.9)</td><td>2.4(1.2 to 4.7)</td><td>3.1(1.5 to 6.4)</td></tr><tr><td>Weight (reference ≥60 kg)</td><td><60 kg</td><td>13 887</td><td>2.1(1.6 to 2.8)</td><td>1.6(1.1 to 2.1)</td><td>1.3(0.8 to 2.0)</td><td>1.2(0.7 to 2.2)</td></tr><tr><td>Concomitant ARV (reference NNRTI)</td><td>PI</td><td>14 571</td><td>1.9(0.8 to 4.7)</td><td>2.0(0.5 to 8.2)</td><td>2.8(0.9 to 8.9)</td><td>6.1(1.4 to 25.6)</td></tr></table>
7281cbb3612cf8e39b598a33456d2e147d269d34e6dc3dd086013f046f777795.png	simple	<table><tr><td>Parameter</td><td>All Patients</td><td>ARMD Group</td><td>Non-ARMD Group</td><td>P Value: ARMD Versus Non-ARMD</td></tr><tr><td>Unilateral BHR</td><td></td><td></td><td></td><td></td></tr><tr><td> No. (%) of patients</td><td>323 (100)</td><td>38 (12)</td><td>285 (88)</td><td></td></tr><tr><td> Sex (F/M)</td><td>117/206</td><td>27/11</td><td>90/195</td><td><0.0001‡</td></tr><tr><td> Age at blood test†<i>(yr)</i></td><td>63.0 (32.5-84.4)</td><td>59.8 (34.3-77.5)</td><td>63.4 (32.5-84.4)</td><td>0.0673</td></tr><tr><td> Time between op. and blood test†<i>(yr)</i></td><td>9.1 (1.9-15.2 )</td><td></td><td></td><td></td></tr><tr><td> Femoral head size†<i>(mm)</i></td><td>50.5 (38-58)</td><td>47.2 (38-58)</td><td>50.9 (38-58)</td><td>0.0001‡</td></tr><tr><td>Bilateral BHR</td><td></td><td></td><td></td><td></td></tr><tr><td> No. (%) of patients</td><td>93 (100)</td><td>17 (18)</td><td>76 (82)</td><td></td></tr><tr><td> Sex (F/M)</td><td>33/60</td><td>12/5</td><td>21/55</td><td>0.0022‡</td></tr><tr><td> Age at blood test†<i>(yr)</i></td><td>63.5 (36.5-82.6)</td><td>59.3 (49.4-70.4)</td><td>64.4 (36.5-82.6)</td><td>0.0069‡</td></tr><tr><td> Time between op. and blood test†<i>(yr)</i></td><td>8.2 (1.2-14.3 )</td><td></td><td></td><td></td></tr><tr><td> Femoral head size†<i>(mm)</i></td><td>50.7 (42-58)</td><td>48.4 (42-54)</td><td>51.0 (42-58)</td><td>0.0088‡</td></tr><tr><td>Unilateral Corail-Pinnacle</td><td></td><td></td><td></td><td></td></tr><tr><td> No. (%) of patients</td><td>294 (100)</td><td>20 (7)</td><td>274 (93)</td><td></td></tr><tr><td> Sex (F/M)</td><td>210/84</td><td>12/8</td><td>198/76</td><td>0.3599</td></tr><tr><td> Age at blood test†<i>(yr)</i></td><td>78.7 (52.1-95.4)</td><td>74.0 (54.6-87.8)</td><td>79.1 (52.1-95.4)</td><td>0.0143‡</td></tr><tr><td> Time between op. and blood test†<i>(yr)</i></td><td>3.6 (1.1-8.4 )</td><td></td><td></td><td></td></tr></table>
eb40529099ce74d2163d8a37034039b3de3a50b160e8ddaff59cc299ac5219a0.png	complex	<table><tr><td rowspan="3">Leading health care problems (ICD code)</td><td colspan="2">Female</td><td colspan="2">Male</td></tr><tr><td>Moran’s I</td><td>p-value<sup>a</sup></td><td>Moran’s I</td><td>p-value<sup>a</sup></td></tr><tr><td>Infectious and parasitic diseases (ICD 01-07)</td><td>0.34</td><td>0.0001</td><td>0.36</td><td>0.0001</td></tr><tr><td>Neoplasms (ICD 08-17)</td><td>0.71</td><td>0.0001</td><td>0.66</td><td>0.0001</td></tr><tr><td>Endocrine, nutritional and metabolic diseases and immunity disorders (ICD 18-19)</td><td>0.60</td><td>0.0002</td><td>0.54</td><td>0.0137</td></tr><tr><td>Diseases of the blood and blood-forming organs (ICD 20)</td><td>0.46</td><td>0.0001</td><td>0.45</td><td>0.0001</td></tr><tr><td>Mental disorders (ICD 21)</td><td>0.49</td><td>0.0001</td><td>0.43</td><td>0.0001</td></tr><tr><td>Diseases of the nervous system and sense organs (ICD 22-24)</td><td>0.63</td><td>0.0001</td><td>0.61</td><td>0.0001</td></tr><tr><td>Diseases of the circulatory system (ICD 25-30)</td><td>0.70</td><td>0.9985</td><td>0.56</td><td>0.0001</td></tr><tr><td>Diseases of the respiratory system (ICD 31-32)</td><td>0.42</td><td>0.0001</td><td>0.53</td><td>0.0001</td></tr><tr><td>Diseases of the digestive system (ICD 33-34)</td><td>0.64</td><td>0.0001</td><td>0.62</td><td>0.0001</td></tr><tr><td>Diseases of the genitourinary system (ICD 35-37)</td><td>0.45</td><td>0.0001</td><td>0.46</td><td>0.0001</td></tr><tr><td>Diseases of the skin and subcutaneous tissue (ICD 42)</td><td>0.46</td><td>0.0001</td><td>0.41</td><td>0.0001</td></tr><tr><td>Diseases of the musculoskeletal system and connective tissue (ICD 43)</td><td>0.73</td><td>0.9968</td><td>0.67</td><td>0.9966</td></tr><tr><td>Congenital anomalies (ICD 44)</td><td>0.51</td><td>0.0001</td><td>0.58</td><td>0.0001</td></tr><tr><td>Certain conditions originating in the perinatal period (ICD 45)</td><td>0.62</td><td>0.0001</td><td>0.64</td><td>0.0001</td></tr><tr><td>Signs, symptoms and ill-defined conditions (ICD 46)</td><td>0.69</td><td>0.0001</td><td>0.65</td><td>0.0001</td></tr><tr><td>Injury and poisoning (ICD 47-56, E47-56)</td><td>0.57</td><td>0.2056</td><td>0.59</td><td>0.0691</td></tr><tr><td>Other reasons for contact with health services (V0)</td><td>0.68</td><td>0.5394</td><td>0.65</td><td>0.0014</td></tr><tr><td>Complications of pregnancy, childbirth and the puerperium (ICD 38-41)</td><td>0.47</td><td>0.0001</td><td>n.d.</td><td>n.d.</td></tr></table>
f92140c4ed50364922849fd41970e9c63767c1cbff82315b02a21af71347fadd.png	complex	<table><tr><td>Parameters</td><td>Coefficients</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">Effect of EQ-5D domains</td><td>Additional effect of patient groups</td><td>Additional effect of valuation own health</td></tr><tr><td></td><td>Cancer</td><td>RA</td><td>General population</td><td>Cancer + RA + Gen. pop</td><td>Cancer + RA</td></tr><tr><td>Constant</td><td>0.96 (0.03)</td><td>0.98 (0.04)</td><td>0.93 (0.02)</td><td>0.94 (0.01)</td><td>0.78 (0.03)</td></tr><tr><td>Mobility (2)</td><td>-0.04 (0.06)</td><td>-0.02 (0.07)</td><td>-0.04 (0.03)</td><td>-0.04 (0.02)</td><td>-0.03 (0.04)</td></tr><tr><td>Self-care (2)</td><td>-0.03 (0.05)</td><td>-0.02 (0.06)</td><td>-0.10 (0.03)</td><td>-0.07 (0.02)</td><td>-0.02 (0.04)</td></tr><tr><td>Usual activities (2)</td><td>-0.04 (0.06)</td><td>-0.02 (0.07)</td><td>-0.02 (0.03)</td><td>-0.04 (0.02)</td><td>-0.03 (0.04)</td></tr><tr><td>Pain/discomfort (2)</td><td>-0.10 (0.04)</td><td>-0.08 (0.05)</td><td>-0.09 (0.02)</td><td>-0.09 (0.01)</td><td>-0.09 (0.03)</td></tr><tr><td>Anxiety/depression (2)</td><td>-0.06 (0.05)</td><td>-0.03 (0.06)</td><td>-0.13 (0.03)</td><td>-0.11 (0.02)</td><td>-0.05 (0.04)</td></tr><tr><td>Mobility (3)</td><td>-0.32 (0.07)</td><td>-0.38 (0.08)</td><td>-0.17 (0.04)</td><td>-0.18 (0.02)</td><td>-0.35 (0.05)</td></tr><tr><td>Self-care (3)</td><td>-0.07 (0.06)</td><td>-0.16 (0.07)</td><td>-0.14 (0.03)</td><td>-0.15 (0.02)</td><td>-0.10 (0.04)</td></tr><tr><td>Usual activities (3)</td><td>-0.09 (0.07)</td><td>-0.06 (0.08)</td><td>-0.06 (0.04)</td><td>-0.07 (0.02)</td><td>-0.08 (0.05)</td></tr><tr><td>Pain/discomfort (3)</td><td>-0.44 (0.05)</td><td>-0.35 (0.06)</td><td>-0.32 (0.03)</td><td>-0.34 (0.02)</td><td>-0.40 (0.04)</td></tr><tr><td>Anxiety/depression (3)</td><td>-0.28 (0.05)</td><td>-0.22 (0.06)</td><td>-0.30 (0.03)</td><td>-0.33 (0.02)</td><td>-0.26 (0.04)</td></tr><tr><td>N3</td><td>-0.12 (0.05)</td><td>-0.12 (0.06)</td><td>-0.25 (0.03)</td><td>-0.21 (0.02)</td><td>-0.11 (0.04)</td></tr><tr><td>Cancer patient</td><td>-</td><td>-</td><td>-</td><td>0.07 (0.02)</td><td>-</td></tr><tr><td>RA patient</td><td>-</td><td>-</td><td>-</td><td>0.12 (0.02)</td><td>-</td></tr><tr><td>TTO value own state</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0.22 (0.03)*</td></tr><tr><td>R<sup>2</sup></td><td>0.45</td><td>0.49</td><td>0.40</td><td>0.41</td><td>0.49</td></tr></table>

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.